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Microbial natural products represent a significant portion of small-molecule 
drugs approved for clinical use, especially as anti-infective and anticancer agents. 
Nevertheless, most clinically used anti-infective and anticancer agents suffer from 
resistance and other drawbacks such as adverse effects, drug interactions and poor 
pharmacokinetic properties. Some of the main challenges in the natural product 
discovery field are the high rediscovery rates and low yield of natural products. One 
of the factors contributing to this problem is the fact that the genes responsible for the 
production of a great number of natural products are transcriptionally inactive (silent) 
or poorly expressed under laboratory conditions, resulting in undetectable 
concentrations of the corresponding products. Therefore, this project aimed at 
activating natural product genes in Euglena microalgae, Aspergillus fungi and 
actinomycete bacteria through nutritional and epigenetic manipulation. 
Nutritional manipulation of Euglena resulted in the discovery of five novel 
natural products from E. gracilis, named euglenatides A-E, with moderate antifungal 
activity and potent antiproliferative activity. The investigation of other Euglena 
species revealed that euglenatide-related metabolites are produced by E. mutabilis and 
E. sanguinea. In Aspergillus fungi, nutritional manipulation led to significant changes 
in metabolite profiles leading to a substantial increase in the antimicrobial activity. 
Similarly, epigenetic manipulation led to a significant increase in the titre levels of 
phenylahistin in A. calidoustus and penicillic acid in A. westerdijkiae. Finally, 
nutritional manipulation in actinomycete bacteria led to higher yields of heronamides 
in Streptomyces sp. CMB-0406 while epigenetic manipulation did not display 
noticeable effects on the metabolite profile. 
 
Access Condition and Agreement 
 
Each deposit in UEA Digital Repository is protected by copyright and other intellectual property rights, 
and duplication or sale of all or part of any of the Data Collections is not permitted, except that material 
may be duplicated by you for your research use or for educational purposes in electronic or print form. 
You must obtain permission from the copyright holder, usually the author, for any other use. Exceptions 
only apply where a deposit may be explicitly provided under a stated licence, such as a Creative 
Commons licence or Open Government licence. 
 
Electronic or print copies may not be offered, whether for sale or otherwise to anyone, unless explicitly 
stated under a Creative Commons or Open Government license. Unauthorised reproduction, editing or 
reformatting for resale purposes is explicitly prohibited (except where approved by the copyright holder 
themselves) and UEA reserves the right to take immediate ‘take down’ action on behalf of the copyright 
and/or rights holder if this Access condition of the UEA Digital Repository is breached. Any material in 
this database has been supplied on the understanding that it is copyright material and that no quotation 





Table of Contents 
Abstract ........................................................................................................................ 2 
Table of Figures ......................................................................................................... 10 
List of Tables.............................................................................................................. 22 
List of Abbreviations and Symbols ............................................................................ 23 
(Dedication) 27 ......................................................................................................... إهداء 
Acknowledgements .................................................................................................... 28 
Conferences and Publications .................................................................................... 30 
Chapter One ............................................................................................................... 31 
1. Overview of bioactive microbial natural products and manipulation of biosynthetic 
pathways ..................................................................................................................... 31 
1.1. Overview of bioactive microbial natural products ......................................... 31 
1.2. Challenges and opportunities in natural product discovery ........................... 40 
1.3. Mining and manipulation of NPBPs for natural product discovery ............... 42 
1.3.1. Nutritional manipulation ................................................................. 49 
1.3.2. Epigenetic manipulation .................................................................. 56 
 HDACIs .................................................................................... 59 
 DNMTIs .................................................................................... 67 
 Concomitant epigenetic modifiers ............................................ 70 
 Final remarks ............................................................................ 72 
1.4. Aims ............................................................................................................... 73 
Chapter Two ............................................................................................................... 74 
2. Nutritional and epigenetic manipulation in E. gracilis .......................................... 74 
2.1. Introduction .................................................................................................... 74 
2.2. Results and discussion .................................................................................... 75 
2.2.1. Acidic and basic extracts of E. gracilis in EG:JM .......................... 75 




 L-Glutamate as a nitrogen source ............................................. 77 
 Metabolic profiles of E. gracilis in modified media................. 78 
 Extraction of E. gracilis with methanol versus ethyl acetate ... 83 
 Three-litre culture and method development for separation..... 84 
 Liquid-liquid extraction ............................................................ 85 
 Epigenetic modifiers for metabolite induction ......................... 86 
 Supplementation of complex medium with glutamate ............. 87 
 Supplementation of synthetic medium with amino acids ......... 88 
 Supplementation of synthetic medium with Asn and Glu ........ 89 
 Determination of the optimum time for extraction ................. 91 
2.3. Conclusions and future work .......................................................................... 92 
2.4. Materials and methods .................................................................................... 93 
2.4.1. General methods and materials ....................................................... 93 
2.4.2. Cultivation of E. gracilis in EG:JM ................................................ 93 
 Acid-base extraction ................................................................. 95 
2.4.3. LC-PDA-MS analysis ..................................................................... 96 
2.4.4. Media modification and cultivation ................................................ 96 
2.4.5. Extraction of modified media cultures ............................................ 97 
2.4.6. HPLC analysis ................................................................................. 97 
2.4.7. Cultivation and extraction of 10-mL cultures in 50-mL tubes ........ 98 
2.4.8. Three-litre culture and method development for separation ........... 99 
2.4.9. UHPLC analysis .............................................................................. 99 
2.4.10. Liquid-liquid extraction ............................................................... 100 
2.4.11. Cultivation with epigenetic modifiers ......................................... 100 




Chapter Three ........................................................................................................... 103 
3. Dereplication, isolation, structure elucidation and bioassays of euglenatides A-E
 .................................................................................................................................. 103 
3.1. Introduction .................................................................................................. 103 
3.2. Results and discussion .................................................................................. 104 
3.2.1. High-resolution MS and dereplication .......................................... 104 
3.2.2. Large-scale cultivation, isolation and purification ........................ 105 
3.2.3. Structure elucidation of E. gracilis metabolites A-E .................... 109 
3.2.4. Stereochemistry assignment of euglenatides A-E ......................... 116 
 Crystallisation ......................................................................... 116 
 Marfey’s analysis .................................................................... 117 
3.2.5. Antimicrobial activity of euglenatides A-E................................... 123 
3.2.6. Antiproliferative activity of euglenatide B .................................... 124 
3.2.7. Antinematodal activity of euglenatide C ....................................... 125 
3.2.8. Algastatic activity of euglenatide B in E. gracilis ........................ 126 
3.2.9. Related metabolites produced by E. sanguinea and E. mutabilis . 128 
3.2.10. Large-scale cultivation of E. sanguinea ...................................... 131 
3.3. Overall discussion and conclusion ............................................................... 133 
3.4. Materials and methods .................................................................................. 134 
3.4.1. General experiments and materials ............................................... 134 
3.4.2. High-resolution MS and dereplication .......................................... 134 
3.4.3. Large-scale cultivation, isolation and purification ........................ 135 
3.4.4. Crystallisation and chemical derivatisation ................................... 136 
3.4.5. Marfey’s analysis .......................................................................... 137 




3.4.7. Antiproliferative assay .................................................................. 141 
3.4.8. Antinematodal and algastatic activity ........................................... 142 
3.4.9. Euglenatide-related metabolites and molecular networking ......... 143 
3.4.10. Large-scale cultivation of E. sanguinea ...................................... 144 
Chapter Four ............................................................................................................ 145 
4. Nutritional and epigenetic manipulation in Aspergillus....................................... 145 
4.1. Introduction .................................................................................................. 145 
4.2. Results and discussion .................................................................................. 146 
4.2.1. Genome mining ............................................................................. 146 
4.2.2. Epigenetic manipulation of A. carbonarius in PDB ..................... 147 
4.2.3. Epigenetic and nutritional manipulation of A. bombycis .............. 150 
4.2.4. Epigenetic experiments in Aspergillus complete medium (this section 
is adapted from our publication in the Journal of Antibiotics[218])................... 153 
4.2.5. Concomitant use of epigenetic modifiers in Aspergillus complete 
medium at different stages (the experiments in this section were performed by 
undergraduate students under my supervision) ................................................ 158 
4.3. Overall discussion and conclusion ............................................................... 159 
4.4. Materials and methods .................................................................................. 160 
4.4.1. General experimental procedures .................................................. 160 
4.4.2. Fungal strains and inocula preparation .......................................... 161 
4.4.3. Epigenetic manipulation of A. carbonarius in PDB ..................... 162 
4.4.4. Epigenetic and nutritional manipulation of A. bombycis .............. 163 
4.4.5. Epigenetic experiments in Aspergillus complete medium ............ 164 
 Small-scale cultivation, extraction and LC-MS analysis ........ 164 




 Large scale fermentation and extraction (this part was conducted 
with the help of undergraduate students) ...................................................... 166 
 Isolation and structure elucidation .......................................... 166 
Chapter Five ............................................................................................................. 168 
5. Epigenetic and nutritional manipulation in actinomycetes .................................. 168 
5.1. Introduction .................................................................................................. 168 
5.2. Results and discussion .................................................................................. 169 
5.3. Overall discussion and conclusion ............................................................... 176 
5.4. Materials and methods .................................................................................. 176 
5.4.1. General experimental procedures .................................................. 176 
5.4.2. Epigenetic and nutritional manipulation ....................................... 177 
Chapter Six ............................................................................................................... 178 
6. Overall conclusion and future work ..................................................................... 178 
7. References ............................................................................................................ 180 
8. Appendices ........................................................................................................... 189 
8.1. IR spectra of euglenatides A-E ..................................................................... 189 
8.2. NMR tables of euglenatides C-E. ................................................................. 191 
8.3. NMR spectra of  euglenatide A in DMSO-d6 ............................................... 194 
8.3.1. 1H NMR spectrum of euglenatide A in DMSO-d6 ........................ 194 
8.3.2. 13C NMR spectrum of euglenatide A in DMSO-d6 ....................... 194 
8.3.3. COSY NMR spectrum of euglenatide A in DMSO-d6 ................. 195 
8.3.4. HSQC NMR spectrum of euglenatide A in DMSO-d6 ................. 195 
8.3.5. HMBC NMR spectrum of euglenatide A in DMSO-d6 ................ 196 
8.3.6. NOESY NMR spectrum of euglenatide A in DMSO-d6 ............... 196 




8.4.1. 1H NMR spectrum of euglenatide B in DMSO-d6 ........................ 197 
8.4.2. 13C NMR spectrum of euglenatide B in DMSO-d6 ....................... 197 
8.4.3. COSY NMR spectrum of euglenatide B in DMSO-d6 .................. 198 
8.4.4. HSQC NMR spectrum of euglenatide B in DMSO-d6 .................. 198 
8.4.5. HMBC NMR spectrum of euglenatide B in DMSO-d6 ................. 199 
8.4.6. NOESY NMR spectrum of euglenatide B in DMSO-d6 ............... 199 
8.5. NMR spectra of  euglenatide C in DMSO-d6 ............................................... 200 
8.5.1. 1H NMR spectrum of euglenatide C in DMSO-d6 ........................ 200 
8.5.2. 13C NMR spectrum of euglenatide C in DMSO-d6 ....................... 200 
8.5.3. COSY NMR spectrum of euglenatide C in DMSO-d6 .................. 201 
8.5.4. HSQC NMR spectrum of euglenatide C in DMSO-d6 .................. 201 
8.5.5. HMBC NMR spectrum of euglenatide C in DMSO-d6 ................. 202 
8.5.6. NOESY NMR spectrum of euglenatide C in DMSO-d6 ............... 202 
8.6. NMR spectra of  euglenatide D in DMSO-d6 ............................................... 203 
8.6.1. 1H NMR spectrum of euglenatide D in DMSO-d6 ........................ 203 
8.6.2. 13C NMR spectrum of euglenatide D in DMSO-d6 ....................... 203 
8.6.3. COSY NMR spectrum of euglenatide D in DMSO-d6 ................. 204 
8.6.4. HSQC NMR spectrum of euglenatide D in DMSO-d6 ................. 204 
8.6.5. HMBC NMR spectrum of euglenatide D in DMSO-d6 ................ 205 
8.6.6. NOESY NMR spectrum of euglenatide D in DMSO-d6 ............... 205 
8.7. NMR spectra of  euglenatide E in DMSO-d6 ............................................... 206 
8.7.1. 1H NMR spectrum of euglenatide E in DMSO-d6 ......................... 206 
8.7.2. 13C NMR spectrum of euglenatide E in DMSO-d6 ........................ 206 




8.7.4. HSQC NMR spectrum of euglenatide E in DMSO-d6 .................. 207 
8.7.5. HMBC NMR spectrum of euglenatide E in DMSO-d6 ................. 208 
8.7.6. NOESY NMR spectrum of euglenatide E in DMSO-d6 ............... 208 
8.8. Comparison of 1H and 13C NMR chemical shifts in euglenatides with 
nemamide A triene sidechain ............................................................................... 209 
8.9. Key NOESY and J coupling in euglenatide E ............................................. 210 
8.10. Key NOESY and J coupling in euglenatide B ........................................... 211 
8.11. Comparison of euglenatide E CD spectrum to nemamide A[186] ................ 212 
8.12. Antimicrobial activity of E. gracilis metabolites (A-E) ............................. 213 
8.13. Lists of natural products known or predicted to be produced by A. calidoustus, 
A. westerdijkiae and their related species ............................................................. 214 
8.14. Spectra of A. calidoustus and A. westerdijkiae metabolites ....................... 224 
8.15. Predicted gene clusters for emericellamides and ochratoxin A ................. 236 
8.16. The complete chromatograms for chapter 2 ............................................... 237 
8.16.1. The complete chromatograms for Figure 2.2 .............................. 237 
8.16.2. The complete chromatograms for Figure 2.4 .............................. 239 
8.16.3. The complete chromatograms for Figure 2.10 ............................ 240 
8.16.4. The complete chromatograms for Figure 2.12 ............................ 240 
8.16.5. The complete chromatograms for Figure 2.13 ............................ 241 
8.16.6. The complete chromatograms for Figure 2.14 ............................ 242 
8.16.7. The complete chromatograms for Figure 2.15 ............................ 244 
8.16.8. The complete chromatograms for Figure 2.16 ............................ 244 
8.17. The complete chromatograms for chapter 3 ............................................... 246 
8.17.1. The complete chromatograms for Figure 3.4 .............................. 246 




8.17.3. The complete chromatograms for Figure 3.31 ............................ 247 
8.17.4. The complete chromatogram for Figure 3.33 .............................. 247 
8.18. The complete chromatograms for chapter 4 ............................................... 248 
8.18.1. The complete chromatograms for Figure 4.3 .............................. 248 
8.18.2. The complete chromatograms for Figure 4.4 .............................. 249 
8.18.3. The complete chromatograms for Figure 4.5 .............................. 249 
8.18.4. The complete chromatograms for Figure 4.12 (A) ..................... 250 
8.18.5. The complete chromatograms for Figure 4.12 (B) ...................... 250 
8.19. The complete chromatograms for chapter 5 ............................................... 251 
8.19.1. The complete chromatograms for Figure 5.2 .............................. 251 
8.20. The complete chromatograms for chapter 5 ............................................... 252 
8.20.1. The complete chromatograms for Figure 5.3 .............................. 252 
8.20.2. The complete chromatograms for Figure 5.6 .............................. 253 
8.20.3. The complete chromatograms for Figure 5.7 .............................. 253 
 
Table of Figures 
Figure 1.1 Small-molecule drugs approved by the FDA between January 1981 and 
September 2019, based on data reported by Newman and Cragg.[11] ........................ 33 
Figure 1.2 Small-molecule anticancer drugs approved by the FDA between January 
1981 and September 2019, based on data reported by Newman and Cragg.[11] ........ 33 
Figure 1.3 Small-molecule anti-infective drugs approved by the FDA between January 
1981 and September 2019, based on data reported by Newman and Cragg.[11] ........ 33 




Figure 1.5 Approved antibacterial agents originating from ascomycetous fungi. ..... 35 
Figure 1.6 Approved antifungal agents isolated from actinomycete bacteria. ........... 36 
Figure 1.7 Approved antifungal agents originating from ascomycetous fungi. ......... 36 
Figure 1.8 Source of antifungal leads from natural products discovered between 2010 
and 2019 with unique scaffolds and an MIC < 10 μg/mL or IC50 < 10 μM against 
human pathogenic fungi, this figure is adapted from Aldholmi et.al.[24] ................... 37 
Figure 1.9 Chemical structures of actinomycin D and plicamycin. ........................... 38 
Figure 1.10 Chemical structures of bleomycins A2 and B2. ....................................... 38 
Figure 1.11 Chemical structures of approved mitomycin and anthracyclines. .......... 39 
Figure 1.12 Chemical structures of ixabepilone and paclitaxel. ................................ 39 
Figure 1.13 BGC of griseofulvin showing the genes involved in griseofulvin 
biosynthesis clustered together, this figure is adapted from Cacho et.al.[48] .............. 41 
Figure 1.14 Workflow for microbial natural product discovery through nutritional and 
epigenetic manipulation. ............................................................................................ 43 
Figure 1.15 Chemical structures of natural products 1-7. .......................................... 50 
Figure 1.16 Chemical structures of natural products 8-10. ........................................ 51 
Figure 1.17 Chemical structures of natural products 11-14. ...................................... 52 
Figure 1.18 Chemical structures of natural products 15-17. ...................................... 53 
Figure 1.19 Chemical structures of natural products 18-24. ...................................... 54 
Figure 1.20 Chemical structures of natural products 25-27. ...................................... 55 
Figure 1.21 Chemical structure of natural product 28. .............................................. 56 
Figure 1.22 An illustrative diagram of heterochromatin and euchromatin. ............... 57 
Figure 1.23 Chemical structures of natural products 29-36. ...................................... 58 




Figure 1.25 Illustration of the interaction between DNA and protonated histones (A), 
and DNA and acetylated histones (B). ....................................................................... 59 
Figure 1.26 Examples of zinc-dependent HDAC inhibitors. ..................................... 60 
Figure 1.27 Examples of secondary metabolites (44-50) induced with TSA. ........... 61 
Figure 1.28 Examples of secondary metabolites (51-61) induced by vorinostat. ...... 62 
Figure 1.29 Examples of secondary metabolites induced by SBHA. ........................ 63 
Figure 1.30 Examples of secondary metabolites induced by SB. .............................. 65 
Figure 1.31 Examples of secondary metabolites induced by VPA. ........................... 65 
Figure 1.32 Examples of NAD-dependent HDAC inhibitors. ................................... 66 
Figure 1.33 Examples of secondary metabolites induced by nicotinamide. .............. 67 
Figure 1.34 Examples of nucleoside and non-nucleoside DNMTIs. ......................... 68 
Figure 1.35 Examples of secondary metabolites induced by 5-AC. .......................... 69 
Figure 1.36 An example of secondary metabolites induced by hydralazine.............. 70 
Figure 1.37 Examples of secondary metabolites induced by the concomitant use of 5-
AC and SBHA. ........................................................................................................... 71 
Figure 1.38 Examples of secondary metabolites induced by the concomitant use of 
RG108 and SBHA. ..................................................................................................... 72 
Figure 2.1 Examples of microalgal PKSs and NRPSs. .............................................. 75 
Figure 2.2 TACs (200-600 nm; 100 × 2.1mm, 2.6μm Kinetex C18 column; 0.5 mL/min 
flow rate; 20-100% acetonitrile over 10 min) of E. gracilis extracts cultivated in 
EG:JM compared to the medium control extracts...................................................... 76 
Figure 2.3 Comparison of the growth rate of E. gracilis in complex medium, synthetic 
medium + 30 mM Glu, synthetic medium + 30 mM Glu + Glc and synthetic medium.




Figure 2.4 HPLC traces (at 270 nm; 150 × 4.6mm, 5μm Agilent C18 column; 1 
mL/min flow rate; 50-100% acetonitrile over 22 min) of E. gracilis cell extracts 
cultivated in synthetic medium + 30 mM Glu, synthetic medium + 30 mM Glu + Glc, 
synthetic medium and complex medium. .................................................................. 79 
Figure 2.5 Total absorbance chromatogram (200-600 nm; 100 × 2.1mm, 2.6μm 
Kinetex C18 column; 0.5 mL/min flow rate; 20-100% acetonitrile over 10 min) of E. 
gracilis extract cultivated in  synthetic medium + 30 mM Glu. ................................ 80 
Figure 2.6 UV profile of E. gracilis metabolites showing maxima of absorbance at 
260, 269 and 280 nm. ................................................................................................. 80 
Figure 2.7 Positive ion mode MS spectra of A-E showing [M+Na]+ and two 
characteristic protonated product ions corresponding to a neutral loss of 50 Da (loss of 
H2O and MeOH) and 32 Da (loss of MeOH). ............................................................ 81 
Figure 2.8  Negative ion mode MS spectra of A-E showing [M-H]- and [M+Cl]-. ... 82 
Figure 2.9 E. gracilis cells suspended in MeOH or EtOAc. ...................................... 83 
Figure 2.10 Comparative TAC (200-600 nm; 100 × 2.1mm, 2.6μm Kinetex C18 
column; 0.5 mL/min flow rate; 20-100% acetonitrile over 10 min) of E. gracilis cells 
extracted with MeOH (MeOH extract) and EtOAc (EtOAc extract). ........................ 84 
Figure 2.11 E. gracilis cell extract partitioned between 90% MeOH (aqueous MeOH 
layer) and pure hexane (hexane layer) in a separating funnel. ................................... 85 
Figure 2.12 Comparative HPLC traces (at 270 nm; 150 × 4.6mm, 5μm Agilent C18 
column; 1 mL/min flow rate; 20-100% acetonitrile over 22 min) of E. gracilis cell 
MeOH extract partitioned with hexane (MeOH + hexane), MeOH extract (MeOH) and 
dried MeOH extract dissolved in water (Water). ....................................................... 86 
Figure 2.13 Comparative TAC (200-600 nm; 100 × 2.1mm, 2.6μm Kinetex C18 




cultivated in the synthetic medium + 30 mM Glu and complex medium + 30 mM Glu.
 .................................................................................................................................... 88 
Figure 2.14 Comparative HPLC traces (at 270 nm; 150 × 4.6mm, 5μm Agilent C18 
column; 1 mL/min flow rate; 20-100% acetonitrile over 22 min) of E. gracilis extracts 
cultivated in different amino acids and complex medium with neutral pH and adjusted 
to 4.8. .......................................................................................................................... 89 
Figure 2.15 Comparative UHPLC traces (at 270 nm; 100 × 2.1mm, 2.6μm Accucore 
C18 column; 0.5 mL/min flow rate; 20-100% acetonitrile over 10 min) of E. gracilis 
cultivated in synthetic medium + 15 mM Glu, in synthetic medium + 15 mM Asn and 
in synthetic medium + 15 mM Glu + 15 mM Asn. .................................................... 90 
Figure 2.16 Comparative UHPLC traces (at 270 nm; 100 × 2.1mm, 2.6μm Accucore 
C18 column; 0.5 mL/min flow rate; 20-100% acetonitrile over 10 min) of E. gracilis 
extracts from day 1 to day 13 of inoculation.............................................................. 91 
Figure 2.17 Acid-base extraction procedure of E. gracilis cultures. ......................... 95 
Figure 3.1 Chemical structures of euglenapterin and euglenophycin. ..................... 103 
Figure 3.2 Negative ion mode high-resolution MS spectra of A-E. ........................ 105 
Figure 3.3 Initial separation of E. gracilis metabolites (target metabolites) on flash 
chromatography........................................................................................................ 106 
Figure 3.4 Semi-preparative HPLC trace (at 270 nm) of E. gracilis metabolites (A-E).
 .................................................................................................................................. 106 
Figure 3.5 LC-UV-MS chromatograms and MS spectra of purified A. .................. 107 
Figure 3.6 LC-UV-MS chromatograms and MS spectra of purified B. .................. 107 
Figure 3.7 LC-UV-MS chromatograms and MS spectra of purified C. .................. 108 
Figure 3.8 LC-UV-MS chromatograms and MS spectra of purified D. .................. 108 




Figure 3.10 Key COSY and HMBC correlations used to establish the molecular 
connectivity of compound B. ................................................................................... 112 
Figure 3.11 Key COSY and HMBC correlations used to establish the molecular 
connectivity of compound E. ................................................................................... 112 
Figure 3.12 Key COSY and HMBC correlations used to establish the molecular 
connectivity of compound C. ................................................................................... 113 
Figure 3.13 Key COSY and HMBC correlations used to establish the molecular 
connectivity of compound A. ................................................................................... 115 
Figure 3.14 Key COSY and HMBC correlations used to establish the molecular 
connectivity of compound D. ................................................................................... 115 
Figure 3.15 Chemical structures of nemamides A and B......................................... 116 
Figure 3.16 Chemical derivatisation and negative ion mode mass spectrum of Asp.
 .................................................................................................................................. 118 
Figure 3.17 Extracted ion chromatograms of the m/z 412 in derivatised Asp standards 
and euglenatides A and B hydrolysates. .................................................................. 118 
Figure 3.18 Chemical derivatisation and negative ion mode mass spectrum of BAIBA.
 .................................................................................................................................. 119 
Figure 3.19 Extracted ion chromatograms of the m/z 382 in derivatised BAIBA 
standards and euglenatides A and B hydrolysates. .................................................. 120 
Figure 3.20 Acid hydrolysis of L-anti-norvalinate derivative, and chemical 
derivatisation and negative ion mode mass spectrum of Dnv. ................................. 121 
Figure 3.21 Extracted ion chromatograms and spectra of the m/z 428 in derivatised 
Dnv standards and euglenatides A and B hydrolysates. .......................................... 122 
Figure 3.22 Chemical structures and proposed configurations of euglenatides A and 




Figure 3.23 Chemical structures and proposed configurations of euglenatides B, C and 
E. .............................................................................................................................. 123 
Figure 3.24 Dose–response curves and corresponding IC50 values of C. albicans 
incubated with euglenatides A, B, C, D and E. ........................................................ 124 
Figure 3.25 Dose–response curves and corresponding IC50 values of A. fumigatus 
incubated with euglenatides A, B, C, D and E. ........................................................ 124 
Figure 3.26 Dose–response curves of THP-1, MCF-7 and A-549 cell lines incubated 
with euglenatide B or vorinostat (positive control). Data points represent the average 
± standard error of three replicates. .......................................................................... 125 
Figure 3.27 Growth of E. gracilis in EG:JM after four days of treatment with 
euglenatide B (1.25 μM to 100 μM), 1mM vorinostat or 1% DMSO (control); data 
represent the average ± standard error of three replicates. ....................................... 127 
Figure 3.28 Growth of E. gracilis in EG:JM after seven days of treatment with 
euglenatide B (1.25 μM to 100 μM), 1mM vorinostat or 1% DMSO (control); data 
represent the average ± standard error of three replicates. ....................................... 127 
Figure 3.29 Growth of E. gracilis in EG:JM (EG:JM) and synthetic medium + 30 mM 
Asn (Asn) after four days of treatment with 50 μM euglenatide B; data represent the 
average ± standard error of three replicates. ............................................................ 127 
Figure 3.30 Comparative TAC (200-600 nm) of E sanguinea cultivated in synthetic 
medium + 60 mM Asn, complex medium and synthetic medium + 30 mM Asn + 30 
mM Glu. ................................................................................................................... 129 
Figure 3.31 Comparative total absorbance (200-600 nm) and total ion chromatograms 
of E. mutabilis cultivated in complex medium. ....................................................... 129 
Figure 3.32 A molecular network of the euglenatide-related metabolites produced by 




node represents the precursor mass of a single metabolite, and the colour indicates the 
relative abundance of each metabolite between strains. .......................................... 131 
Figure 3.33 Semi-preparative HPLC trace (at 270 nm) of euglenatide-related 
metabolites produced by E. sanguinea..................................................................... 132 
Figure 4.1 BGCs detected by antiSMASH in the genomes of  A. calidoustus, A. 
westerdijkiae, A. bombycis, A. carbonarius and A. fischeri, and their corresponding 
growth on PDA plates. ............................................................................................. 146 
Figure 4.2 A. carbonarius cultures treated with 100 µM vorinostat (B), 200 µM 5-AC 
(C), or a combination of 50 µM vorinostat and 100 µM 5-AC (D) compared to the 
epigenetic-free control (A). ...................................................................................... 147 
Figure 4.3 HPLC-UV chromatograms (360 nm) of A. carbonarius (first experiment, 
seven-day cultivation), control and with 100 μM vorinostat, 200 μM 5-AC or a 
combination of 50 μM vorinostat and 100 μM 5-AC. ............................................. 148 
Figure 4.4 HPLC-UV chromatograms (360 nm) of A. carbonarius (second experiment, 
one-week cultivation), control and with 200 μM 5-AC or a combination of 50 μM 
vorinostat and 100 μM 5-AC. .................................................................................. 149 
Figure 4.5 HPLC-UV chromatograms (360 nm) of A. carbonarius (second experiment, 
two-week cultivation), control and 200 μM 5-AC or a combination of 50 μM vorinostat 
and 100 μM 5-AC. ................................................................................................... 149 
Figure 4.6 Volcano plot representation of variation in A. bombycis metabolite profiles 
with two different inocula, SMYA and agar plugs, (n = 8) (-log10 of t-test statistical 
p-value on y-axis vs. log2 of ion intensity ratio on x-axes; the horizontal dashed line 
shows where p-value = 0.05). .................................................................................. 150 
Figure 4.7 Volcano plot representation of variation in A. bombycis metabolite profiles 




p-value on y-axis vs. log2 of ion intensity ratio on x-axes; the horizontal dashed line 
shows where p-value = 0.05). .................................................................................. 151 
Figure 4.8 Volcano plot representation of variation in A. bombycis metabolite profiles 
in the presence of vorinostat using agar plugs inoculum, (n = 8) (-log10 of t-test 
statistical p-value on y-axis vs. log2 of ion intensity ratio on x-axes; the horizontal 
dashed line shows where p-value = 0.05). ............................................................... 152 
Figure 4.9 Growth inhibition of MRSA (A) and A. fumigatus (B) in the presence of A. 
bombycis extracts obtained from cultures grown in PDB with and without epigenetic 
modifiers using two types of inocula, SMYA inoculum (*) or agar plugs (#), along 
with extracts from cultures grown in elven different media inoculated with SMYA 
culture. Data points represent the average ± standard error of eight replicates. ...... 152 
Figure 4.10 (A) Volcano plot representation of variation in metabolite profiles of A. 
calidoustus extracts (n = 6), (-log10 of t-test statistical p-value on y-axis vs. log2 of 
ion intensity ratio on x-axes; the horizontal dashed line shows where p-value = 0.05). 
Three metabolites were identified: emericellamides A and B were reduced in 
production levels by vorinostat whereas phenylahistin was increased. (B) Volcano plot 
representation of variation in metabolic profiles of A. westerdijkiae extracts (n = 6). 
Two metabolites were identified: ochratoxin A was reduced in production levels by 
vorinostat whereas penicillic acid was increased. .................................................... 154 
Figure 4.11 Chemical structures of emericellamide A, emericellamide B and 
phenylahistin from A. calidoustus, and ochratoxin A and penicillic acid from A. 
westerdijkiae. ........................................................................................................... 155 
Figure 4.12 (A) HPLC-UV chromatograms (254 nm) of A. calidoustus fermentations, 
control and with 100 μM vorinostat. The metabolite I induced by vorinostat is 




control and with 100 μM vorinostat. The metabolite II induced by vorinostat is 
indicated, as well as the drug itself. ......................................................................... 156 
Figure 4.13 Chemical structure of the phenylahistin synthetic analogue, plinabulin.
 .................................................................................................................................. 157 
Figure 5.1 Examples of medically important drugs that originated from actinomycete 
bacteria. .................................................................................................................... 168 
Figure 5.2 Comparative TACs of Streptomyces sp. CMB-0406 EtOAc extracts from 
cultures cultivated in the absence (control) or the presence of epigenetic modifiers.
 .................................................................................................................................. 170 
Figure 5.3 Comparative TACs (200-600 nm) of Streptomyces sp. CMB-0406 MeOH 
extracts from cultures cultivated in the absence (control) or the presence of 10 µM or 
50 µM vorinostat as well as the vorinostat control (100 µM vorinostat in MeOH) 
showing a peak of vorinostat at 2.65 min retention time. ........................................ 171 
Figure 5.4 MS (positive ion mode) and UV spectra of vorinostat (vorinostat control) 
and vorinostat-related products (peak 1 and peak 2). .............................................. 172 
Figure 5.5 Chemical structures of heronamides A-C. .............................................. 173 
Figure 5.6 Comparative TACs (200-600 nm) of Streptomyces sp. CMB-0406 
cultivated in SM7 and SV2 medium for four days in the absence (control) and the 
presence of 50 µM vorinostat................................................................................... 174 
Figure 5.7 Comparative TACs (200-600 nm) of vorinostat-related products observed 
with Streptomyces sp. CMB-0406 and Saccharopolyspora KY21 cultivated in SM7 
for four days in the presence of 50 µM vorinostat. .................................................. 175 
Figure 5.8 UV and MS (positive ion mode) spectra of the new vorinostat-related 
product observed with Saccharopolyspora KY21 in SM7 containing 50 µM vorinostat.




Figure 8.1 IR spectrum of euglenatide A. ................................................................ 189 
Figure 8.2 IR spectrum of euglenatide B. ................................................................ 189 
Figure 8.3 IR spectrum of euglenatide C. ................................................................ 190 
Figure 8.4 IR spectrum of euglenatide D. ................................................................ 190 
Figure 8.5 IR spectrum of euglenatide E. ................................................................ 190 
Figure 8.6 Dose–response curves of bacterial strains (MSSA, MRSA and E. coli) 
incubated with euglenatides A, B, C, D and E. ........................................................ 213 
Figure 8.7 Euglenatides A-E dose-response curves tested against C. tropicalis. The 
growth inhibition with the compound is calculated relative to the growth inhibition in 
the negative controls that is equal to 0. .................................................................... 213 
Figure 8.8 Euglenatides A-E dose-response curves tested against C. krusei. The growth 
inhibition with the compound is calculated relative to the growth inhibition in the 
negative controls that is equal to 0. .......................................................................... 214 
Figure 8.9 HRMS spectrum of phenylahistin. ......................................................... 224 
Figure 8.10 UV spectrum of phenylahistin. ............................................................. 224 
Figure 8.11 1H NMR spectrum of phenylahistin in CDCl3. ..................................... 225 
Figure 8.12 13C NMR spectrum of phenylahistin in CDCl3. ................................... 225 
Figure 8.13 COSY NMR spectrum of phenylahistin in CDCl3. .............................. 226 
Figure 8.14 HSQC NMR spectrum of phenylahistin in CDCl3. .............................. 226 
Figure 8.15 HMBC NMR spectrum of phenylahistin in CDCl3. ............................. 227 
Figure 8.16 HRMS spectrum of penicillic acid. ...................................................... 227 
Figure 8.17 UV spectrum of penicillic acid. ............................................................ 228 
Figure 8.18 IR spectrum of penicillic acid. .............................................................. 228 
Figure 8.19 1H NMR spectrum of penicillic acid in DMSO-d6. ............................. 229 




Figure 8.21 DEPT 135 NMR spectrum of penicillic acid in DMSO-d6. ................. 230 
Figure 8.22 COSY NMR spectrum of penicillic acid in DMSO-d6. ....................... 230 
Figure 8.23 HSQC NMR spectrum of penicillic acid in DMSO-d6. ....................... 231 
Figure 8.24 HMBC NMR spectrum of penicillic acid in DMSO-d6. ...................... 231 
Figure 8.25 Fragmentation patterns of emericellamides A and B. .......................... 232 
Figure 8.26 MS spectrum of emericellamide A. ...................................................... 233 
Figure 8.27 MS/MS spectrum of emericellamide A. ............................................... 233 
Figure 8.28 MS spectrum of emericellamide B. ...................................................... 234 
Figure 8.29 MS/MS spectrum of emericellamide B. ............................................... 234 
Figure 8.30 MS spectrum of ochratoxin A............................................................... 235 
Figure 8.31 MS/MS spectrum of ochratoxin A. ....................................................... 235 
Figure 8.32 Ochratoxin A predicted gene cluster. ................................................... 236 






List of Tables 
Table 2.1 EG (E. gracilis) medium. ........................................................................... 94 
Table 2.2 JM (Jaworski's medium). ........................................................................... 94 
Table 3.1 1H and 13C NMR data (500 and 125 MHz, DMSO-d6) of compound B. . 110 
Table 3.2 1H and 13C NMR data (500 and 125 MHz, DMSO-d6) of compound A.. 114 
Table 5.1 Comparison of the intensities of the vorinostat products and heronamides in 
Streptomyces sp. CMB-0406 cultures in SM7 and SV2 media with and without 50 µM 
vorinostat. ................................................................................................................. 173 
Table 8.1 1H and 13C NMR data (500 and 125 MHz, DMSO-d6) for euglenatide E.
 .................................................................................................................................. 191 
Table 8.2 1H and 13C NMR data (500 and 125 MHz, DMSO-d6) for euglenatide C.
 .................................................................................................................................. 192 
Table 8.3 1H and 13C NMR data (500 and 125 MHz, DMSO-d6) for euglenatide D.
 .................................................................................................................................. 193 
Table 8.4 Known metabolites from A. calidoustus and A. ustus.............................. 214 
Table 8.5 Known metabolites from A. westerdijkiae and A. ochraceus. ................. 219 
Table 8.6 Natural product BGCs predicted by antiSMASH from A. calidoustus.... 222 

















































Human lung adenocarcinoma epithelial cells 
Adenosine diphosphate ribose 
Alanine 
antibiotics and Secondary Metabolite Analysis Shell 
Asparagine 
Aspartate 
Biosynthetic gene clusters 
Broad doublet of doublets 
Broad doublet 
Broad singlet 






Doublet of doublets 
Dimethyl sulfoxide 
Deoxyribonucleic acid 
Inhibitors of DNMTs 
DNA methyltransferases 
Dictionary of natural products 
Doublet of triplets 
1:1, euglena gracilis medium:Jaworski's medium 
Epigallocatechin gallate 
Ethyl acetate 
















































Global natural product social molecular networking 





Inhibitors of HDACs 
Histone deacetylases 
Heteronuclear multiple bond coherence 
High-performance liquid chromatography 
High-resolution mass spectrometry 
Heteronuclear single quantum coherence  
Hertz 
Half maximal inhibitory concentration 
Infrared radiation 







Per square meter 
















































Methicillin-resistant Staphylococcus aureus 
Mass spectrometry 
Coupled mass spectrometers 











Mimics of natural products 
Nuclear magnetic resonance 
Nuclear overhauser effect spectroscopy 
Natural products atlas 
Natural product biosynthetic pathways 
Non-ribosomal peptides 
Non-ribosomal peptide synthetases 
One strain, many compounds 
Photodiode array 
Potato dextrose agar medium 
Potato dextrose broth 
PDB medium supplemented with agar 
Potato dextrose yeast broth 




Pounds per square inch 
Quartet 
Ribosomally synthesised and post-translationally modified peptides 


































Sabouraud dextrose agar 
Serine 
Secondary metabolite unknown regions finder 
Triplet 
Zero time 
Total absorbance chromatogram 
Final time 
Acute monocytic leukaemia 
Trichostatin a 
Unit 













 (Dedication) إهداء  
    ﷽ 
إلى:  العمل  اهذ أهدي وشكره عد حمد هللاب   
.دراستي عن انتباهي يُشتتايَل  ك  ل   وهمومهما أوجاعهما عني أخفياو   دعماني يناللذ   العزيزين ي  الد  و  
.ربتيغُ عانتني أثناء أ التي الغالية زوجتي  
. غلبها النعاسي  قبل أنعودتي من المعمل ت انتظر   ما ا  ركثي  التي الحبيبة ابنتي  
. ت إلى ربها وما زالت طفلةل  وأختي التي رح   طفَل   لتُ إلى ربه وما ز   ل  أخي الذي رح    
وفخورين بي.داعمين لي كانوا إخواني وأخواتي الذين   
. دراستيفترة  طوالدعموني الذين  زوجتي وإخوان ي  والد    
.هماحلين إلى رب  الباقين منهم والر  وأصدقائي  اربيأق  
.المخلصينأساتذتي   
 
In the Name of Allah, the Most Gracious, the Most Merciful 
After praising and thanking Allah, I dedicate this work to: 
My dear parents who supported me and hid their diseases and concerns 
from me so that they do not distract me from my studies. 
My beloved wife who assisted me through my expatriate experience. 
My beloved daughter who had often been waiting for my return from the lab before 
falling asleep. 
My late brother who passed away when I was still a child and my late sister who 
passed away when she was still a child. 
My brothers and sisters who have been supportive and proud of me. 
My parents and brothers-in-law who supported me throughout my studies. 
My relatives and friends who are still alive and those who have passed away. 





I would like to express my profound appreciation to my supervisor Prof. A. 
Ganesan for the encouragement, advice, patience, motivation and intellectual support 
throughout my doctoral journey. I am extremely thankful to Prof. Ganesan for 
providing me with the opportunities to grow up as a researcher and build an excellent 
network with natural product scientists around the world through conferences, 
meetings and a short-term scientific mission. I would also like to thank my second 
supervisor Prof. Barrie Wilkinson, for his supportive suggestions and guidance during 
my PhD. I greatly appreciate the supervision and guidance provided by Prof. Rob Field 
during my work in his lab. I would also like to extend my sincere thanks to the students 
and researchers in my supervisors’ labs for being supportive and great friends. 
I am grateful to professors, researchers, technicians and students at the 
University of East Anglia and John Innes Centre for their collaboration, training and 
support. I express my sincere gratitude to Prof. Maria O'Connell for the excellent 
training and guidance regarding cytotoxic assays. I also thank Dr Alexei Maklakov 
and Hanne Carlsson (School of Biological Sciences, UEA) for performing the 
antinematodal experiments. Special thanks to Philip Schuler for being a supportive 
labmate and friend, as well as an amazing mycologist and pharmacologist. My thanks 
extend to Dr Mahmoud Abdelhamid, Dr Marco Cominetti, Dr Antony Hinchliffe, 
Lionel Hill, Paul Brett, Dr Gerhard Saalbach and Julia Mundy for their technical 
support and training. I am also thankful to the undergraduate students (Elizabeth 
Everingham and James Murphy) who contributed to the Aspergillus chapter of this 
thesis. 
I am grateful to our collaborators outside the Norwich Research Park for their 




molecular network and for supplying the Euglena strains. I also want to express my 
appreciation to Dr Olga Genilloud and her group at Fundación Medina, Granada, 
Spain, for hosting the short-term scientific mission. Special thanks to Dr Fernando 
Reyes, Dr Ignacio Pérez-Victoria, Dr Ruben Tormo, Dr Mercedes de la Cruz, Dr 
Caridad Díaz, Dr Jesús Martín and Daniel Carretero for their support and guidance 
during my mission. I am incredibly grateful to Prof. Thierry Gefflaut (Université 
Clermont Auvergne, France) and Dr Armin Bauer (Sanofi, UK) for supplying the 
standard amino acids that were vital for the stereochemistry assignment of 
euglenatides. 
I owe a great debt of gratitude to my dear parents, Jaber Aldholmi and Jameelah 
Alfaifi, and to my wife and daughter, Abrar Alfaifi and Reetal Aldholmi, respectively, 
for their endless support, love, encouragement and prayers. I want to extend my sincere 
gratitude to my brothers, sisters, relatives and friends who have constantly encouraged 
me and supported me throughout my studies.  
Finally, I appreciate the generous financial support provided by Imam 
Abdulrahman Bin Faisal University, Saudi Arabia. Equally appreciated is the financial 
funding of the short-term scientific mission in Spain provided by the COST action 







Conferences and Publications 
1. The results obtained with Aspergillus calidoustus and Aspergillus westerdijkiae 
have been published in the Journal of Antibiotics. M. Aldholmi, B. Wilkinson, A. 
Ganesan, J. Antibiot. (Tokyo). 2020, 73, 410–413. 
2. A review of antifungal natural products has been published in Pharmaceuticals. M. 
Aldholmi, P. Marchand, I. Ourliac-Garnier, P. Le Pape, A. Ganesan, 
Pharmaceuticals 2019, 12, 182. 
3. Poster presentation, 27th Annual GP2A Medicinal Chemistry Conference, 21st – 
23rd August 2019 in Nottingham, UK. 
4. Poster presentation, RSC Chemical Biology and Bio-organic Group Postgraduate 
Symposium, 26th April 2019 in Southampton, UK. 
5. Oral presentation, COST CM1406 Epigenetic Chemical Biology, 18th – 20th 
February 2019 in Faro, Portugal. 
6. Poster presentation, 30th International Symposium on the Chemistry of Natural 
Products and the 10th International Congress on Biodiversity (ISCNP30 & 





1. Overview of bioactive microbial natural products and 
manipulation of biosynthetic pathways 
1.1. Overview of bioactive microbial natural products 
Natural products are defined differently from one field to another with the 
broadest definition applying the term natural products to all substances from nature, 
including crude materials, extracts and isolated compounds.[1] Within the field of 
organic chemistry, the definition is confined to single chemical compounds produced 
by living organisms and commonly known as primary and secondary metabolites.[2] 
The definition within the medicinal chemistry field is restricted further to use the term 
natural products as a synonym for low-molecular-weight secondary metabolites.[3] 
Unlike secondary metabolites, primary metabolites are present in abundant amount in 
many organisms and are essential for their survivability.[2] In contrast, secondary 
metabolites are not directly involved in the growth of the producing organisms but are 
produced in small amounts for specific purposes such as competitive functions and 
communication between organisms.[4] Many secondary metabolites have biological 
activity against specific targets in prokaryotes, eukaryotes or both of them as they have 
been optimized through evolution for use against competing organisms.[5] Natural 
products can also involve compounds that are derived from natural products by partial 
synthesis (semi-synthesis) or prepared by chemical synthesis (total synthesis) if the 
resultant product is chemically equivalent to the original natural product.[6]  
There are different ways for classifying natural products, but they are commonly 




peptides, polyketides and fatty acid-derived substances, alkaloids, terpenoids and 
steroids, specialised carbohydrates and shikimic-acid-derived natural products.[1,2] 
Some natural products are hybrid products arising from more than one biosynthetic 
pathway or undergoing further modifications after the main biosynthetic reactions. 
Most microbial natural products are derived from polyketides (PKs), non-ribosomal 
peptides (NRPs) and ribosomally synthesised and post-translationally modified 
peptides (RiPPs).[7,8] PKs and NRPs are biosynthesised through chemical reactions 
catalysed by domains of mega-enzymes known as polyketide synthases (PKSs) and 
non-ribosomal peptide synthetases (NRPSs), respectively.[9]  
Natural products, their derivatives and their synthetic analogues have been 
significant contributors in the medical field as medicines themselves or as leads for 
other medicines, especially as anti-infective and anticancer agents.[10] Analysis of all 
small-molecule drugs approved by the FDA between January 1981 and September 
2019 indicated that approximately 31.6% are natural products (N) or semisynthetic 
derivatives (ND) and 35.1% are mimics of natural products or synthetic drugs with 
natural product pharmacophore (NM and S*) while only 33.3% are totally synthetic 
(S) drugs (Figure 1.1).[11] The analysis also revealed that only 15.7% of small-molecule 
anticancer drugs approved by the FDA between January 1981 and September 2019 are 
totally synthetic drugs, while the remaining owe their origin to natural products (Figure 
1.2). Of all small-molecule anti-infective drugs approved by the FDA between January 
1981 and September 2019, around 66% belong to the natural products categories (N, 





Figure 1.1 Small-molecule drugs approved by the FDA between January 1981 and September 2019, based on 
data reported by Newman and Cragg.[11] 
 
Figure 1.2 Small-molecule anticancer drugs approved by the FDA between January 1981 and September 2019, 
based on data reported by Newman and Cragg.[11] 
 
Figure 1.3 Small-molecule anti-infective drugs approved by the FDA between January 1981 and September 2019, 
based on data reported by Newman and Cragg.[11] 





















Microbial natural products represent a significant portion of approved drugs, 
particularly antimicrobial and anticancer drugs. It is estimated that 97% of all 
antibacterial natural products approved by the FDA between 1930 and 2013 were 
isolated or derived from microorganisms.[12] The main classes of antibacterial agents 
originated from actinomycete bacteria (Figure 1.4) and ascomycetous fungi (Figure 
1.5). 
 





Figure 1.5 Approved antibacterial agents originating from ascomycetous fungi. 
The first antibacterial natural product approved by the FDA was the 
aminoglycoside streptomycin, isolated from the actinomycete Streptomyces 
griseus.[13] Other examples for approved antibacterial agents originating from 
actinomycetes include tetracyclines (e.g. chlortetracycline), macrolides (e.g. 
erythromycin),  ansamycins (e.g. rifampicin), carbapenems (e.g. imipenem), 
amphenicols  (e.g. chloramphenicol), lincosamides (e.g. clindamycin), glycopeptides 
(e.g. vancomycin) and cyclic lipopeptides (e.g. daptomycin).[13–18] The antibacterial 
agents isolated from ascomycetous fungi involve penicillins (e.g. benzylpenicillin) and 
cephalosporines (e.g. cefalotin).[19,20] 
All approved antifungals of natural product origin arise from actinomycete 
bacteria (Figure 1.6) and ascomycetous fungi (Figure 1.7). Actinomycete bacteria are 
the producers of approved antifungal polyenes such as amphotericin B, nystatin and 
natamycin[21], while ascomycetous fungi are the origin of the antifungal lipopeptides 
(echinocandins) and polyketide griseofulvin.[22,23] Since the echinocandin natural 
products are not optimal in terms of pharmacokinetics, semisynthetic derivatives were 
optimised and approved for clinical use, including anidulafungin prepared from 
echinocandin B, caspofungin prepared from pneumocandin Bo, and micafungin 
prepared from FR901379.[22] In our recent review of antifungal leads from natural 
products discovered between 2010 and 2019, microbial natural products represent 65% 
of the discovered compounds with unique scaffolds and an MIC < 10 μg/mL or IC50 < 





Figure 1.6 Approved antifungal agents isolated from actinomycete bacteria. 
 





Figure 1.8 Source of antifungal leads from natural products discovered between 2010 and 2019 with unique 
scaffolds and an MIC < 10 μg/mL or IC50 < 10 μM against human pathogenic fungi, this figure is adapted from 
Aldholmi et.al.[24] 
Microbial natural products such as actinomycin D, anthracyclines, bleomycins, 
mitosanes and anthracenones are among the most important approved anticancer 
agents.[25] Actinomycin D and plicamycin (anthracenone) were the first microbial 
anticancer agents approved by the FDA between 1960 and 1970 (Figure 1.9).[26,27] In 
1973, a mixture of two closely related glycopeptides, bleomycin A2 (55-70%) and 
bleomycin B2 (25-32%), was approved by the FDA for cancer treatment (Figure 
1.10).[28] After this approval, two new classes of microbial anticancer agents, 
mitosanes (i.e. mitomycin) and anthracyclines (i.e. doxorubicin, daunorubicin and 
idarubicin), were approved between 1974 and 1990 (Figure 1.11).[29,30] All approved 
drugs mentioned above are microbial natural products isolated from Streptomyces 











Figure 1.9 Chemical structures of actinomycin D and plicamycin. 
 





Figure 1.11 Chemical structures of approved mitomycin and anthracyclines. 
The soil myxobacterium Sorangium cellulosum is the source of microbial 
secondary metabolites known as epothilones with significant anti-neoplastic 
activity.[31] In 2007, ixabepilone, a semi-synthetic analogue of epothilone B, was 
approved by the FDA for the treatment of aggressive metastatic and locally advanced 
breast cancer no longer responding to currently available therapies.[31] Ixabepilone has 
a similar mechanism to paclitaxel, interfering with tubulin, but it has a simpler 
structure than paclitaxel (Figure 1.12).[32] Paclitaxel was first isolated from the plant 
Taxus brevifolia but has also been reported from endophytic fungi such as Taxomyces 
andeanae and Fusarium redolens.[33,34] 
 




1.2. Challenges and opportunities in natural product 
discovery 
Although a long list of anti-infective and anticancer drugs has been approved by 
regulatory authorities, most clinically used drugs suffer from resistance and other 
drawbacks such as adverse effects, drug interactions and poor pharmacokinetic 
properties.[24,35,36] Moreover, most large pharmaceutical companies have reduced or 
even terminated their natural product discovery programs despite the inspiring history 
of microbial natural products. Some of the main factors that contributed to this 
situation are the high rediscovery rates and low yield of natural products being 
insufficient for isolation, structure elucidation and pharmacological evaluation.[37,38]  
To overcome the above-mentioned challenges, unusual environments such as 
caves, hydrothermal vents and  Antarctic waters have been explored to increase the 
opportunity for discovering novel natural products.[39] This approach has been 
effective in terms of discovering novel metabolites, but it has some challenges, 
including the accessibility of the unique environments, experience requirement for 
taxonomical identification and costs of field trips for sample collection.[37,40] An 
alternative approach is the manipulation of natural product biosynthetic pathways 
(NPBPs) using several strategies, including OSMAC (one strain, many compounds), 
co-cultivation of organisms, genetic engineering and epigenetic manipulation.[41] 
OSMAC approach states that a single strain produces different metabolites with the 
variation of medium composition (nutritional manipulation) and other cultivation 
conditions such as pH, temperature, oxygen concentration, salinity and cultivation 




in this PhD project to induce the production of novel natural products and increase the 
yield of other metabolites. 
The sequencing of microbial genomes has demonstrated that genes involved in 
the biosynthesis of microbial secondary metabolites typically exist in clusters known 
as biosynthetic gene clusters (BGCs, Figure 1.13).[44] Analysis of BGCs revealed that 
even well-studied organisms such as Streptomyces bacteria and Aspergillus fungi are 
capable of producing a significantly larger number of secondary metabolites than has 
been previously identified from those organisms.[45] This is probably because the genes 
responsible for the production of a great number of secondary metabolites are 
transcriptionally inactive (silent) or poorly expressed under laboratory conditions, 
resulting in undetectable concentrations of the corresponding products.[46] Such 
biosynthetic genes are referred to as “cryptic”. For example, Streptomyces coelicolor 
A3 (2) that has served as a model organism for bioactive-metabolite producers for 
more than five decades had been known to produce five secondary metabolites before 
genome sequencing.[47] Upon the release of the genome sequence, initial bioinformatic 
analysis unveiled 24 potential BGCs that were extended later to 31 BGCs with the 
development of bioinformatics tools for BGCs analysis.[45,47] 
 
Figure 1.13 BGC of griseofulvin showing the genes involved in griseofulvin biosynthesis clustered together, this 




Remarkably, genomic and transcriptomic analysis has also shown that many 
microorganisms previously considered incompetent candidates for natural product 
discovery harbour considerable numbers of BGCs.[49,50] For instance, genomic analysis 
of several strains of Clostridium proposed that this group can be a promising source of 
novel natural products.[51] Moreover, genomic and transcriptomic analysis of several 
microalgal species revealed the presence of a great number of NRPSs and PKSs.[52,53] 
Two of those species are Coccomyxa subellipsoidea and Euglena gracilis, which are 
well known as green algae model organisms but were not believed to be rich sources 
of secondary metabolites before genome and transcriptome release.  Therefore, 
genome mining (the recognition of previously uncharacterised natural product BGCs) 
can be exploited for identification and manipulation of cryptic BGCs to enable the 
production of novel natural products and increase the yield of minor metabolites. For 
instance, genome mining of S. coelicolor sequence and other microbial sequences 
prompted the induction and identification of new natural products.[54–58] Noteworthy, 
most organisms with sequenced genomes or transcriptomes can be effortlessly 
obtained from private or public culture collections. 
1.3. Mining and manipulation of NPBPs for natural product 
discovery 
This project is guided by genomic and transcriptomic information, beginning 
with genome or transcriptome mining and finishing with molecular networking of 
related metabolites (Figure 1.14). The first step in the genome or transcriptome-based 
natural product discovery is to select the candidate microorganism for mining. The 
selection is based on several factors, including the accessibility of the genome or 




collaborating laboratories. In addition, the candidates should be easy to cultivate 
within the available facilities and have a reasonable growth rate. Furthermore, 
literature is searched to ensure that the candidate organism is suitable for the employed 
manipulation strategy. 
 
Figure 1.14 Workflow for microbial natural product discovery through nutritional and epigenetic manipulation. 
Genome or transcriptome mining is the identification of previously 
uncharacterised natural product BGCs within genome or transcriptome sequences 
based on homology with portions of known BGCs.[59] The genome contains all genes 
of an organism while the transcriptome only represents the expressed genes that were 
transcribed from the genome under specific conditions.[60] Although the transcriptome 
only covers transcriptionally active genes, it is valuable when the genome is not 
available as it shows the BGCs that are poorly expressed or their respective secondary 
metabolites are not detected for other reasons. The genome and transcriptome 
sequences are obtained from public databases (e.g. GenBank) and analysed for the 
presence of BGCs using bioinformatics tools such as antibiotics and Secondary 
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Regions Finder (SMURF).[62] These tools can identify genes encoding most of the 
common microbial biosynthetic enzymes such as NRPSs and PKSs. If the natural 
product BGCs analysis has been previously published, the first step is skipped, and the 
published data is used for guided-natural product discovery. 
The next step is the manipulation of cryptic BGCs through the cultivation of 
microorganisms with different nutrients or chemical epigenetic modifiers. The cultures 
are then extracted with organic solvents and the extracts from different conditions are 
compared using one of two different methods: comparative metabolomics or 
comparative bioassays. Comparative metabolomics is the comparison of the metabolic 
profiles of an organism, at a specific point in time and under specific conditions.[63] 
This is a crucial step for determination and prioritisation of conditions that produce 
high quantities of metabolites of interest. Targeted metabolic profiling aims at 
analysing defined groups of metabolites, while untargeted metabolomics is a 
comprehensive analysis of all the measurable metabolites in the analysed sample.[64] 
The latter is utilized in this project. 
One of the main techniques employed to obtain chemical profiles is the high-
performance liquid chromatography (HPLC) connected to ultraviolet (UV) or 
photodiode array (PDA) detectors. The absorbance intensity of the peaks on 
chromatograms is proportional to the concentration of the respective metabolites 
enabling the comparison of the production in different conditions. A chromatogram 
can contain spectral information at a single wavelength or within a specified range 
(total absorbance chromatogram, TAC), depending on the type of detector. The 
limitations in this technique are the coelution of different metabolites and the absence 
of UV chromophores leading to a set of metabolites being undetectable. Nuclear 




molecular class but the major limitation in this technique is its inherently low 
sensitivity.[65] In contrast, the mass spectrometry (MS) is an extraordinarily sensitive 
analytical method that is usually combined with ultra-performance liquid 
chromatography (UPLC) or HPLC. The ion intensity of metabolites is typically 
proportional to the concentration of the respective metabolites which enables relative 
quantification of a broad range of metabolites, but this technique is limited by the bias 
in ionisation efficiency.[63] However, none of the analytical methods are perfect but the 
high sensitivity of UV and MS detectors coupled to HPLC or UPLC provides a general 
overview of the relative amounts of metabolites present in samples. 
The obtained metabolomics datasets can be compared and visualised using 
different methods. In this project, comparative overlaid chromatograms and volcano 
plots are employed for the visualisation of the results. Volcano plots are commonly 
used with statistical results of omics data such as genomics, transcriptomics, 
proteomics and recently metabolomics.[66,67] In metabolomics, they are used to identify 
changes in metabolite quantities produced under different conditions. They represent 
the statistical significance from a t-test (as -log10 of the p-value) versus the log2 of 
fold change on the y and x-axes, respectively.[68] Consequently, metabolites that are 
present in nearly equivalent amounts in two samples appear near the centre of the 
volcano plot and those with large fold changes appear farther left or right from the 
centre. The reproducible components with high statistical significance (low p values) 
appear toward the top of the plot. 
Another method to compare extracts obtained from microbial cultivation under 
different conditions is by evaluation of their biological activity. If a bioactive 
compound is induced, the biological activity should be proportional to the induced 




on crude extracts or their fractions to evaluate relevant biological activities for drug 
discovery. However, this strategy is limited by the types of bioassays that can be 
performed and it suffers from overlooking low abundance compounds in complex 
mixtures.[69] Additionally, the observed biological activity might be due to the 
presence of previously known molecules. Moreover, some natural product chemistry 
labs do not have access to the required bioassay screening facilities. Collaboration with 
bioassay screening labs is an option, but it usually takes time to get the results from 
collaborators, leading to delay in the process of natural product discovery. If the 
comparative bioassays approach is used, isolation and purification of bioactive 
metabolites can be guided by bioassays (bioassay-guided isolation).[70]  
Large-scale cultivation is normally required for the isolation and structure 
elucidation of the desired metabolites. Isolation and structure elucidation of natural 
products require time, finance and considerable skills, especially with low-yield 
natural products. Therefore, it is vital to ensure that the target metabolites are novel 
via searching informative databases such as METLIN, Natural Products Atlas (NP 
Atlas), Dictionary of Natural Products (DNP) and SciFinder, a process known as 
“dereplication”.[71] Literature searching of the organisms under investigation is a 
crucial step to avoid isolating previously identified metabolites from the same 
organism. Some metabolites are produced by unrelated organisms; therefore, different 
characteristics should be used for literature searching. High-resolution mass 
spectrometry (HRMS) is one of the critical techniques used for dereplication through 
searching databases with accurate mass. Fragmentation data from coupled mass 
spectrometers (MS/MS) can be used to search spectral libraries such as Global Natural 
Product Social Molecular Networking (GNPS), METLIN and MassBank. Mass 




identification of structurally similar molecules through MS/MS fragmentation 
pattern.[72] Moreover, UV/Vis spectra can assist in dereplication when used with MS 
and MS/MS data for literature searching. Accordingly, MS, MS/MS and UV/Vis 
detectors combined to liquid chromatography can be used for the analysis of crude 
extracts and dereplication before conducting the next expensive and time-consuming 
stages of natural product discovery. 
Initial separation of metabolites can be obtained by partitioning and flash 
chromatography. Some pure natural products can be obtained with initial separation 
methods, but most require method development and purification on HPLC 
instruments. This is more likely when metabolites are produced in small amounts or 
belong to the same chemical class with minor structural differences. After purification, 
several methods are utilised for structural analysis such as MS, MS/MS, infrared 
radiation (IR), NMR, UV, polarimeter, X-ray crystallography and chemical 
derivatisation. While low-abundance metabolites can be satisfactorily analysed by 
sensitive mass spectrometry, NMR analysis is more challenging with scarce samples. 
Nevertheless, the recent evolution of high-field NMR spectrometers equipped with 
microcryoprobes has increased the NMR sensitivity enabling structural 
characterisation by one dimensional (1D) and two dimensional (2D) NMR with a few 
micrograms.[73] 
X-ray structural analysis is the most powerful method for the assignment of the 
three-dimensional structure of natural products. However, this technique requires a 
single crystal with suitable quality for the X-ray diffraction. The stereochemistry of 
peptide natural products can be assigned by chromatographic comparison of the amino 
acid residues with standard amino acids. The direct separation without chemical 




phases known as a chiral phase. This chromatography system is more expensive and 
complicated than the normal and reversed-phase chromatography.[74] Moreover, most 
amino acids have poor UV absorption requiring expensive types of detectors such as 
mass spectrometry. However, chromatographic separation of enantiomeric amino 
acids can be achieved on achiral stationary phases after chemical derivatisation, 
indirect approach. This approach is often simpler, less expensive and offers greater 
resolution and choices of chromatographic conditions over most direct methods.[75] 
Chemical derivatisation is normally performed by reacting the enantiomers with 
an optically pure chiral reagent to form diastereomers prior to chromatographic 
analysis.[75] Marfey’s reagent, 1-fluoro-2,4-dinitrophenyl-5-L-alanine amide (FDAA), 
is commonly used as a chiral reagent for chemical derivatisation and separation of 
enantiomeric amino acids.[76] Moreover, structural variants of Marfey’s reagent have 
been prepared by the replacement of the alanine moiety with other amino acids such 
as phenylalanine and valine.[77] The structural variant 1-fluoro-2,4-dinitrophenyl-5-L-
valine amide (FDVA) has been shown to offer the largest difference in retention times 
of diastereomers compared to reagents containing alanine or phenylalanine 
moieties.[78] All of these reagents normally react within an hour under mild alkaline 
conditions at 40 °C and allow detection at sub-nanomolar range due to the presence of 
the dinitrophenyl chromophore that strongly absorbs at 340 nm.[77,78] 
The pure metabolite is evaluated for its biological activity once it is confirmed 
to be a novel natural product. Moreover, a molecular network can be constructed from 
structurally related compounds produced by other organisms. This step paves the way 
toward the discovery of related molecules that might have some advantages over the 
original natural product such as higher yield, higher potency, superior selectivity or 




structurally related compounds that share similar MS/MS fragmentation patterns.[79] 
GNPS is the most common molecular networking tool that aligns the MS/MS spectra 
and generates molecular networks.[80] Network visualisation can be performed online 
on the GNPS web platform or preferably with specialised visualisation software such 
as Cytoscape.[81] 
1.3.1. Nutritional manipulation 
Nutrients are organic and inorganic ingredients required for microbial growth 
and metabolism. The main nutrients in cultivation media function as sources of carbon, 
nitrogen, sulphur, phosphorus, potassium, magnesium, calcium, iron and trace 
elements. Organic carbon represents the source of energy for all heterotrophs, in 
contrast to autotrophs which acquire their energy from light (photosynthesis) or 
inorganic compounds (chemosynthesis).[82] Nitrogen is required for the synthesis of 
nitrogen-containing cellular substances such as proteins and nucleic acids.[83] In 
addition to their use for energy and biomass building, carbon and nitrogen sources 
provide carbon and nitrogen units for the production of secondary metabolites. The 
type and concentration of carbon and nitrogen sources employed for microbial 
cultivation have been shown to have a remarkable effect on microbial secondary 
metabolism.[42] Nutritional manipulation is the alteration of nutrients in the media 
employed for microbial cultivation. Although this is probably one of the simplest 
strategies for the induction of cryptic BGCs, the mechanisms behind the influence on 
secondary metabolism are much more complex and vary significantly between 
microorganisms.[84,85] Nevertheless, this strategy has led to the discovery of a variety 




Martin et al.[85] reported global regulatory effects on primary and secondary 
metabolism in Streptomyces coelicolor when cultivated with different sources and 
concentrations of carbon, nitrogen and phosphorous. Nutritional manipulation in 
actinomycete bacteria led to the isolation of a variety of new natural products such as 
a spectinabilin derivative (1) from Streptomyces sp. 1H-GS5,[88] three new streptazolin 
derivatives (2-4) and streptenol E (5) from Streptomyces sp. A1,[89]  and a new 
eudesmane sesquiterpenoid (6) and one new analogue of virginiae butanolide E (7) 
from Lentzea violacea AS08[90] (Figure 1.15). The production of the polyketide 
antibiotic SBR-22 by Streptomyces psammoticus BT-408 varied significantly between 
different carbon and nitrogen sources, with the highest yield observed with the carbon 
and nitrogen sources glucose and ammonium nitrate, respectively.[91] Although SBR-
22 displayed antibacterial activity against MRSA (methicillin-resistant 
Staphylococcus aureus), the complete structure of this antibiotic is still unknown. 
 




Genome mining and nutritional manipulation in Streptomyces sp. CS led to the 
isolation of several natural products, including three new ansamycin antibiotics 
(Figure 1.16, 8-10).[92] Similarly, the cultivation of Streptomyces strain C34 in two 
different media containing glucose or glycerol as carbon sources resulted in the 
isolation of four new ansamycin polyketides (Figure 1.17, 11-14).[93] Remarkably, 
compounds 11 and 12 were produced in the glucose-containing medium while 
compounds 11, 13, and 14 were found in the glycerol-containing medium. 
 





Figure 1.17 Chemical structures of natural products 11-14. 
This strategy has also resulted in higher yields of important antibiotics produced 
by non-actinomycete species (Figure 1.18). Genomic analysis of two Vibrionaceae 
strains, Vibrio coralliiltycus S2052 and Photobacterium galatheae S2753, revealed a 
capability for the biosynthesis of secondary metabolites and utilisation of chitin as a 
carbon source.[94] When the strains were cultured on chitin-containing media, several 
secondary metabolite BGCs were significantly up-regulated compared to culturing on 
glucose-containing media. The up-regulation was more significant during the 
stationary phase than the exponential phase for the majority of the BGCs. The 
production of two antibiotics andrimid (15) and holomycin (16) biosynthesised by V. 
coralliiltycus S2052 and P. galatheae S2753, respectively, was stimulated in media 
containing chitin as the sole carbon source compared to glucose-cultivated cells. In the 
aquaculture probiotic strain Pseudomonas sp. MCCB 103, comparison of different 
nutrients revealed that mannitol and urea were the carbon and nitrogen sources, 
respectively, that allowed the highest production of both the biomass and the 
phenazine antibiotic pyocyanin (17).[95] Furthermore, the combination of mannitol and 
urea, as well as the supplementation with mineral salts, were necessary for the 





Figure 1.18 Chemical structures of natural products 15-17. 
The type and concentration of nutrients have been widely reported as inducers 
or inhibitors of fungal growth and metabolism. Nutritional manipulation has led to the 
isolation of novel natural products from the fungal genus Aspergillus (Figure 1.19). 
The cultivation of the sediment-derived Aspergillus niger BRF-074 in different media 
led to the isolation of a novel furan ester derivative (18) with cytotoxic activity against 
HCT-116 cell line.[96] This compound was only produced in MPDB (malt peptone 
dextrose broth) medium and absent in others such as PDB (potato dextrose broth) and 
PDYB (potato dextrose yeast broth) media. Similarly, four new rubasperone 
derivatives (19-22) were isolated from the mangrove endophytic fungus Aspergillus 
tubingensis GX1‐5E upon replacing the PDB medium with rice medium.[97] In in vitro 
cytotoxicity assays, compound 19 displayed mild activity against tumour cell lines. 
Genome mining and nutritional manipulation of Aspergillus nidulans HKI 0410 
resulted in the isolation of two novel prenylated quinolin-2-one alkaloids furnished 
with unprecedented terpenoid side chains (23, 24) from the culture grown on rice 
medium.[98] In Aspergillus fumigatus, the production of fumagillin (25) was increased 
by 15-fold when the nitrogen source sodium nitrate was replaced with L-glutamic acid, 
while the replacement with L-aspartic acid led to lower production even though the 





Figure 1.19 Chemical structures of natural products 18-24. 
The nutritional effect on the number, type and yield of produced secondary 
metabolites has also been reported in several Penicillium species (Figure 1.20). The 
effect of the carbon source on the production of fumagillin (25) was investigated in 
Penicillium scabrosum, and the maximum yield of fumagillin was reported when 
employing 1% glucose as a carbon source.[100] Conversely, fumagillin production was 
repressed by using 3% glucose in the medium, although this concentration allowed the 
maximum biomass growth. In Penicillium janthinellum and Penicillium duclauxii, the 
greatest number of metabolites was observed when the medium contained 10 % 
sucrose, and the number decreased in direct proportion to the increase in the sucrose 




metabolite production in Penicillium oxalicum and Penicillium citrinum.[102] 
Consequently, two new alkaloids named citrinalins A (26) and B (27) were isolated 
and characterised from P. citrinum. Interestingly, the highest yield of compound 27 
was observed with a nutrient-depleted medium containing only 10% of the nutrients 
in the original medium. 
 
Figure 1.20 Chemical structures of natural products 25-27. 
Nutritional manipulation strategy has also been applied for the discovery of 
bioactive metabolites from microalgae. Lauritano et al.[103] investigated the bioactivity 
of crude extracts of 32 microalgal species cultivated in media containing different 
concentrations of nitrogen and phosphate. Two strains of the diatom Skeletonema 
marinoi (FE60 and FE6) displayed anticancer and antibacterial activities when 
cultured in nutrient-depleted media while no activity was observed in extracts of 
nutrient-rich cultures. Interestingly, the nutritional effect can be strain dependent as 
reported in the two strains of S. marinoi. Strain FE60 showed anticancer and 
antibacterial activities only when cultured in a nitrogen-depleted medium, while strain 
FE6 had antibacterial properties only when cultivated in a phosphate-depleted 
medium.[103] On the contrary, extracts of two microalgae, Skeletonema costatum and 




cultivated in a nitrogen-rich medium and phosphate-depleted medium, while the 
nitrogen-depleted cultures had no activity.[104]  Furthermore, the influence of the 
nitrogen concentration on natural product yield has been reported with the microalga 
Eustigmatos cf. polyphem.[105] The microalgal growth and the production of the 
antioxidant pigment violaxanthin (Figure 1.21, 28) were adversely affected by either 
excessive or insufficient nitrogen concentrations.[105] 
 
Figure 1.21 Chemical structure of natural product 28. 
1.3.2. Epigenetic manipulation 
The epigenetic processes refer to the chemical modifications of DNA and its 
structural proteins without alterations in the DNA nucleotides sequence.[106] In 
eukaryotes, chromatin is the complex of DNA and histone proteins that are packed 
within the nucleus of eukaryotic cells. The nucleosome is the fundamental component 
of chromatin that consists of an octamer of histone proteins (H2A, H2B, H3, and H4), 
around which 147 base-pairs of DNA are wrapped.[107] In prokaryotes, it is 
hypothesised that nucleoid structure plays a similar role to eukaryotic chromatin 
structure being a potential target for epigenetic modifications.[108] The epigenetic 
processes, including the covalent modifications of DNA and amino acids on histones, 
are used by organisms to regulate the expression of genes involved in natural product 
biosynthesis.[109,110] Therefore, manipulation of these epigenetic processes has been 
used as a strategy for activation of cryptic secondary metabolite BGCs.[110] 
Histone proteins undergo several post-translational modifications involving 




methylation and acetylation.[111] The acetylation of lysine on histones by histone 
acetyltransferases (HATs) is typically associated with transcriptional activation, 
whereas histone deacetylases (HDACs) reverse this modification leading to 
transcriptional inactivation.[112–114] DNA methylation is another major epigenetic 
process in prokaryotes and eukaryotes, where a cytosine in CpG dinucleotides is 
methylated by DNA methyltransferases (DNMTs) to generate a 5-methylcytosine.[115] 
When the DNA is methylated, and histones are deacetylated, chromatin is condensed 
and inaccessible to transcription factors (heterochromatin), which is repressive 
regulation of transcription, while the unmethylated DNA and acetylated histones 
transform the chromatin into a loose transcriptionally active form known as 
euchromatin (Figure 1.22).[116] The chemical inhibitors of HDACs (HDACIs) and 
DNMTs (DNMTIs) have an activating effect upon gene transcription, and small 
molecule inhibitors of these enzymes are approved for clinical use as anticancer 
agents.[117] 
 
Figure 1.22 An illustrative diagram of heterochromatin and euchromatin. 
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The deletion of cclA, a component of the COMPASS complex responsible for 
catalysing histone lysine methylation, induced the expression of secondary metabolite 
BGCs in Aspergillus nidulans.[118] The induced expression of one of the BGCs, named 
mdp, resulted in the production of several secondary metabolites (Figure 1.23) 
including emodin (29), emodin analogues (30-35) and monodictyphenone (36). 
Similarly, the deletion of the hdaA gene (encoding a class II HDAC) in Aspergillus 
nidulans using a molecular genetics approach initiated the transcriptional activation of 
two gene clusters.[119] The up-regulation of these two gene clusters resulted in 
increased levels of the corresponding secondary metabolites (Figure 1.24), 
sterigmatocystin (37) and benzylpenicillin (38).[119,120] The role of hdaA in secondary 
metabolite production has also been confirmed in Aspergillus fumigatus.[121]  
However, the removal of those genes is not always possible and has been shown to be 
lethal to some organisms.[122] Therefore, the molecular genetics approach has been 
extended by using sublethal doses of chemical epigenetics supplemented to the culture 
without the necessity for advanced molecular genetics knowledge and equipment. The 
DNMT and HDAC inhibitors are the major classes of chemical epigenetic modulators 
utilised in natural product discovery. 
 





Figure 1.24 Chemical structures of natural products 37 and 38. 
 HDACIs 
Histone deacetylase inhibitors can be classified, based on the classification of 
HDACs, into zinc-dependent (class I and II) HDAC inhibitors and NAD-dependent 
HDAC (class III, also known as sirtuins) inhibitors. These inhibitors increase histone 
acetylation through the inhibition of HDACs, and consequently, increase the 
expression of secondary metabolite genes.[110] The amino groups of the lysines on 
histones are usually protonated having electrostatic interaction with the negatively 
charged phosphate backbone of DNA (Figure 1.25, A).[123] The acetylation of histone 
lysine eliminates the positive charge and weakens the electrostatic interaction between 
the acetylated histone and its DNA (Figure 1.25, B). This opens up access to DNA for 
transcription factors and other enzymes allowing for increased transcription of the 
previously down-regulated genes.[124] 
 





Several zinc-dependent HDACIs including trichostatin A (TSA, 39), 
suberoylanilide hydroxamic acid (vorinostat, 40), suberohydroxamic acid (SBHA, 41), 
sodium butyrate (SB, 42) and valproic acid (VPA, 43) have been used to induce 
secondary metabolite production (Figure 1.26). TSA is a natural product produced by 
Streptomyces platensis and one of the most potent zinc-dependent HDAC 
inhibitors.[125] This modifier demonstrated various transcriptional effects on 
Saccharomyces cerevisiae, including both the down-regulation and up-regulation of 
genes involved in cell cycle progression, as well as the biosynthesis of amino acids 
and transport and utilisation of carbohydrates.[126] Interestingly, some of these effects 
were detectable within 15 min of exposure to TSA.  
 
Figure 1.26 Examples of zinc-dependent HDAC inhibitors. 
The fermentation of Aspergillus species with TSA has been employed for the 
activation of cryptic BGCs and the discovery of new natural products (Figure 1.27).  
The treatment of Aspergillus nidulans culture with 1 µM TSA led to the reduction of 
major secondary metabolites while many low-abundance metabolites were 
significantly increased compared to the untreated culture.[67] The author’s explanation 
for this phenomenon was that the building blocks used in the biosynthesis of 
previously abundant secondary natural products were consumed by the secondary 




repressive regulators were activated with the HDACI leading to down-regulation of 
some secondary metabolite genes. The activated BGCs resulted in the production of 
lipopeptide aldehydes known as fellutamides: fellutamide B (44), antibiotic 1656-G 
(45) and antibiotic 3127 (46). It was the first report of 44 and 45 from Aspergillus 
nidulans. However, 46 is known to be produced by Aspergillus nidulans but was only 
biosynthesised by this strain when treated with TSA. In another epigenetic 
manipulation study, epigenetic modification of Aspergillus terreus OUCMDZ-2739 
with 10 μM TSA induced the secondary metabolome and led to the characterisation of 
four new meroterpenoids (47-50).[127] 
 




Vorinostat is a potent synthetic zinc-dependent HDACI with a similar molecular 
structure to TSA. The cultivation of fungal species on media containing 10-100 μM 
vorinostat led to the discovery of novel natural products (Figure 1.28) such as a new 
4-pyridone, named nygerone A (51) from Aspergillus niger,[128] two new 
perylenequinones, cladochromes F (52) and G (53), from Cladosporium 
cladosporioides,[129] a novel cyclodepsipeptide, named EGM-556 (54), from the 
marine Microascus sp.,[130] three novel cyclodepsipeptides, desmethylisaridin E (55), 
desmethylisaridin C2 (56), and isaridin F (57) from Beauveria feline,[131] a new 
chlorinated pentacyclic polyketide, daldinone E (58), from Daldinia sp.,[132] and three 
new norditerpenes, aspewentins A-C (59-61) from Aspergillus wentii.[133] 
 




Another synthetic analogue of TSA is SBHA, which is an inexpensive 
alternative to TSA and vorinostat albeit less potent.[123] The treatment of several fungal 
species with SBHA resulted in substantial changes in the secondary metabolism and 
induced the production of new secondary metabolites (Figure 1.29) including three 
new prenylated tryptophan analogues (62–64) from Torrubiella luteorostrata,[134] two 
new fusaric acid derivatives from Fusarium oxysporum (65, 66),[135] and six novel 
prenylated aromatic polyketides (67-72)[136] and two novel spironolactone polyketides 
(73, 74) from Chaetomium indicum.[137] 
 




While the deletion of hdaA (encoding HDAC) in Calcarisporium arbuscular 
triggered the production of new natural products, SBHA failed to induce any changes 
in the metabolic profile.[138] The concentration of SBHA used in this study was not 
specified. Therefore, higher doses might be able to induce secondary metabolite 
production. Alternatively, more potent epigenetic modifiers such as vorinostat might 
be a better alternative to SBHA. However, it is possible that this fungal species has a 
defence mechanism against SBHA. This resistance has been already described in the 
fungal pathogen Cochliobolus caronum, which is responsible for the production of the 
HDAC inhibitor, HC-toxin. This species produces a modified HDAC that is insensitive 
to HDACIs such as TSA.[139] It is proposed that this modified HDAC protects this 
fungus from the auto-toxic effect of HC-toxin. 
Butyrate is a short-chain fatty acid produced via anaerobic bacterial 
fermentation, and its salt, SB, has been used as an inducer of secondary metabolite 
gene expression.[140] For example, the pellet of Penicillium restrictum cultivated in the 
presence of 5 µM SB demonstrated significantly higher antimicrobial activity against 
MRSA compared to the pellet cultured in the absence of SB.[141] Moreover, the marine 
fungi Leucostoma persoonia and Cochliobolus lunatus were cultivated with SB 
resulting in the activation of cryptic BGCs and enhanced production of new 
metabolites (Figure 1.30).[142,143] One previously unidentified cytosporone was 
characterised from the L. persoonia culture treated with  100 μM SB and named as 
cytosporone R (75).[143] Furthermore, two new brominated resorcylic acid lactones, 5-
bromozeaenol (76) and 3,5-dibromozeaenol (77), were isolated and identified from the 
C. lunatus culture containing 10 mM SB.[142] Intriguingly, it was discovered that the 
effect of SB was dose-dependent as the yield of metabolites was lower at 




modifier might cause some effects other than epigenetic such as changing the pH or 
functioning as a carbon source. 
 
Figure 1.30 Examples of secondary metabolites induced by SB. 
VPA is another short-chain fatty acid, which is an antiepileptic drug that has also 
been reported as an inhibitor of HDACs.[144] The cultivation of Aspergillus clavatus 
with 5 µM VPA induced the production of cytochalasin E (78) and pseurotin A (79) 
within 48 h of incubation (Figure 1.31).[145] Additionally, the addition of 5 µM VPA, 
5µM TSA or 5 µM SB to the cultures of several fungal species including Aspergillus 
clavatus and Penicillium alberechii increased the antimicrobial activity of their 
supernatants compared to untreated samples.[141] Similarly, Aspergillus fumigatus GA-
L7 was treated with 500 µM VPA leading to significant overexpression of the BGC 
involved in the biosynthesis of fumiquinazoline C (Figure 1.31, 80).[146] This resulted 
in approximately ten-fold enhancement of fumiquinazoline C yield. 
 




The second class of HDAC inhibitors is NAD-dependent HDAC (class III) 
inhibitors (Figure 1.32). The best example for this class is nicotinamide (81) which is 
the amide form of vitamin B3 (nicotinic acid) and an important regulator of 
deacetylation caused by NAD-dependent HDAC.[147] Sirtinol (82) and splitomicin (83) 
are also NAD-dependent HDACIs but with poor activity and stability.[148] The 
treatment of Chaetomium mollipilium with the latter two epigenetic modifiers did not 
produce a detectable enhancement in the metabolic profile. Additionally, the main 
constituents in the extracts were degradation and hydroxylation products of sirtinol 
and splitomicin due to their instability.[149] 
 
Figure 1.32 Examples of NAD-dependent HDAC inhibitors. 
In contrast to modifiers 82 and 83, epigenetic manipulation with nicotinamide 
led to the discovery of over ten new secondary metabolites from three fungal species 
(Figure 1.33). The addition of 100 µM nicotinamide to the Chaetomium mollipilium 
culture induced the secondary metabolism and resulted in the isolation of five new 
polyketides, mollipilins A-E (84-88).[149] Similarly, the cultivation of Graphiopsis 
chlorocephala, isolated from the medicinal plant Paeonia lactiflora, with 10 µM 
nicotinamide yielded a remarkable enhancement in secondary metabolite 
production.[150] This resulted in the isolation of six new benzophenones, cephalanones 
A-F (89-94). Moreover, the treatment of Chaetomium cancroideum with 50 µM 
nicotinamide led to the isolation of three new polyketides, chaetophenol G (95) and 





Figure 1.33 Examples of secondary metabolites induced by nicotinamide. 
 DNMTIs 
The main classes of DNMTIs are nucleoside and non-nucleoside analogues 
(Figure 1.34). Nucleoside analogues contain a modified cytosine ring attached to a 
ribose or deoxyribose moieties, which can incorporate into DNA and cause 
demethylation.  The most well-known examples of the nucleoside analogues are 5-
azacytidine (5-AC, 98) and its analogue decitabine (99), but they suffer from 




expensive.[123] The other class of DNMTIs is the non-nucleoside analogues which bind 
to the methyltransferase and alter the catalytic action of the enzyme rather than 
incorporating into DNA.[152] Examples of these inhibitors include the natural product 
epigallocatechin gallate (EGCG, 101), antihypertensive hydralazine (102) and 
tryptophan derivative RG108 (103). 
 
Figure 1.34 Examples of nucleoside and non-nucleoside DNMTIs. 
The cultivation of the fungal species, Neurospora crassa, on a growth medium 
containing 30 µM 5-AC increased the carotenoid production by more than 700-fold in 
comparison to the inhibitor-free control.[153] Nevertheless, 5-AC was toxic to this 
fungus at doses higher than 30 µM. In another epigenetic experiment, the addition of 
50 µM 5-AC to the growth medium resulted in the isolation of two new meroterpenes 
(104, 105) from Penicillium citreonigrum,[154] and a new diethylene glycol phthalate 
ester monomer (106), along with several oligomers of 106, from Cochliobolus 
lunatus[155]  (Figure 1.35). Likewise, the treatment of the endophytic fungus, Muscodor 




genes including polyketides genes. Interestingly, this effect was even more significant 
in the next generation when the fungus was transferred to a new medium and studied 
without any subsequent exposure to 5-AC.[156] Moreover, the effect of 5-AC treatment 
was more profound than vorinostat on the overexpression of polyketides genes in this 
fungal species. The presence of 100-500 µM 5-AC in the media led to the discovery 
of two new polyketides (107, 108) from Diatrype disciformis,[129] three new 
sesquiterpenoids (109-111) from Aspergillus sydowii,[157] and a new coumarin (112) 
from Pestalotiopsis (Figure 1.34).[158] 
 
Figure 1.35 Examples of secondary metabolites induced by 5-AC. 
The addition of 100 µM hydralazine to the endophytic fungus Dothiora sp. CF-
285353 increased the production of some secondary metabolites by 32 folds and 




products was isolated and characterised as cyclo(phenylalanyl-prolyl) (Figure 1.36, 
113). It was demonstrated that the increase in the production of secondary metabolites 
was slightly higher when the epigenetic modifier was added into both seed and 
production cultures. Moreover, several biotransformation products of the epigenetic 
modifier were identified in the hydralazine-treated cultures. 
 
Figure 1.36 An example of secondary metabolites induced by hydralazine. 
 Concomitant epigenetic modifiers 
The concomitant supplementation of HDACIs and DNMTIs has been 
demonstrated to have an enhanced effect on the expression of microbial secondary 
metabolite BGCs. The combined use of 5-AC and SBHA has led to the discovery of 
several novel natural products (Figure 1.37). For example, the addition of 500 µM 5-
AC and 500 µM SBHA induced the secondary metabolism in the plant endophytic 
fungus Pestalotiopsis acacia.[160] This resulted in the production of a novel depside 
(114) and two new methylcoumarins (115, 116). Similarly, the plant pathogen 
Ustilago maydis was shown to produce a novel glycolipid, ustilagic acid C (117), when 
cultivated in the presence of 500 µM 5-AC and 500 µM SBHA.[161] The addition of 1 
mM 5-AC and 1 mM SBHA to the growth media led to the isolation of three new 
eremophilane-type sesquiterpenes (118-120) from Aspergillus sp. SCSIOW2[162] and 
a new diphenyl ether-O-glycoside (121) from Aspergillus sp. SCSIOW3.[163] 
Compounds 118-120 had moderate nitric oxide inhibitory activities[162] while 





Figure 1.37 Examples of secondary metabolites induced by the concomitant use of 5-AC and SBHA. 
A significant enhancement was reported in the production of fungal secondary 
metabolites with the combination of RG108 and SBHA, leading to the discovery of 
novel natural products (Figure 1.38). The presence of 100 µM RG108 and 100 µM 
SBHA in the growth medium resulted in the isolation of a novel polyketide with a 
unique tetracyclic ring system (122), from the entomopathogenic fungus Isaria 
tenuipes.[164] The cultivation of another entomopathogenic fungus, Gibellula 
formosana, with both 1 mM RG108 and 1 mM SBHA, either 1 mM SBHA or 1mM 
RG108, or modifiers-free control showed that the extract obtained from the cultivation 
in the presence of both epigenetic modifiers contained numerous induced 
compounds.[165] This resulted in the isolation of two novel ergosterols (123, 124), and 





Figure 1.38 Examples of secondary metabolites induced by the concomitant use of RG108 and SBHA. 
 Final remarks 
Natural products and their derivatives represent a high percentage of clinically 
approved medicines with most of the approved anti-infective and anticancer drugs 
originating from natural products. The sequences of microbial genomes and 
transcriptomes provide excellent guidance for microbial natural product discovery. 
Genomic and transcriptomic data of microalgae revealed several BGCs that might 
encode novel natural products. Transcriptomic analysis indicated that the freshwater 
microalga E. gracilis can be an appropriate candidate for natural product discovery. 
This microalgal species was selected based on the transcriptomic data and other 




Genome sequencing of several Aspergillus species has shown their capability to 
produce a great number of secondary metabolites. Additionally, nutritional and 
epigenetic manipulations have been demonstrated as effective strategies for the 
activation of cryptic BGCs in Aspergillus. Five Aspergillus species were selected for 
natural product discovery after genome mining based on the number of cryptic BGCs 
as well as other criteria, as described in chapter 4. 
Finally, although most researchers have been using epigenetic modifiers for 
natural product discovery from eukaryotes, particularly fungi, some epigenetic 
modifiers have shown transcriptional effects in bacteria. For example, the treatment of 
Streptomyces coelicolor with HDACIs resulted in the upregulation of certain 
biosynthetic pathways, including the pigmented polyketides and non-ribosomal 
peptides.[108] Actinomycete bacteria represent a prolific source of natural products and 
might be an appropriate candidate for natural product discovery through epigenetic 
manipulation. Therefore, two actinomycete bacteria were employed for the epigenetic 
experiments, as described in chapter 5. 
1.4. Aims 
• Activation of cryptic NRPSs and PKSs in E. gracilis through nutritional and 
epigenetic manipulation. 
• Activation of cryptic BGCs in Aspergillus through nutritional and epigenetic 
manipulation. 
• Activation of cryptic BGCs in actinomycete bacteria through epigenetic 
manipulation. 
• Isolation and characterisation of induced natural products. 





2. Nutritional and epigenetic manipulation in E. gracilis 
2.1. Introduction 
Microalgae are microscopic photosynthetic organisms that contain one cell 
(unicellular) and are commonly found in freshwater and marine systems. Microalgae 
have conventionally been employed in ecological, biogeochemical, evolutionary, and 
biological applications.[166] However, the analysis of microalgal genomes and 
transcriptomes has shown that many microalgae contain genes encoding PKSs and 
NRPSs that might represent an untapped source of novel natural products (Figure 2.1). 
The genome and transcriptome data can be used as guidance to select the best 
microalgal candidate for natural product discovery. For example, Coccomyxa 
subellipsoidea has ten possible PKSs, whereas Chlorella variabilis has only two PKSs 
and a single NRPS.[52] Another microalgal species, Chlamydomonas reinhardtii, has 
been shown to contain a single PKS that is involved in the last condensation step of 
cell-wall fatty acids identified as mycolic acids.[167,168] 
Recently, transcriptome analysis has revealed that Euglena gracilis var. 
saccharophila Klebs (strain 1224/7a) has 19 putative NRPSs and 14 PKSs with their 
corresponding natural products remain to be identified.[169,170] Although E. gracilis is 
the most studied species of Euglena; no NRPs or PKs have been isolated from this 
species.[171] This offers a strong motivation to explore the secondary metabolome of 
E. gracilis. E. gracilis is a freshwater microalga that is able to grow in a wide range of 
conditions: photoautotrophically (using light as an energy source and carbon dioxide 
as a carbon source), heterotrophically (using an external carbon source), or 




varies dramatically with alterations of growth conditions, and the gene silencing 
mechanisms in E. gracilis involves epigenetic modifications such as histone 
methylation, histone deacetylation and DNA methylation.[170] Yuji et al.[173] reported 
significant effects of nitrogen and carbon sources on E. gracilis growth with some 
amino acids causing complete growth inhibition. Interestingly, the toxic effect of some 
amino acids was antagonised by the addition of other nitrogen and carbon sources 
suggesting that different nitrogen and carbon sources at different ratios have 
significant effects on the metabolism of E. gracilis. Therefore, E. gracilis appears as 
an appropriate candidate for natural product discovery through nutritional and 
epigenetic manipulation. 
 
Figure 2.1 Examples of microalgal PKSs and NRPSs. 
2.2. Results and discussion 
2.2.1. Acidic and basic extracts of E. gracilis in EG:JM 
The ethyl acetate (EtOAc) extracts of E. gracilis cultivated in EG:JM (1:1, 
Euglena gracilis medium:Jaworski’s medium) were treated with HCl or NaOH and 








































PDA-MS contained a few peaks, which are present in both culture extracts and 
medium extracts (Figure 2.2). The acid-base extraction was performed to simplify the 
metabolic profiles and assist the extraction of any acidic and basic minor metabolites. 
However, based on the LC-PDA-MS results, the extraction protocol used for these 
samples failed to extract any detectable natural products either from the supernatant or 
the cells. It is possible that some secondary metabolites are neutral compounds not 
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Figure 2.2 TACs (200-600 nm; 100 × 2.1mm, 2.6μm Kinetex C18 column; 0.5 mL/min flow rate; 20-100% 
acetonitrile over 10 min) of E. gracilis extracts cultivated in EG:JM compared to the medium control extracts. 
2.2.2. Nutritional and epigenetic manipulation 
It is well known that amino acids are essential as nutrients for microbial growth, in 
addition to their function as precursors for secondary metabolites (e.g. NRPs). 




of secondary metabolites. For instance, methionine and norleucine induced the 
production of cephalosporins by Cephalosporium sp.[174] In contrast, lysine inhibited 
benzylpenicillin biosynthesis in Penicillium chrysogenum and was demonstrated to be 
involved in the regulation of penicillin biosynthesis in low and high-producing 
strains.[175,176] Moreover, fumagillin production by Aspergillus fumigatus was 
increased by 15-fold with L-glutamic acid compared to sodium nitrate while L-aspartic 
acid was inferior to sodium nitrate, even though growth was stimulated.[99] Based on 
the paper published by Yuji et al.[173] about the utilisation and toxicity of exogenous 
amino acids in E. gracilis, it was hypothesised that amino acids might have negative 
or positive effects on the secondary metabolism of Euglena. EG:JM medium might 
contain amino acids impairing secondary metabolite biosynthesis and others with a 
positive impact but in small amounts not enough for the production of secondary 
metabolites. Therefore, individual amino acids were used to replace the nitrogen 
source in EG:JM medium.  
 L-Glutamate as a nitrogen source 
Glutamate (Glu) was selected as a nitrogen source as it had been reported by 
Yuji et al.[173] as the most effective nutrient among 21 amino acids. Figure 2.3 shows 
the growth rate of E. gracilis in three different media (synthetic medium, complex 
medium, and synthetic medium + 30 mM Glu) cultivated in the light, and one medium 
(synthetic medium + 30 mM Glu supplemented with glucose (Glc) as a carbon source) 
cultivated in the dark. Complex medium, synthetic medium + 30 mM Glu and 
synthetic medium + 30 mM Glu + Glc were efficient media. The cultures in these three 
media appeared healthy with a high growth rate and cell density. The culture in the 




incubation, followed by the complex medium and synthetic medium + 30 mM Glu 
reaching the stationary phase by the seventh day. The synthetic medium had the 
slowest growth rate and the lowest cell density even after 13 days of incubation. 
 
Figure 2.3 Comparison of the growth rate of E. gracilis in complex medium, synthetic medium + 30 mM Glu, 
synthetic medium + 30 mM Glu + Glc and synthetic medium. 
 Metabolic profiles of E. gracilis in modified media 
E. gracilis was cultivated in the modified media mentioned above, and the 
growth was monitored using a photobioreactor. Each culture was harvested at the 
stationary phase, and the cell biomass and supernatant were extracted separately with 
EtOAc and analysed by HPLC-UV using a 50-100% acetonitrile/water gradient over 
22 min. The HPLC traces (at 270 nm) of cell extracts presented a distinct difference 
between the cultures supplemented with Glu and those without Glu (Figure 2.4). The 
former showed a major peak at 4.22 min retention time that is hardly detected and 
completely absent in complex medium and synthetic medium, respectively. Moreover, 
the intensity of the peak at 4.22 min was at least three times higher in the culture 
cultivated in the light compared to cultivation in the dark in the presence of Glc as a 



























Synthetic medium + 30 mM Glu





in addition to the effect of the nitrogen source on metabolite production, the 
metabolites are produced in higher amounts in the photoautotrophic culture compared 
to heterotrophic. The metabolites are likely to be intracellular as they were not detected 
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Figure 2.4 HPLC traces (at 270 nm; 150 × 4.6mm, 5μm Agilent C18 column; 1 mL/min flow rate; 50-100% 
acetonitrile over 22 min) of E. gracilis cell extracts cultivated in synthetic medium + 30 mM Glu, synthetic 
medium + 30 mM Glu + Glc, synthetic medium and complex medium. 
LC-PDA-MS analysis of the E. gracilis extract (cultivated in synthetic medium 
+ 30 mM Glu) using a 20-100% acetonitrile/water gradient over 10 min exhibited an 
improved separation (Figure 2.5) indicating that the peak observed on the HPLC trace 
contains five separated metabolites (A-E) along with other mixtures (M1-M2). This 
improved separation might be due to the change of the gradient system, the column, 
the flow rate, or the LC system. The UV profiles of all metabolites presented maxima 
of absorbance at 260, 269 and 280 nm, suggesting a conjugated triene substructure 




metabolites showing [M + Na]+ and two characteristic protonated product ions in the 
positive ion mode (Figure 2.7) corresponding to a neutral loss of methanol (MeOH, 32 
Da) and water (H2O, 18 Da) and a loss of MeOH (32 Da). In the negative ion mode, 
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Figure 2.5 Total absorbance chromatogram (200-600 nm; 100 × 2.1mm, 2.6μm Kinetex C18 column; 0.5 mL/min 
flow rate; 20-100% acetonitrile over 10 min) of E. gracilis extract cultivated in  
synthetic medium + 30 mM Glu. 
 
























































































Figure 2.7 Positive ion mode MS spectra of A-E showing [M+Na]+ and two characteristic protonated product 



















































































 Extraction of E. gracilis with methanol versus ethyl acetate 
To investigate the best method for cell disruption and extraction, E. gracilis cells 
were harvested by centrifugation from 10 mL cultures and suspended in MeOH or 
EtOAc. MeOH was effective in cell disruption resulting in the release of the cell 
contents in the solvent without any additional disruption methods while the cells 
suspended in EtOAc formed cell clumps retaining their contents inside the cells 
(Figure 2.9). Therefore, EtOAc requires additional disruption methods to enable cell 
lysis and release of intracellular components. To compare the extraction with MeOH 
to EtOAc assisted by a mechanical disruption method, E. gracilis cells were harvested 
from 10 mL cultures and extracted with MeOH or ground in liquid nitrogen and 
extracted with EtOAc. Both methods appeared effective in cell disruption, releasing 
the contents of the cells in the employed solvent. After evaporation of the solvents, the 
residues were dissolved in MeOH and analysed by LC-PDA-MS. Comparing the 
intensity of the metabolites in MeOH extract to EtOAc extract, it was apparent that 
MeOH resulted in extraction of a larger amount of the metabolites (Figure 2.10). This 
could be attributed to the solubility of the metabolites or the cell lysis efficiency of the 
disruption method. 
 










2 3 4 5 6
 
Figure 2.10 Comparative TAC (200-600 nm; 100 × 2.1mm, 2.6μm Kinetex C18 column; 0.5 mL/min flow rate; 
20-100% acetonitrile over 10 min) of E. gracilis cells extracted with MeOH (MeOH extract) and EtOAc (EtOAc 
extract). 
 Three-litre culture and method development for separation 
E. gracilis cells were harvested from three-litre culture cultivated in synthetic 
medium + 30 mM Glu and extracted with 90% MeOH.[177] Since E. gracilis contains 
substantial amounts of lipids and pigments, the aqueous MeOH was partitioned with 
hexane.[177] This transfers most of the lipids and pigments from the aqueous MeOH 
layer to the hexane layer (Figure 2.11). After partitioning, the aqueous MeOH residue 
was fractionated on flash chromatography, and the fractions containing the target 
metabolites were used to develop an HPLC method for separation and purification. 
The best separation was achieved with a 34% isocratic system of acetonitrile in water 
without additives and a flow rate of 3 mL/min. However, the purified amount from 




good amount of the target metabolites was wasted during method development. 
Moreover, although the extraction protocol is useful for lipids and pigments removal, 
it might also remove some amount of the target metabolites if they are soluble in 
hexane.  
 
Figure 2.11 E. gracilis cell extract partitioned between 90% MeOH (aqueous MeOH layer) and pure hexane 
(hexane layer) in a separating funnel. 
 Liquid-liquid extraction 
A small-scale experiment was performed to find the best protocol for removal of 
lipids and pigments without losing the target compounds. E. gracilis cells were 
extracted with 90% MeOH, and the extract was equally distributed in three vials. The 
aqueous MeOH extract of one of the vials was partitioned with an equal volume of 
hexane and then dried in a centrifugal evaporator together with the other two vials. 
The residue from the partitioned extract and one of the remaining residues were each 
dissolved in 1 mL MeOH. The residue in the third vial was dissolved in 1 mL water, 





and all samples were analysed by HPLC using a 20-100% acetonitrile in water 
gradient. Dissolving the residue in water after evaporation of aqueous MeOH removes 
lipids and pigments due to their limited solubility in water. However, comparative 
HPLC traces presented that water is an inappropriate solvent for the target metabolites 
and has low dissolving capacity compared to aqueous MeOH (Figure 2.12). On the 
other hand, partitioning of aqueous MeOH extract with hexane did not cause any 
notable decrease in the metabolite quantity based on comparison of the peak intensity 
of the partitioned and non-partitioned extracts (Figure 2.12). This makes the extraction 
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Figure 2.12 Comparative HPLC traces (at 270 nm; 150 × 4.6mm, 5μm Agilent C18 column; 1 mL/min flow rate; 
20-100% acetonitrile over 22 min) of E. gracilis cell MeOH extract partitioned with hexane (MeOH + hexane), 
MeOH extract (MeOH) and dried MeOH extract dissolved in water (Water). 
 Epigenetic modifiers for metabolite induction 
Epigenetic modifiers were investigated to induce the production of E. gracilis 
metabolites. Vorinostat (HDACI) and 5-AC (DNMTI) were selected as it has been 




silencing machinery in the E. gracilis transcription.[170] The appropriate doses of these 
modifiers were determined using two-fold serial dilutions performed in a 96-well plate 
with the highest concentration at 2 mM for vorinostat and 12.5 mM for 5-AC.  The 
growth of E. gracilis in the presence of vorinostat at doses equal to or lower than 250 
μM did not appear to be negatively affected. However, doses higher than 250 μM of 
vorinostat were lethal to the strain. Similarly, 5-AC was lethal at doses greater than 
781 μM but the growth was completely normal at 781 μM. Nevertheless, the actual 
lethal dose of 5-AC might be different from the calculated dose as 5-AC suffers from 
instability, and some of it might have degraded during preparation or directly after 
addition to the medium.  
E. gracilis was cultivated in 50-mL tubes containing 10 mL of synthetic medium 
+ 30 mM Glu and 100 μM vorinostat, 500 μM 5-AC or a combination of the two 
modifiers (50 μM vorinostat + 250 μM 5-AC). Comparative analysis of MeOH extracts 
by HPLC (UV detection at 270 nm) did not show noticeable differences between the 
cultures treated with epigenetic modifiers and control cultures. However, this 
experiment was limited to UV active metabolites, and it is possible that some 
metabolites are induced with the epigenetic modifiers but are not UV active or their 
absorbance is outside the employed UV detection range.  
 Supplementation of complex medium with glutamate 
E. gracilis was cultivated in 50-mL tubes containing 10 mL of the complex 
medium + 30 mM Glu or synthetic medium + 30 mM Glu. The cells were harvested 
by centrifugation and extracted with 90% MeOH. The extracts were analysed by LC-
PDA-MS, and the intensity of the metabolites was compared by overlaying the TACs 




(Figure 2.13). Comparative TACs revealed that the metabolites are produced in 
significantly higher amounts in synthetic medium + 30 mM Glu. Although the 
complex medium + 30 mM Glu contained all components of the synthetic medium, 
the metabolite production was considerably affected by the presence of yeast extract 
and tryptone. This confirms that the induction observed with 30 mM Glu is not only 
attributed to the presence of this amino acid but also to the absence of other 
components that might have a negative effect on the secondary metabolism. Therefore, 
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Figure 2.13 Comparative TAC (200-600 nm; 100 × 2.1mm, 2.6μm Kinetex C18 column; 0.5 mL/min flow rate; 
20-100% acetonitrile over 10 min) of E. gracilis cultivated in the synthetic medium + 30 mM Glu and complex 
medium + 30 mM Glu. 
 Supplementation of synthetic medium with amino acids 
E. gracilis was cultivated in 50-mL tubes containing 10 mL of complex medium 
(neutral pH and pH 4.8) or synthetic medium supplemented with asparagine (30 mM 
Asn), 30 mM Glu, serine (30 mM Ser), proline (30 mM Pro), glycine (30 mM Gly), 




were harvested and extracted with 90% MeOH. The extracts were analysed by HPLC 
using a 20-100% acetonitrile in water gradient, and the intensity of the metabolites was 
compared by overlaying the HPLC traces (Figure 2.14). Asn allowed the highest 
production of A-E and M2 followed by, in decreasing order, Glu, Gln, Ala, Gly, Asp 
and Pro. Nevertheless, M1 appeared to be produced in higher amount in Glu compared 
to the other amino acids. The metabolites were not detected in the complex medium 
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Figure 2.14 Comparative HPLC traces (at 270 nm; 150 × 4.6mm, 5μm Agilent C18 column; 1 mL/min flow rate; 
20-100% acetonitrile over 22 min) of E. gracilis extracts cultivated in different amino acids and complex medium 
with neutral pH and adjusted to 4.8. 
 Supplementation of synthetic medium with Asn and Glu 
As the highest production of M1 was observed with 30 mM Glu, and A-E and 
M2 with 30 mM Asn, it was assumed that combination of the two amino acids might 




50-mL tubes containing 10 mL of synthetic medium supplemented with 15 mM Glu, 
15 mM Asn or both 15 mM Glu and 15 mM Asn. The cells were harvested and 
extracted with 90% MeOH. The extracts were analysed by UHPLC, and the intensity 
of the metabolites was compared by overlaying the UHPLC traces (Figure 2.15).  
In synthetic medium + 15 mM Glu + 15 mM Asn, a small amount of M1 was 
detected while the intensity of A-E was higher in this medium compared to synthetic 
medium + 15 mM Glu but not significantly different from synthetic medium + 15 mM 
Asn. Moreover, synthetic medium + 15 mM Glu had the highest intensity of M1, 
although that of A-E was lower than the other two media. M2 was nearly undetectable 
in any of the three media. To conclude, although the production of A-E is higher in 15 
and 30 mM Asn, the production of M1 is higher in 15 and 30 mM Glu. Therefore, 
synthetic medium + 30 mM Glu is the ideal medium that will enable the production of 
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Figure 2.15 Comparative UHPLC traces (at 270 nm; 100 × 2.1mm, 2.6μm Accucore C18 column; 0.5 mL/min 
flow rate; 20-100% acetonitrile over 10 min) of E. gracilis cultivated in synthetic medium + 15 mM Glu, in 




 Determination of the optimum time for extraction 
To determine the optimum time for extraction, E. gracilis was cultivated in a 1-
L flask containing 500 mL of synthetic medium + 30 mM Glu. An aliquot of 10 mL 
was taken every day for 13 days, starting 24 h after inoculation, and the cells were 
harvested and extracted with 90% MeOH. The extracts were analysed by UHPLC, and 
the intensity of the metabolites was compared by overlaying the UHPLC traces (Figure 
2.16). The metabolite production had been increasing gradually to reach the highest 
concentration after ten days of inoculation before it started decreasing for the following 
three days. This decline in the detected amounts of metabolites might be caused by 
degradation or conversion of metabolites by E. gracilis. Alternatively, it might be a 
result of cell death and lysis leading to the release of metabolites in the medium as 
only cell extracts were analysed in this experiment. However, the purpose of this 
experiment was to determine the optimum time for extraction when the production of 
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Figure 2.16 Comparative UHPLC traces (at 270 nm; 100 × 2.1mm, 2.6μm Accucore C18 column; 0.5 mL/min 




2.3. Conclusions and future work 
Nutritional manipulation of E. gracilis was effective in the induction of 
secondary metabolites, leading to the production of several metabolites in synthetic 
medium + 30 mM Glu which are nearly undetectable in the complex medium even 
when supplemented with Glu. The cultivation of E. gracilis in the dark was less 
efficient for metabolite production than cultivation in the light. MeOH appeared to be 
superior to EtOAc for cell lysis and extraction. Additionally, partitioning of aqueous 
MeOH with hexane was an efficient protocol for the removal of lipids and pigments. 
The small amounts of the produced metabolites were not enough for structure 
elucidation on the instruments available at UEA facilities. Therefore, epigenetic 
modifiers and amino acids supplementation were experimented to increase the yield 
of secondary metabolites, but both did not improve the yield of all target metabolites. 
Asn improved the yield of the major metabolites but failed to improve that of the minor 
metabolites. The optimum time for extraction was found to be ten days after 
inoculation. Hence, E gracilis will be cultured in synthetic medium + 30 mM Glu for 
ten days to obtain sufficient amounts of these compounds for structure elucidation and 
biological assays. However, prior to large-scale cultivation, dereplication is an 
essential step to ensure that the induced metabolites are novel. Finally, other Euglena 





2.4. Materials and methods 
2.4.1. General methods and materials 
Unless stated otherwise, all chemicals and solvents were purchased from Sigma-
Aldrich, Alfa Aesar or Fisher Scientific. All solvents were of HPLC grade or 
equivalent. Commercial media and media components were purchased from Sigma-
Aldrich, Alfa Aesar, Fisher Scientific or Formedium. Unless stated otherwise, the pH 
of media was adjusted to 4.8 with 1 N HCl and 1 N KOH prior to autoclaving. 
2.4.2. Cultivation of E. gracilis in EG:JM 
Euglena gracilis var. saccharophila Klebs (strain 1224/7A) was obtained from 
the Culture Collection of Algae and Protozoa (CCAP) (https://www.ccap.ac.uk) and 
treated with antibiotics to produce axenic cultures using the protocol recommended by 
CCAP.[178] Cultures were cultivated in EG:JM (Euglena gracilis medium (Table 2.1) 
plus Jaworski’s Medium (Table 2.2), replacing ‘‘Lab- Lemco’’ with Tryptone)[169] and 
incubated in a light chamber at 22 oC on a 14 h light /10 h dark cycle with a light 
intensity of 100 μmol. photons. m-2 s-1. After four days of incubation, E. gracilis cells 
were harvested by centrifugation at 2000 x g and 10 oC for 5 min and suspended in 
EG:JM medium. The absorbance at 740 nm was adjusted on a CLARIOstar microplate 
reader to 0.1 (≈ 4 g of wet cells per litre) using EG:JM medium as a diluent and blank. 
This suspension was used to inoculate the production media to obtain approximately 
0.2 g of wet cells per litre (1:20 dilution). For cultivation in the dark, 2 L of EG:JM, 
supplemented with 15 g/ L Glc, were inoculated with E. gracilis cells, and incubated 





Table 2.1 EG (E. gracilis) medium. 
Components Per 1000 mL 
Sodium acetate trihydrate  
"Lab-Lemco" powder  
Tryptone   







Add constituents above to 1 litre of deionised water and autoclave at 15 psi for 15 minutes. 
 
Table 2.2 JM (Jaworski's medium). 
Stock solutions Per 200 mL 
 (1) Ca(NO3)2.4H2O                                                                     
(2) KH2PO4                                                                                
(3) MgSO4.7H2O                                                                        
(4) NaHCO3                                                                               
(5) EDTAFeNa                                                                           
EDTANa2.2H2O                                                                          
(6) H3BO3                                                                                  
MnCl2.4H2O                                                                               
(NH4)6Mo7O24.4H2O                                                                   
(7) Cyanocobalamin                                                                   
Thiamine HCl                                                                             
Biotin                                                                                        
(8) NaNO3                                                                                  















Take 1 mL of each stock solution, make up to 1 litre with deionised water and autoclave at 15 psi 





 Acid-base extraction 
After four days of cultivation in the dark, the culture was centrifuged at 3130 x 
g and 4 oC for 20 min. The pellet and supernatant were separated and extracted with 
EtOAc followed by acid-base extraction procedure (Figure 2.17). The pellet had been 
ground in liquid nitrogen using a mortar and pestle before extraction with EtOAc. A 
medium control was also extracted in the same way to be used for comparison. After 
solvent evaporation, the residue of each extract was dissolved in an appropriate volume 
of MeOH to obtain a final concentration of 1 mg/mL and filtered using 0.2 μm PTFE 
filter (Whatman, Sigma-Aldrich). The extracts from the cells were also passed through 
SOLA HRP SPE cartridges (Thermo Fisher Scientific) to remove lipids. 
 
Figure 2.17 Acid-base extraction procedure of E. gracilis cultures. 
Centrifuge cultures at 3130 x g and 4 oC for 
20 minutes
Supernatant
Extract with EtOAc (600 mL x 3)
Concentrate the EtOAc layers to 100 mL
Partition the EtOAc layer with 100 mL 
of 1 N HCl
EtOAc layer, partition with equal volume of 
1 N NaOH
1 N NaOH layer, neutralise with 
HCl to pH =7
Partition this layer with equal 
volume of EtOAc
Treat the EtOAc layer with MgSO4 and 
filter through a filter paper
Evaporate the solvent and 
prepare the samples for 
analysis
1 N HCl layer, neutralise with NaOH to 
pH =7
Partition this layer with 
equal volume of EtOAc
Treat the EtOAc layer with 
MgSO4 and filter through a 
filter paper
Evaporate the solvent and 
prepare the samples for 
analysis
Pellet
Grind in liquid nitrogen and extract 
with EtOAc (600 mL x 3)





2.4.3. LC-PDA-MS analysis 
LC-PDA-MS data were acquired on a Shimadzu Nexera UHPLC attached to a 
Shimadzu ion-trap-ToF (IT-ToF) mass spectrometer. A 5-μL aliquot of each sample 
was injected onto a Phenomenex Kinetex EVO-C18 column (100 × 2.1mm, 2.6μm). 
The following gradient was used (acetonitrile versus 0.1% formic acid in water, at 0.5 
mL/min and 40°C): 0 min (20% acetonitrile), 10 min (100% acetonitrile), 12 min 
(100% acetonitrile), 12.1 (20% acetonitrile), 16.1 min (20% acetonitrile). The 
instrument collected UV/visible spectra from 200-600 nm and MS spectra from m/z 
200-2000. MS also collected MS/MS (fragmentation) spectra from the most abundant 
ions using collision-induced dissociation energy of 50% and a precursor ion width of 
3 Da. Spray chamber conditions were 250°C curved desorbation line (CDL), 300°C 
heat block, 1.5 L.min-1 nebuliser gas, and drying gas “on”. Sodium trifluoroacetate 
was used for mass calibration according to the manufacturer’s instructions. The LC 
and MS data were analysed using LabSolutions (Shimadzu), profiling solutions 
(Shimadzu) and ACD/Spectrus Processor (Advanced Chemistry Development). 
2.4.4. Media modification and cultivation 
Four different media were prepared: synthetic medium (JM + 1 g L-1 sodium 
acetate trihydrate + 0.1 g L-1 calcium chloride), complex medium (synthetic medium 
+ 2 g L-1 yeast extract + 3 g L-1 tryptone), synthetic medium + 30 mM Glu and synthetic 
medium + 30 mM Glu + 15 g L-1 Glc. The pH was adjusted to 4.8 with 1 N HCl and 1 
N KOH [179–181] prior to autoclaving. E. gracilis inocula were cultivated in EG:JM 
medium, and the absorbance at 740 nm was adjusted on a CLARIOstar microplate 
reader to 0.1 (≈ 4 g of wet cells per litre) using EG:JM medium as a diluent and blank. 




times with sterile Milli-Q water to remove any trace components of EG:JM medium, 
and suspended in the modified medium used for cultivation. This suspension was used 
to inoculate four 1-L flasks each containing 400 mL of the medium to obtain 
approximately 0.2 g of wet cells per litre (1:20 dilution). Cultures cultivated in 
synthetic medium, complex medium and synthetic medium + 30 mM Glu were 
incubated in a light chamber at 22 oC on a 14 h light /10 h dark cycle with a light 
intensity of 100 μmol. photons. m-2 s-1. Synthetic medium + 30 mM Glu + Glc culture 
was incubated in the dark at 30 oC and shaken at 200 rpm. The growth was measured 
daily in the flasks using a photobioreactor Algem (Algenuity).  
2.4.5. Extraction of modified media cultures 
E. gracilis was cultivated in the modified media mentioned above (section 
2.4.4), and the growth was monitored using a photobioreactor Algem (Algenuity). 
Each culture was harvested at the stationary phase by centrifugation at 3130 x g and 4 
oC for 20 min. The cells were ground in liquid nitrogen and extracted with 200 mL 
EtOAc. The supernatant was freeze-dried and extracted with 200 mL EtOAc. The 
solvents were evaporated, and the residue of each extract was then re-dissolved in 20 
mL MeOH, and 1 mL of each solution was filtered using a 0.2 μm PTFE filter 
(Whatman, Sigma-Aldrich). The extracts from the cells were also passed through 
SOLA HRP SPE cartridges (Thermo Fisher Scientific) to remove lipids. 
2.4.6. HPLC analysis 
HPLC analysis was performed on an Agilent 1200 series system (Agilent 
Technologies) and an Agilent C18 column (4.6 x 150mm, 5μm). For 50-100% 
acetonitrile/water gradient, the following gradient was used (acetonitrile versus 0.1% 




acetonitrile), 24 min (100% acetonitrile), 26 min (50% acetonitrile), 30 min (50% 
acetonitrile), and the detection was set at 210, 270, 290 and 450 nm. For 20-100% 
acetonitrile/water gradient, the following gradient was used (acetonitrile versus 0.1% 
formic acid in water, at 1.3mL/min and 40°C): 0 min (20% acetonitrile), 20 min (100% 
acetonitrile), 24 min (100% acetonitrile), 25 min (20% acetonitrile), 30 min (20% 
acetonitrile), and the detection was set at 210, 270, 290 and 450 nm.  
2.4.7. Cultivation and extraction of 10-mL cultures in 50-mL tubes 
E. gracilis inocula were cultivated in EG:JM medium, and the absorbance at 740 
nm was adjusted on a CLARIOstar microplate reader to 0.1 (≈ 4 g of wet cells per 
litre) using EG:JM medium as a diluent and blank. Cells were harvested by 
centrifugation at 2000 x g and 10 oC for 5 min, washed three times with sterile Milli-
Q water to remove any trace components of EG:JM medium, and suspended in the 
modified medium (pH adjusted to 4.8 prior to autoclaving) used for cultivation. This 
suspension was used to inoculate 50-mL tubes each containing 10 mL of the medium 
to obtain approximately 0.2 g of wet cells per litre (1:20 dilution). Cultures were 
cultivated at ambient temperature 22-25 oC under daylight lamps (2000 lumens). After 
six days, cultures were centrifuged at 3000 x g and 4 oC for 20 min, and cells were 
vortexed in 10 mL 90% MeOH or ground in liquid nitrogen and extracted with 10 mL 
EtOAc. Cell debris was removed by centrifugation at 3000 x g and 4 oC for 10 min. 
After centrifugation, the solvents were evaporated, and the residue of each extract was 
then dissolved in 1 mL MeOH and passed through SOLA HRP SPE cartridges 




2.4.8. Three-litre culture and method development for separation 
E. gracilis inocula were prepared as described above and used to inoculate six 
1-L flasks each containing 500 mL of synthetic medium + 30 mM Glu to obtain 
approximately 0.2 g of wet cells per litre (1:20 dilution). The culture was incubated at 
ambient temperature 22-25 oC under daylight lamps (2000 lumens). After six days, the 
culture was centrifuged at 3130 x g and 4 oC for 20 min, and the cells were extracted 
with 1 L 90% MeOH and magnetic stirrer. After an hour, the aqueous MeOH extract 
was partitioned with an equal volume of hexane to remove lipids and pigments. The 
aqueous MeOH layer was centrifuged to remove the debris and then evaporated to get 
the residue (400 mg). This residue was fractionated on a 26 g reversed-phase column 
attached to an automated flash-chromatography system (CombiFlash Rf, Teledyne 
Isco) using 30 mL/min flow rate and a linear gradient from 50% to 100% acetonitrile 
in water (in 6 min) before washing the system with 100% acetonitrile (for 3 min). 
Fractions containing the target compounds were concentrated to dryness on a 
centrifugal evaporator to give a residue amount of 43 mg. This amount was dissolved 
in MeOH, and purification was attempted on an Agilent HPLC system with a semi-
preparative C18 column and UV detection at 210 and 270 nm. Method development 
for purification was performed by changing the following parameters: solvents 
(acetonitrile, MeOH, water, water + trifluoroacetic acid and water + formic acid); oven 
temperature; gradient and isocratic systems; flow rate. 
2.4.9. UHPLC analysis 
UHPLC analysis was performed on a Thermo Scientific Ultimate 3000 UHPLC 
system and a Thermo Scientific Accucore C18 column (2.1 × 100 mm, 2.6 μm). The 




mL/min and 40 °C): 0 min (20% acetonitrile), 10 min (100% acetonitrile), 12 min 
(100% acetonitrile), 12.1 (20% acetonitrile), 16.1 min (20% acetonitrile). The 
detection was set at 210, 270, 290 and 450 nm.  
2.4.10. Liquid-liquid extraction 
E. gracilis inocula were prepared as described above and used to inoculate a 100-
mL flask containing 50 mL of synthetic medium + 30 mM Glu to obtain approximately 
0.2 g of wet cells per litre (1:20 dilution). The culture was incubated at ambient 
temperature 22-25 oC under daylight lamps (2000 lumens). After six days, the culture 
was centrifuged at 3130 x g and 4 oC for 20 min, and the cells were extracted with 50 
mL 90% MeOH. The extract solution was equally distributed in three vials. The 
aqueous MeOH extract of one of the vials was partitioned with an equal volume of 
hexane, and then dried in a centrifugal evaporator together with the other two vials. 
The residue from the partitioned extract and one of the remaining residues were 
dissolved in 1 mL MeOH. The residue in the third vial was dissolved in 1 mL water, 
all samples were analysed by HPLC with UV detection at 270 nm.  
2.4.11. Cultivation with epigenetic modifiers 
The appropriate doses of vorinostat and azacytidine were determined using two-
fold serial dilutions in synthetic medium + 30 mM Glu (containing 2% DMSO) with 
the highest concentration at 2 mM for vorinostat and 12.5 mM for 5-AC. E. gracilis 
cells were harvested from four-day-old culture by centrifugation at 2000 x g and 10 oC 
for 5 min and suspended in EG:JM medium. The absorbance at 740 nm was adjusted 
on a CLARIOstar microplate reader to 0.1 (≈ 4 g of wet cells per litre) using EG:JM 
medium as a diluent and blank. This cell suspension was used to inoculate a 96-well 




synthetic medium + 30 mM Glu containing the epigenetic modifiers or 2% DMSO 
(control). The plate was incubated for six days at ambient temperature 22-25 oC under 
daylight lamps (2000 lumens) and the growth was measured using a CLARIOstar 
microplate reader in addition to visual inspection. 
Epigenetic experiments were performed in 10-mL flacon tubes containing 9.9 mL 
of cell suspension and 100 μL of epigenetic stock solutions or DMSO (control). 
Vorinostat and 5-AC stock solutions were prepared in DMSO and sterilised by 
filtration under aseptic conditions. The cell suspension was prepared in synthetic 
medium + 30 mM Glu to obtain approximately 0.2 g of wet cells per litre. The final 
concentrations of the epigenetic modifiers were 100 μM vorinostat, 500 μM 5-AC or 
a combination of the two modifiers (50 μM vorinostat + 250 μM 5-AC). Cultures were 
incubated at ambient temperature 22-25 oC under daylight lamps (2000 lumens). After 
six days, the cultures were centrifuged at 3000 x g and 4 oC for 20 min, and cells were 
vortexed in 10 mL 90%. MeOH.  Cell debris was removed by centrifugation at 3000 
x g and 4 oC for 10 min. After centrifugation, the solvent was evaporated, and the 
residue of each extract was then dissolved in 1 mL MeOH and passed through SOLA 
HRP SPE cartridges (Thermo Fisher Scientific) and a 0.2 μm PTFE filter (Whatman, 
Sigma-Aldrich). 
2.4.12. Determination of the optimum time for extraction 
E. gracilis inocula were prepared as described above and used to inoculate a 1-L 
flask containing 500 mL of synthetic medium + 30 mM Glu to obtain approximately 
0.2 g of wet cells per litre (1:20 dilution). An aliquot of 10 mL was taken every day 
for 13 days, starting 24 h after inoculation, and centrifuged at 3000 x g and 4 oC for 20 




evaporated, and the residue of the extract was stored in a freezer at - 20 oC until 
UHPLC analysis. Samples were prepared immediately before analysis by adding 1 mL 
MeOH and passing the solutions through SOLA HRP SPE cartridges (Thermo Fisher 








3. Dereplication, isolation, structure elucidation and 
bioassays of euglenatides A-E 
3.1. Introduction 
Nutritional manipulation of E. gracilis led to the induction of several 
metabolites. Three-litre culture was insufficient for the isolation and characterisation 
of the metabolites. However, preliminary literature search suggested that the induced 
metabolites are novel as their measured masses and UV profiles do not match those of 
any metabolites previously known from Euglena. Besides chlorophyll derivatives, 
xanthophyll derivatives and fatty acids, there are two metabolites known from Euglena 
genus. These metabolites are euglenapterin from E. gracilis[182] and euglenophycin 
from E. sanguinea and other species[183,184] (Figure 3.1). Nevertheless, before 
implementing large-scale cultivation, extensive dereplication of the induced 
metabolites is conducted using high-resolution accurate masses, UV profiles and 
MS/MS spectra. After confirming the novelty of the metabolites, large-scale 
cultivation is performed to characterise the structure of the metabolites and evaluate 
their biological activity. Finally, a molecular network is constructed to identify related 
metabolites produced by other Euglena species.   
 




3.2. Results and discussion 
3.2.1. High-resolution MS and dereplication 
 High-resolution analysis of metabolites A-E in negative ion mode (Figure 3.2) 
revealed two signals at m/z 825.4612 [M-H]- (calcd. for C39H65N6O13, 825.4615, Δ= -
0.4 ppm) and m/z 871.4667 [M+FA-H]- (calcd. for C40H67N6O15, 871.4670, Δ= -0.3 
ppm) indicative of the molecular formula C39H66N6O13 for A, two signals at m/z 
808.4464 [M-H]- (calcd. for C38H62N7O12, 808.4462, Δ= 0.3 ppm) and m/z 854.4519 
[M+FA-H]- (calcd. for C39H64N7O14, 854.4517, Δ= 0.3 ppm) indicative of the 
molecular formula C38H63N7O12 for B, two signals at m/z 822.4615 [M-H]
- (calcd. for 
C39H64N7O12, 822.4618, Δ= -0.4 ppm) and m/z 868.4670 [M+FA-H]
- (calcd. for 
C40H66N7O14, 868.4673, Δ= -0.4 ppm) indicative of the molecular formula 
C39H65N7O12 for C, two signals at m/z 809.4659 [M-H]
- (calcd. for C39H65N6O12, 
809.4666, Δ= -0.9 ppm) and m/z 855.4714 [M+FA-H]- (calcd. for C40H67N6O14, 
855.4721, Δ= -0.8 ppm) indicative of the molecular formula C39H66N6O12 for D, and 
two signals at m/z 792.4516 [M-H]- (calcd. for C38H62N7O11, 792.4513, Δ= 0.4 ppm) 
and m/z 838.4571 [M+FA-H]- (calcd. for C39H64N7O13, 838.4568, Δ= 0.4 ppm) 
indicative of the molecular formula C38H63N7O11 for E.  
Databases (METLIN, NP Atlas, DNP and SciFinder) were searched using the 
accurate masses and UV profiles, but no known matching natural products were found, 
suggesting that these are novel metabolites. Likewise, METLIN, GNPS and MassBank 
were searched with MS/MS spectra. Although some metabolites in databases exhibit 
some MS/MS spectral similarities to metabolites A-E, their accurate mass and UV 

















































Figure 3.2 Negative ion mode high-resolution MS spectra of A-E. 
3.2.2. Large-scale cultivation, isolation and purification 
E. gracilis cells (53 g) were harvested from 18-L culture, extracted with 90% 
MeOH, partitioned with hexane and the aqueous MeOH was evaporated to obtain a 
residue of 1.679 g. Initial separation was performed on an automated flash-
chromatography system (Figure 3.3) to obtain a mixture of the target metabolites 
(186.7 mg). This mixture was dissolved in MeOH, and the compounds were purified 
on a semi-preparative HPLC (Figure 3.4) to afford 2.8 mg of A, 5.7 mg of B, 2.8 mg 
of C, 2.3 mg of D and 2.4 mg of E. The purity of compounds A-E was confirmed by 
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Figure 3.4 Semi-preparative HPLC trace (at 270 nm) of E. gracilis metabolites (A-E). 
















Run Length 60.0 Min 
Wavelength 1 (red): 210 nm                                                      Wavelength 2 (purple): 270 nm  



























































































































































































































































Figure 3.9 LC-UV-MS chromatograms and MS spectra of purified E. 
3.2.3. Structure elucidation of E. gracilis metabolites A-E 
The UV profiles of all metabolites presented maxima of absorbance at 260, 269 
and 280 nm, suggesting a conjugated triene substructure.[185] IR absorptions at 3347 
cm−1 (NH) and 1651 cm−1 (CO) indicated the presence of amide carbonyl groups while 
a broad peak at 2873 cm−1 indicated the presence of an aliphatic chain (Appendix 8.1). 
Compound B structure was elucidated by NMR during my placement in Fundación 
Medina in collaboration with Dr Fernando Reyes and Dr Ignacio Pérez-Victoria.  
The 13C NMR (Table 3.1) displayed carbonyl carbon signals at δC 176.3, 173.4, 
172.4, 172.3, 172.1, 171.1 and 169.6. The 1H NMR spectrum (Table 3.1) revealed nine 
amide protons at δH 6.88 (1H, s), 6.90 (1H, d), 7.06 (1H, s), 7.29 (1H, s), 7.36 (1H, s), 
7.65 (1H, d), 7.77 (1H, d), 7.78 (1H, s) and 9.02 (1H, d). These data indicated that 
compound B was a peptide. The overlapped signals at δH 1.25 in the 
1H NMR spectrum 




addition to a methyl group at δH 0.85 (3H, t) and δC 13.9 indicated that compound B is 
a lipopeptide containing a long alkyl chain. The signals at δH 4.31, 4.38, 4.44 and 5.13 
were indicative of four hydroxyls while the signals at δH 3.13 and δC 55.5 indicated 
the presence of a methoxy group. The presence of a triene was confirmed by the 
presence of six proton signals at δH 5.51 (1H, dd), 5.72 (1H, dt), 6.07 (1H, dd), 6.15 
(1H, dd), 6.20 (1H, dd), 6.24 (1H, dd), and six carbon signals at δC 135.1, 133.9, 132.8, 
131.3, 130.3, 130.0. Analysis of 1H, 13C, and HSQC data (Table 3.1), in addition to the 
COSY and HMBC correlations (Figure 3.10), revealed the presence of two asparagine 
residues (Asn I and Asn II), a β-aminoisobutyric acid residue (BAIBA) and a 4,5-
Dihydroxynorvaline residue (Dnv I). In addition, there is a unique β-amino-2,5-
dihydroxy-7-methoxy-8,10,12-eicosatrienoic acid residue that we have named 
graciline (Gra) after its origin from E. gracilis.  
The connectivity of the amino acid residues was established by COSY and 
HMBC as shown in Figure 3.10. All NH protons correlated to the carbonyls of the 
amino acid residues in the HMBC spectrum. This with the COSY correlations of the 
NH protons to the CHα and CHβ protons in the alpha and beta amino acid residues, 
respectively, concluded the sequence of the five amino acids of compound B as shown 
in Figure 3.10.  
Comparing the NMR spectra of E to those of B revealed that C-2 on Gra was 
shielded from 73.0 ppm to 40.9 ppm and the hydroxyl group on this carbon was 
replaced with an extra hydrogen (Appendix 8.2) as observed on the 1H, 13C, HSQC, 
COSY and HMBC (Figure 3.11). This confirmed that Gra observed in compound B is 
replaced with a β-amino-5-hydroxy-7-methoxy-8,10,12-eicosatrienoic acid residue 
(DeoxyGra) in compound E. 
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Figure 3.10 Key COSY and HMBC correlations used to establish the molecular connectivity of compound B. 
 
Figure 3.11 Key COSY and HMBC correlations used to establish the molecular connectivity of compound E. 
The NMR spectra of C were similar to those of B except that the former contained 
an extra methyl group (1H, δ 1.02 ppm; 13C, δ 19.5 ppm) and the chemical shift of C-
5 on Dnv I increased from 66.3 ppm to 69.9 ppm (Appendix 8.2). Careful analysis of 
COSY and HMBC revealed correlations between the new methyl group and C-5 on 




and C-4 and C-5 on the Dnv. This unambiguously confirmed that the new methyl 
group is located at C-5 of the Dnv converting the Dnv to 4,5-Dihydroxynorleucine 
(Dnl). 
 
Figure 3.12 Key COSY and HMBC correlations used to establish the molecular connectivity of compound C. 
Detailed analysis of NMR data of A revealed that it contains the same amino acid 
residues as B except that Asn II residue is replaced with a second Dnv (Dnv II, Table 
3.2). The connectivity of the amino acid residues was established by COSY and 
HMBC as shown in Figure 3.10. The correlation of the NH protons to the carbonyls 
of the amino acid residues in the HMBC spectrum and the COSY correlations of the 
NH protons to the CHα and CHβ protons in the alpha and beta amino acid residues, 
respectively, concluded the sequence of the five amino acids of compound A as shown 
in Figure 3.13.. The NMR spectra of D resembles those of A except that the C-2 on 
the triene amino acid is shielded from 73.0 ppm to 41.0 ppm because the hydroxyl 
group on this carbon is replaced with an extra hydrogen (Appendix 8.2) transforming 
Gra to DeoxyGra as observed on the 1H, 13C, HSQC, COSY and HMBC (Figure 3.14). 




contain unusual amino acids with some similarities to Caenorhabditis elegans 
metabolites (nemamides A and B, Figure 3.15).[186] 
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Figure 3.13 Key COSY and HMBC correlations used to establish the molecular connectivity of compound A. 
 
 





Figure 3.15 Chemical structures of nemamides A and B. 
The optical rotations of euglenatides A-E were as follows: euglenatide A: [α] D
25 
-24.2 (c 0.76, MeOH); euglenatide B: [α] D
25 -27.7 (c 0.97, MeOH); euglenatide C: [α] 
D
25 -22.1 (c 0.59, MeOH); euglenatide D: [α] D
25 -11.2 (c 0.88, MeOH); euglenatide E: 
[α] D
25 -14.7 (c 0.65, MeOH). 
3.2.4. Stereochemistry assignment of euglenatides A-E 
 Crystallisation 
Several crystallisation techniques were utilised, including slow solvent 
evaporation, slow cooling and vapour diffusion.[187] Some transparent glassy materials 
formed and were sent to Southampton X-ray diffraction unit for structural analysis, 
but all crystals did not have adequate quality for X-ray diffraction. Euglenatides A and 
B were tested for crystallization in 96-well crystallization plates against two 
commercial screens (PACT-premier and JCSG-plus, each with 96 conditions) using 
sitting-drop vapour diffusion method but this also failed to produce a crystal with a 
suitable quality.  
A sample of pure euglenatide B was sent to crystallisation experts at Crystallise! 
AG, Switzerland, for crystallisation and X-ray structural analysis. Although some 




turned to a yellowish viscous oil. This suggests that moisture and oxygen might destroy 
the compound or change its physical consistency. Although one particle provided 
diffraction, it had low intensities and resolution (3A) being ineffective for structural 
analysis. Since chemical derivatisation by converting hydroxyl groups to halobenzoic 
esters or halobenzyl ethers has been shown to facilitate the formation of single crystals 
for the purpose of X-ray diffraction studies,[188,189] replacement of hydroxyl groups 
with halobenzyl ethers was trialled with euglenatide B. After 20 h reaction, only a 
small amount of the original compound was detected by LC-MS along with other 
molecules smaller than 600 Da which might be degradation products, while the 
expected derivatised compound was not detected in this sample. After 48 h, neither the 
original compound nor the expected derivatives were detected.  
 Marfey’s analysis 
Chemical derivatisation with L-FDVA was used to determine the 
stereochemistry of the amino acids present in euglenatides A and B.[76,190,191] Asp and 
BAIBA were commercially available and purchased from Sigma-Aldrich. Dnv 
authentic standards were not commercially available but were kindly synthesized and 
provided by Prof. Thierry Gefflaut and Dr Armin Bauer.[192,193] The LC-MS analysis 
of the hydrolysates indicated that Asn was converted to Asp and reacted with FDVA 
providing an m/z 412.2 in the negative ion mode corresponding to [FDVA-Asp-H]- 
(Figure 3.16). Comparing the extracted chromatograms of the m/z 412.2 in the 
hydrolysates to the authentic standards revealed the presence of both L-FDVA-L-Asp 
(RT= 20.66 min) and L-FDVA-D-Asp (RT= 25.52 min) in euglenatide B while 
























































































































































































































Chromatographic separation of BAIBA enantiomers is more challenging as it is 
difficult to obtain reasonable resolution for derivatised BAIBA diastereomers even 
when using a relatively long shallow gradient.[194] Nevertheless, with the optimization 
of chromatographic conditions including mobile phase, stationary phase, temperature, 
flow rate and isocratic solvent system, it was possible to obtain chromatographic 
resolution sufficient for assignment of BAIBA configuration. The LC-MS analysis of 
the hydrolysates and BAIBA enantiomers indicated that the amino acid reacted with 
L-FDVA to provide an m/z 382.0 in the negative ion mode corresponding to [FDVA-
BAIBA-H]- (Figure 3.18). Comparing the extracted chromatograms of the m/z 382.0 
in the hydrolysates to the authentic standards (L-FDVA-L-BAIBA, RT= 59.47 min; 
and L-FDVA-D-BAIBA, RT= 56.98 min) revealed the presence of L-FDVA-D-













































Figure 3.19 Extracted ion chromatograms of the m/z 382 in derivatised BAIBA standards and euglenatides A and 
B hydrolysates. 
 The Dnv standards provided by Prof. Thierry Gefflaut were not pure but 
mixtures of L-series: L-Ala (70%) + L-syn-Dnv (26%) + L-anti-Dnv (4%) or D-series: 
D-Ala (25%) + D-syn-Dnv (9%) + D-anti-Dnv (66%). Nevertheless, the ratio of the 
isomers was adequate to assign a retention time for each isomer. Moreover, L-anti-
norvalinate derivative provided by Dr Armin Bauer was hydrolysed to obtain L-anti-
Dnv that was used to confirm the configuration of the Dnv moiety. The LC-MS 
analysis of the hydrolysates and Dnv diastereomers indicated that the amino acids 
reacted with L-FDVA to provide an m/z 428.1488 in the negative ion mode 
corresponding to [FDVA-Dnv-H]- (Figure 3.20). Comparing the extracted 
chromatograms of the m/z 428.1488 in the hydrolysates to the authentic standards (L-
FDVA-L-anti-Dnv, RT= 17.03 min; L-FDVA-L-syn-Dnv, RT= 32.38 min; L-FDVA-
D-anti-Dnv, RT= 24.92 min; L-FDVA-D-syn-Dnv, RT= 29.90 min) revealed the 
presence of L-FDVA-L-anti-Dnv in both euglenatides A and B (Figure 3.21). 




approximately double that in euglenatide B, confirming the presence of two Dnv 






















Figure 3.20 Acid hydrolysis of L-anti-norvalinate derivative, and chemical derivatisation and negative ion mode 




























Figure 3.21 Extracted ion chromatograms and spectra of the m/z 428 in derivatised Dnv standards and 
euglenatides A and B hydrolysates. 
Finally, the relative configurations of Gra and DeoxyGra were determined by 
comparison of 1H and 13C NMR chemical shifts, coupling constants, NOESY 
correlations and CD spectrum to those of nemamide A (Appendices 8.8-8.11). As all 
data matched those of nemamides, the absolute configurations of euglenatides A-E 
were proposed as shown in Figures 3.22 and 3.23. 
 





Figure 3.23 Chemical structures and proposed configurations of euglenatides B, C and E. 
3.2.5. Antimicrobial activity of euglenatides A-E 
Euglenatides A-E were evaluated for their antimicrobial activity against bacteria 
(methicillin-sensitive Staphylococcus aureus (MSSA ATCC 29213), methicillin-
resistant S. aureus (MRSA MB5393) and E. coli ATCC 25922), yeast (Candida 
albicans ATCC 64124), and mould (Aspergillus fumigatus ATCC 46645) following 
previously described methods.[190,195,196] Euglenatides presented antifungal activity, 
with IC50 values ranging from 10.2 to 32.7 µg/mL against C. albicans (Figure 3.24) 
and 3.5 to 6.9 µg/mL against A. fumigatus (Figure 3.25). The activity against both 
yeast (C. albicans) and mould (A. fumigatus) suggests a broad-spectrum antifungal 
activity. Remarkably, A-E did not display any activity against bacteria at the highest 
tested concentration of 128 µg/mL (Appendix 8.12) suggesting that these compounds 
have a specific target in eukaryotic cells rather than prokaryotes. Euglenatides A-E 
were also tested against C. tropicalis ATCC 750 and C. kruseii ATCC 6258 by Dr 
Mercedes de la Cruz and Dr Caridad Díaz (Fundación Medina, Spain). The level of 










































Figure 3.24 Dose–response curves and corresponding IC50 values of C. albicans incubated with euglenatides A, 
B, C, D and E.  











































Figure 3.25 Dose–response curves and corresponding IC50 values of A. fumigatus incubated with euglenatides A, 
B, C, D and E. 
3.2.6. Antiproliferative activity of euglenatide B 
The IC50 of euglenatide B was determined in a panel of human cancer cell lines, 
including acute monocytic leukaemia (THP-1), breast adenocarcinoma cells (MCF-7) 
and human lung adenocarcinoma epithelial cells (A-549). Euglenatide B displayed 
cytotoxic activity at nanomolar levels with IC50 values of 533, 773 and 292 nM against 




(vorinostat) exhibited cytotoxic activity at micromolar levels with IC50 values of 2.3, 
3.5 and 2.4 µM against THP-1, MCF-7 and A-549, respectively (Figure 3.26). 
 
Figure 3.26 Dose–response curves of THP-1, MCF-7 and A-549 cell lines incubated with euglenatide B or 
vorinostat (positive control). Data points represent the average ± standard error of three replicates. 
3.2.7. Antinematodal activity of euglenatide C 
Since nemamides A and B were shown to have a positive effect on starvation 
recovery in C. elegans, it was worthy of testing if euglenatides have a similar effect in 
C. elegans. Therefore, three different concentrations of euglenatide C (10 μM, 25 μM 
and 50 μM) were tested in C. elegans by our collaborators in the school of biological 
sciences, UEA. The conclusion drawn from this experiment was that euglenatide C 
has a toxic effect at early larval stages of development and does not display an apparent 
positive effect on starvation recovery. 





























































































3.2.8. Algastatic activity of euglenatide B in E. gracilis 
It is widely believed that a species is capable of avoiding autotoxicity via 
defensive mechanisms including biosynthesis of toxic compounds in extracellular 
compartments, excretion of biosynthesised toxic compounds into extracellular 
compartments, vacuolar sequestration, efflux pumps and modification of the toxic 
compounds or their target.[197,198] Nevertheless, it has been demonstrated that 
organisms use toxic metabolites for the regulation of their reproduction and 
development.[199,200] While low concentrations of toxic metabolites might serve 
regulatory purposes without negative effects on the producing organism, higher 
concentrations might result in abnormal processes or even death.[199,200] Moreover, an 
external application of toxic metabolites might bypass defensive mechanisms, 
especially when toxic metabolites are biosynthesised or sequestered in extracellular 
compartments.[200] 
To examine the toxicity of euglenatides against the producer, E. gracilis was 
cultivated in EG:JM and treated with different concentrations of euglenatide B, 1 mM 
vorinostat (positive control) or 1% DMSO (negative control). After four days of 
treatment, growth was significantly inhibited compared to culture controls (Figure 
3.27). However, it appears that the effect is cytostatic rather than cytotoxic as the strain 
recovered later and achieved a growth level close to the control levels after seven days 
of treatment (Figure 3.28). This experiment was repeated at 50 μM concentration of 
euglenatide B in EG:JM and synthetic medium + 30 mM Asn to investigate if the latter 
medium offers the strain higher tolerance to euglenatides as they are highly produced 
in this medium. After four days of treatment, there was no significant difference 




euglenatides might be biosynthesised or stored in isolated compartments to be released 






















































Figure 3.27 Growth of E. gracilis in EG:JM after four days of treatment with euglenatide B (1.25 μM to 100 μM), 






















































Figure 3.28 Growth of E. gracilis in EG:JM after seven days of treatment with euglenatide B (1.25 μM to 100 























Figure 3.29 Growth of E. gracilis in EG:JM (EG:JM) and synthetic medium + 30 mM Asn (Asn) after four days 




3.2.9. Related metabolites produced by E. sanguinea and E. mutabilis 
Although E. gracilis metabolites displayed potent antifungal and 
antiproliferative activities, some related metabolites produced by other Euglena 
species might have a higher yield, higher potency, superior selectivity or better 
physicochemical properties. Therefore, two Euglena species, E. sanguinea and E. 
mutabilis, were cultivated in complex medium or synthetic medium supplemented 
with different concentrations of Glu and Asn. E. sanguinea displayed limited growth 
in synthetic medium + 30 mM Glu, synthetic medium + 30 mM Asn and synthetic 
medium + 60 mM Glu, good growth in synthetic medium + 30 mM Glu + 30 mM Asn, 
and excellent growth in synthetic medium + 60 mM Asn and complex medium. E. 
mutabilis only had good growth in complex medium. 
After ten days of incubation, cultures with good or excellent growth were 
extracted and analysed by LC-PDA-MS. The TAC of E. sanguinea cultivated in 
synthetic medium + 60 mM Asn contained over 15 peaks while fewer metabolites were 
detected in the complex medium and even fewer and less abundancy were observed in 
synthetic medium + 30 mM Glu + 30 mM Asn (Figure 3.30). E. sanguinea metabolites 
showed a UV profile identical to that of E. gracilis metabolites. The extract of E. 
mutabilis cultivated in complex medium contained few meltabilities that appeared as 
intense peaks on the mass spectrometry but were scarcely detected on the TAC (Figure 
3.31). This suggests that those metabolites do not contain the conjugated triene system 
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Figure 3.30 Comparative TAC (200-600 nm) of E sanguinea cultivated in synthetic medium + 60 mM Asn, 
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Figure 3.31 Comparative total absorbance (200-600 nm) and total ion chromatograms of E. mutabilis cultivated 




MS/MS spectra of E. gracilis, E. sanguinea and E. mutabilis were obtained in 
negative ion mode and used to construct a molecular network of related metabolites 
(Figure 3.32). The molecular network is a visual representation of structurally related 
compounds that share similar MS/MS fragmentation patterns.[79] Each node in the 
molecular network is labelled with the precursor mass of the molecule deduced from 
the corresponding MS/MS spectrum. The constructed molecular network contains 
three groups of three Euglena species in different media. Group 1 (pink colour) 
contains the MS/MS spectra of E. gracilis cultivated in the synthetic medium + 30 mM 
Glu and synthetic medium + 60 mM Asn, group 2 (blue colour) contains the MS/MS 
spectra of E. sanguinea cultivated in the complex medium and synthetic medium + 60 
mM Asn, and group 3 (green colour) contains the MS/MS spectra of E. mutabilis 
cultivated in the complex medium.  
The structurally similar metabolites are grouped in a cluster, the higher the 
similarity of compounds, the closer they are in a cluster. For example, precursor 
masses 808 and 822 represent the MS/MS spectra of euglenatides B and C which are 
structurally similar with a difference of an extra methyl group in the latter. Precursor 
masses of euglenatides A and D (825 and 809) appear on the left of the cluster close 
to each other as they are structurally similar with an additional hydroxyl group in 
euglenatide A. The colour of the nodes indicates the relative abundance of each 
metabolite between strains based on the ion intensities of precursors. For instance, 
metabolite 847 is produced by all three strains while 849 is only produced by E. 
mutabilis. Although all metabolites in the clusters share some fragments, most 
metabolites are specific to one strain with limited overlapping. Only five metabolites 
of the euglenatide-related metabolites have been characterized while over 40 




euglenatide-related metabolites under the investigated conditions, followed by E. 
gracilis. Nevertheless, only the most abundant metabolites are selected for MS/MS 
fragmentation, and minor metabolites are not included in the molecular network.  
 
Figure 3.32 A molecular network of the euglenatide-related metabolites produced by E. gracilis, E. sanguinea 
and E. mutabilis in pink, blue, and green, respectively. Each node represents the precursor mass of a single 
metabolite, and the colour indicates the relative abundance of each metabolite between strains. 
3.2.10. Large-scale cultivation of E. sanguinea 
E. sanguinea cells (11.8 g) were harvested from a 12-L culture, extracted with 
90% MeOH and partitioned with hexane to afford 300 mg of residue. This amount was 
fractionated on an automated flash-chromatography system to afford 38.3 mg mixture 







purification of the compounds was attempted on a UHPLC system using a semi-
preparative C18 column. Several methods were trialled to separate the metabolites, 
including the method used to purify E. gracilis metabolites, with different solvents, 
temperatures, injection volumes and flow rates. The best separation was achieved with 
1 μL injection volume, 20% to 80% acetonitrile in water gradient and 3 mL/min flow 
rate over 47 min, and all target metabolites were eluted with a retention time between 
16 and 25 min (Figure 3.33). However, the separation was not enough to purify 
individual compounds. Additionally, the increase of the injection volume resulted in 
poor separation, making it even more difficult to purify enough amount for bioassays 
and structure elucidation. Therefore, separation and purification of those metabolites 
require exceptionally long analysis which is time consuming and cost-ineffective. 
Some options to achieve good separation might be using a normal-phase column or 
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3.3. Overall discussion and conclusion 
Euglenatides contain Asn and unusual amino acids (BAIBA, Gra, DeoxyGra, 
Dnv and Dnl). All euglenatides isolated from E. gracilis cells, cultivated in synthetic 
medium + 30 mM Glu, contain at least one Asn residue although Asn is absent in the 
cultivation medium. Moreover, asparagine synthetase, the enzyme that catalyses the 
last step of asparagine biosynthesis, has not been reported from Euglena.[171] BAIBA 
is an uncommon amino acid in natural products, but it has been reported in a few 
bacterial and fungal natural products.[201–204] It has also been isolated as a sole amino 
acid from plants[205,206] and is known as a catabolite of thymine and valine metabolism 
in human.[207] While the R-form is the enantiomer found in bacteria, plants, fungi and 
human urine, the S-form has only been reported from human plasma.[201–207] The Gra 
moiety in euglenatides is similar to the fatty amino acid residue reported from 
nemamides, but the former has an extra hydroxyl group and two additional methylenes. 
To the best of our knowledge, the original Dnv and Dnl have not been discovered as a 
component of natural products although the 5-O-carbamoylated form of Dnv has been 
found in polyoxin nucleoside peptides[208] and GE81112 tetrapeptides.[209] Moreover, 
Dnv has been isolated as a sole amino acid from the plant Lunaria annua.[210], and is 
used as an intermediate for the chemical synthesis of clavalanine and 
echinocandin.[193,211,212] 
Euglenatides have a broad spectrum of biological activity against eukaryotic 
cells with the highest activity against human cell lines and the lowest against the 
producer E. gracilis. Although euglenatides have some structural similarity to 
nemamides, no biological activity has been reported for the latter metabolites. 
Moreover, the yield of nemamide A (~ 1.4 µg/L) [186] is considerably lower than that 




are yet to be characterized and evaluated, which might have higher yields and superior 
properties in comparison to nemamides and euglenatides A-E. 
3.4. Materials and methods 
3.4.1. General experiments and materials 
Unless stated otherwise, all chemicals and solvents were purchased from Sigma-
Aldrich, Alfa Aesar or Fisher Scientific. All solvents were of HPLC grade or 
equivalent. Commercial media and media components were purchased from Sigma-
Aldrich, Alfa Aesar, Fisher Scientific or Formedium. Unless stated otherwise, the pH 
of media was adjusted to 4.8 with 1 N HCl and 1 N KOH prior to autoclaving. 
UV spectra were acquired on an SPD-M20A photodiode array detector attached 
to a Shimadzu Prominence/Nexera UHPLC. NMR spectra were recorded on a Bruker 
Avance III spectrometer (500 and 125 MHz for 1H and 13C NMR, respectively) 
equipped with a 1.7-mm TCI MicroCryoProbe. Chemical shifts were reported in ppm 
using the signals of the residual solvent as internal reference (δH 2.50 and δC 39.5 
ppm for DMSO-d6). Optical rotations were acquired on a Jasco P-2000 polarimeter 
(JASCO Corporation, Tokyo, Japan). IR spectra were measured with a JASCO FT/IR-
4100 spectrometer (JASCO Corporation) equipped with a PIKE MIRacle™ (JASCO 
Corporation) single reflection ATR accessory. 
3.4.2. High-resolution MS and dereplication 
For the accurate mass measurement, high-resolution mass spectra were acquired 
on a Synapt G2-Si mass spectrometer (Waters) operated in negative ion mode with a 
scan time of 1.0 second in the mass range of m/z 50 to 1200. An aliquot of 7 μL of 




mm (Waters) maintained at 45 °C and eluted with mobile phases A (water + 0.1% 
formic acid) and B (acetonitrile + 0.1% formic acid) at a flow rate of 80 µL/min. The 
following gradient was used: 0-1 min (15% B), 11 min (99% B), 11.1 min (15 % B), 
15 min (15 % B). The following parameters were used: capillary voltage = 2.5 kV; 
cone voltage = 40 V; source temperature = 130 °C; desolvation temperature = 350 °C; 
source offset 80 V. Leu-enkephalin peptide was used as a lock mass (m/z = 554.2620) 
measured every 30 seconds during the run. 
MS/MS spectra E. gracilis metabolites were acquired using the LC-PDA-MS 
analysis method, as described in chapter 2 (section 2.4.3). The spectra were converted 
to a compatible format using LabSolutions software (Shimadzu) and used to search 
Global Natural Products Social Molecular Networking.[80] For METLIN and 
MassBank searching, spectra of metabolites were extracted using ACD/Spectrus 
Processor and exported as lists of peaks. The peaks lists were used to search METLIN 
and MassBank for structurally similar molecules. 
3.4.3. Large-scale cultivation, isolation and purification 
E. gracilis inocula were prepared as described in chapter 2 (section 2.4.4) and 
used to inoculate 18 L of synthetic medium + 30 mM Glu to obtain approximately 0.2 
g of wet cells per litre (1:20 dilution). The culture was cultivated at ambient 
temperature 22-25 oC under daylight lamps (2000 lumens). After ten days, the culture 
was centrifuged at 3130 x g and 4 oC for 20 min, and the pellet (53 g) was extracted 
with 1 L 90% MeOH on a magnetic stirrer. After an hour, the aqueous MeOH extract 
was partitioned with an equal volume of hexane to remove lipids and pigments. The 
aqueous MeOH layer was centrifuged to remove the debris and then evaporated to get 




C18 powder, and the solvent was evaporated. The resulting powder was halved into 
two columns packed with 65 g reversed-phase resin, previously equilibrated with 20% 
acetonitrile before a frit was added on the top. The extract loaded on the column was 
fractionated on an automated flash-chromatography system (CombiFlash Rf, Teledyne 
Isco) using 18 mL/min flow rate and a linear gradient from 20% to 70% acetonitrile in 
water (in 40 min) followed by a ramp to 100% acetonitrile in 4 min before washing 
the column for 16 min.  
Fractions containing the target compounds were concentrated to dryness on a 
centrifugal evaporator to give a residue amount of 186.7 mg. This amount was 
dissolved in MeOH, and the compounds were purified on a semi-preparative C18 
column attached to Gilson HPLC system with UV detection at 210 and 270 nm, using 
34% isocratic acetonitrile in water and 3 mL/min flow rate. The purity of the isolated 
compounds was confirmed by injecting an aliquot in an Agilent 1100 LC-DAD-MS 
system using a Zorbax SB‑C8 column (2.1 × 30 mm, 5 μm, flow rate 0.3 mL/min, 40 
°C) with a linear gradient from 10% B to 100% B in 6 min followed by 2 min hold at 
100% B before returning to10% B and equilibrating the system for 2 min. Solvent A 
was 10% acetonitrile in water, and solvent B was 90% acetonitrile in water, both 
supplemented with 1.3 mM trifluoroacetic acid and ammonium formate. 
3.4.4. Crystallisation and chemical derivatisation 
Slow solvent evaporation and slow cooling of euglenatides A, B and C were 
performed using different percentages of MeOH in water, acetone, EtOAc or toluene, 
and vapour diffusion using MeOH in the inner vial and diethyl ether in the outer 
vial.[187] For the sitting-drop vapour diffusion method, two commercial screens 




in 96-well crystallisation plates.[213] Euglenatides A and B were prepared in Milli-Q 
water to obtain a concentration of 1.8 mg/mL and centrifuged at 13000 rpm to remove 
insoluble materials. Each well contained 0.4 µL of euglenatides A or B and 0.4 µL of 
precipitant, and a reservoir containing 50 µL of precipitant. Plates were incubated at 
20 °C in the dark and monitored daily under a microscope for three months. This 
experiment was repeated with a higher concentration of euglenatide B (10 mg/mL). 
Chemical derivatisation to facilitate the formation of single crystals for the 
purpose of X-ray diffraction studies was performed as described by Kuroda et al.[188] 
Briefly, triethylamine (5.5 μL, 75 mM), and 4-bromobenzyl chloride (7.7 mg, 75 mM) 
were successively added to a solution of euglenatide B (3 mg, 7.5 mM) in N,N-
dimethylformamide (0.5 mL) at 0 °C. The reaction mixture was stirred at room 
temperature for 20 h, then an aliquot (20 μL) of the reaction mixture was diluted with 
200 μL MeOH and analysed by LC-PDA-MS. After 48 h, brine (2 mL) was added, 
and the resulting mixture was extracted with EtOAc (10 mL x 3). The organic phase 
was combined and concentrated on a Rotavapor. The residue was dissolved in 1 mL 
MeOH and analysed by LC-PDA-MS. 
3.4.5.  Marfey’s analysis 
To determine the configurations of the two asparagine amino acids, euglenatides 
A and B were hydrolysed in sealed vials with 6 N HCl (0.5 mg/mL) at 110 °C for 16 
h. The hydrolysates were evaporated to dryness in a centrifugal evaporator, and the 
residues were dissolved in 50 μL of Milli-Q water. Stock solutions of the amino acid 
standards (50 mM, L-Asp and D-Asp, Sigma-Aldrich) were prepared in Milli-Q water. 
The hydrolysates and standard amino acids (50 μL) were treated with 20 μL of 1 M 




Marfey’s reagent; 1% w/v in acetone) and heated at 40 °C for 1 h. Reactions were 
quenched with 20 μL of 1 N HCl, and an aliquot (10 μL) was diluted with acetonitrile 
(40 μL) and analysed by an Agilent 1100 LC-DAD-MS system (UV detection at 340 
nm and ESI-MS detection in positive and negative modes). The following gradient 
was used (solvent A versus solvent B) on a Waters X-Bridge C18 column (4.6 × 150 
mm, 5 μm) maintained at 40 °C, 0.0 min (10% B), 50.0 min (27% B), 54.0 min (100% 
B), 60.0 min (100% B), 61.0 min (10% B), 70.0 min (10% B),  at a flow of 1 mL/min. 
Solvent A was 10% acetonitrile in water, and solvent B was 90% acetonitrile in water, 
both supplemented with 1.3 mM trifluoroacetic acid and ammonium formate. 
L-BAIBA and D-BAIBA were purchased from Sigma-Aldrich and prepared 
similarly to Asp standards. The LC-PDA-MS analysis was performed on a Shimadzu 
2020 single quadrupole LC-PDA-MS system (UV/visible detection range from 200 to 
600 nm and ESI-MS detection in positive and negative modes) using an Accucore C18 
column (2.1 × 100 mm, 2.6 μm) maintained at 50 °C. An isocratic solvent system of 
MeOH/water (25/75) with 0.1% formic acid was used at a flow of 0.350 mL/min over 
70 min. L-syn-Dnv, L-anti-Dnv, D-syn-Dnv, D-anti-Dnv and L-anti-norvalinate 
derivative were kindly provided by Prof. Thierry Gefflaut and Dr Armin Bauer.[192,193] 
The L-anti-norvalinate derivative was hydrolysed in a sealed vial with 6 N HCl (1 
mg/mL) at 110 °C for 16 h, and the hydrolysate was evaporated to dryness in a 
centrifugal evaporator. The hydrolysates and reference standards were prepared as 
described for the Asp standards. The LC-PDA-MS analysis was performed on a 
Shimadzu Prominence/Nexera IT-ToF LC-PDA-MS system (UV/visible detection 
range from 200 to 600 nm and ESI-MS detection in positive and negative modes) using 
an Accucore C18 column (2.1 × 100 mm, 2.6 μm) maintained at 30 °C. The following 




0.0-34.0 min (30% MeOH), 35.0 min (100% MeOH), 40.0 min (100% MeOH), 42.0 
(30% MeOH), 50.0 min (30% MeOH). 
3.4.6. Antimicrobial assays 
Euglenatides A-E were evaluated for their antimicrobial activity against bacteria 
(methicillin-sensitive S. aureus (MSSA ATCC 29213), methicillin-resistant S. aureus 
(MRSA MB5393) and E. coli ATCC 25922), yeast (C. albicans ATCC 64124), and 
mould (A. fumigatus ATCC46645) following previously described methods.[190,195,196] 
Each peptide was serially diluted in DMSO with a dilution factor of 2 to provide ten 
concentrations for all assays, and the final concentrations of each peptide were ranging 
from 128 to 0.25 µg/mL. Results were analysed using Microsoft Excel and GraphPad 
Prism 8.0 software. 
To assess the antibacterial activity, thawed stock inocula suspensions from 
cryovials of each microorganism (MSSA ATCC 29213, MRSA MB5393 and E. coli 
ATCC 25922) were streaked onto LBA (Luria-Bertani agar plates, 40 g/L) and 
incubated overnight at 37 °C. Isolated colonies of each microorganism were inoculated 
into Luria-Bertani broth medium (LB, 25 g/L) and incubated overnight (MSSA and 
MRSA) or for two hours (E.coli) at 37 °C with shaking at 220 rpm. After incubation 
for the specified periods, cultures were diluted in Miller Hinton II medium to attain 
assay inocula of approximately 5-6 × 105 CFU/mL (MSSA and E. coli) and 1.1 × 106 
CFU/mL (MRSA). In 96-well microplates, 90 μL/well of the diluted inoculum were 
mixed with 1.6 μL/well of each concentration of each compound and 8.4 μL/well of 
Miller Hinton II medium. Aztreonam 20-0.078125 µg/mL was used as a positive 
control with E. coli and vancomycin 32-0.25 µg/mL with MSSA and MRSA. 




Elmer) at T0 (zero time) immediately before incubation at 37 °C for 20 h. After this 
period, the assay plates were agitated using a DPC Micromix-5 and the absorbance 
was measured at Tf (final time). The following equation was used to calculate growth 
inhibition: Growth (% control) = 100 × {[(Tf Absorbance of treated culture - T0 
Absorbance of treated culture) - (Tf Absorbance of broth medium - T0 Absorbance of 
broth medium)]/ [(Tf Absorbance of untreated culture - T0 Absorbance of untreated 
culture) - (Tf Absorbance of broth medium - T0 Absorbance of broth medium)]}. 
To evaluate the activity against yeast, Sabouraud Dextrose Agar (SDA) plates 
were inoculated with frozen stocks of C. albicans ATCC 64124 and incubated at 35 
°C. After 24 h, a few colonies were harvested from the plates and suspended in RPMI 
liquid medium prepared from RPMI-1640 medium (20.8 g of RPMI powder in 1.8 L) 
supplemented with 13.4 g of yeast nitrogen base, 72 mL of 50% glucose and 80 mL of 
1 M HEPES. The liquid medium was filtered after adjusting the volume to 2 L with 
Milli-Q water. The optical density of C. albicans suspension was adjusted to 0.25 at 
660 nm using the liquid medium as a diluent and blank. This inoculum was diluted 
1:10 and reserved on ice until used for inoculation. In 96-well microplates, 90 μL/well 
of the diluted inoculum was mixed with 1.6 μL/well of each concentration of each 
compound and 8.4 μL/well of the liquid medium. Amphotericin B was used as a 
positive control. Absorbance was measured at 612 nm with a multimode plate reader 
(EnVision Perkin Elmer) at T0 (zero time) immediately before incubation at 37 °C for 
20 h. After this period, the assay plates were agitated using a DPC Micromix-5, and 
the absorbance was measured at Tf (final time). Growth inhibition was calculated using 
the equation mentioned above. 
To test the antifungal activity against A. fumigatus, PDA plates were flooded 




harvested in RPMI liquid medium by gently scraping the surface of the agar with a 
sterile spatula to prepare a conidial suspension. This suspension was filtered through 
sterile chiffon, and the concentration was determined by counting the conidia in a 
Neubauer chamber. The inoculum was approximately 2.5 × 104 CFU/mL. Resazurin 
stock solution of 0.02 g in 100 mL was prepared from resazurin sodium salt (R7017, 
Sigma Aldrich) in Milli-Q water, sterilised by filtration and used as an indicator of 
eukaryotic cell viability (0.002% final concentration). Resazurin is a blue oxidation-
reduction dye that is itself weakly fluorescent until it is irreversibly reduced to the 
pink-coloured and highly red-fluorescent resorufin.[195] In 96-well microplates, 90 
μL/well of the inoculum were mixed with 1.6 μL/well of each concentration of each 
compound and 8.4 μL/well of the liquid medium. Amphotericin B and Rifampicin 
were used as positive and negative controls, respectively. The plates were incubated 
at 37 °C for 25-30 h without agitation. After incubation, fluorescence was recorded on 
a multimode plate reader (EnVision Perkin Elmer) using wavelength settings for 
resorufin (excitation 570 nm, emission 600 nm). Growth inhibition was calculated 
using the equation mentioned above but using the fluorescence instead of absorbance. 
Wells with 0.002% resazurin in broth medium were used as blanks. 
3.4.7. Antiproliferative assay 
Three cancer cell lines (from ECACC) were cultured in RPMI 1640 medium 
(A549 and THP-1 cell lines) or DMEM (MCF-7 cell line) medium supplemented with 
10% fetal calf serum, 2 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL 
streptomycin (Invitrogen). Cells (3 × 104 /100 µL for THP-1 and 6 × 103 /100 µL for 
A549 and MCF-7) were seeded in 96-well plates and treated immediately (THP-1) or 




compound in DMSO at different concentrations in triplicate, and plates were incubated 
at 37 °C and 5% CO2. Cell viability was assessed by CellTiter 96 Aqueous One 
Solution Cell Proliferation Assay (Promega) following the manufacturer’s 
instructions. The assay contains MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) reagent, which is a 
colourimetric method that measures mitochondrial metabolic activity. After 72 h of 
incubation, MTS assay reagent (10 µL) was added to the cells, and plates were 
incubated further for 1.5 h for A549 and MCF-7 and 4 h for THP-1. Following this, 
absorbance was measured at 490 nm using a Polarstar Optima microplate reader (BMG 
Labtech). Wells with only culture medium and MTS solution were used to determine 
the background, and cells treated with 1% DMSO were used as the negative controls. 
Cell viability of treated cells was calculated relative to the negative controls after 
background correction of all wells. IC50 values were calculated using GraphPad Prism 
8.0 software. 
3.4.8. Antinematodal and algastatic activity  
Antinematodal activity experiments were conducted by our collaborators in the 
School of Biological Sciences, UEA. 
For algastatic activity, E. gracilis cells were harvested from four-day-old culture 
by centrifugation at 2000 x g and 10 oC for 5 min and suspended in EG:JM or synthetic 
medium + 30 mM Asn. The absorbance at 740 nm was adjusted on a CLARIOstar 
microplate reader to 0.1 (≈ 4 g of wet cells per litre) using EG:JM or synthetic medium 
+ 30 mM Asn as a diluent and blank. This inoculum was diluted 1:20 (≈ 0.2 g of wet 
cells per litre) and used to inoculate a 96-well microtiter plate. Each well contained 99 




compound in DMSO at two-fold serial dilutions with the highest concentration at 100 
μM and the lowest at 1.25 μM. The plate was incubated at ambient temperature 22-25 
oC under daylight lamps (2000 lumens), and the absorbance was measured at 740 nm 
after four and seven days of incubation. Wells with only growth medium were used 
for background correction, cells treated with 1% DMSO were used as negative 
controls, and cells treated with 1 mM of vorinostat were used as positive controls. 
Three replicates per condition were performed, and the percentage of growth inhibition 
was calculated relative to the negative controls after background correction of all 
wells. Results were analysed using Microsoft Excel and GraphPad Prism 8.0 software. 
3.4.9. Euglenatide-related metabolites and molecular networking 
E. sanguinea and E. mutabilis were provided by Dr Ellis O'Neill (Nottingham 
University, UK). E. gracilis, E. sanguinea and E. mutabilis were cultivated in the 
following media: synthetic medium + 30 mM Glu; synthetic medium + 30 mM Asn; 
synthetic medium + 60 mM Asn; synthetic medium + 60 mM Glu; synthetic medium 
+ 30 mM Glu + 30 mM Asn; complex medium. Inocula preparation, cultivation and 
extraction were performed as described in chapter 2 (section 2.4.7). Extracts were 
analysed by a Shimadzu LC-PDA-MS as described in chapter 2 (section 2.4.3). The 
LC and MS data were processed using ACD/Spectrus, and the MS/MS spectra were 
converted to an mzXML file format using LabSolutions software (Shimadzu). GNPS 
spectral library[80] was searched for similar molecules using the converted files of 
MS/MS spectra (GNPS; https://gnps.ucsd.edu) and used to construct a molecular 
network of euglenatide-related metabolites. The following GNPS parameters were 
used:[214] Parent Mass Tolerance = 1 Da, Min Pairs Cos = 0.6, Min Matched Peaks = 




Precursor Window = OFF, Filter Library = OFF, and Filter peaks in 50 Da Window = 
OFF. The molecular network was exported from GNPS and analysed using the 
visualisation software Cytoscape.[81] 
3.4.10. Large-scale cultivation of E. sanguinea 
E. sanguinea inocula were prepared as described for E. gracilis in chapter 2 
(section 2.4.7) and used to inoculate 12 L of the complex medium. The culture was 
cultivated at ambient temperature 22-25 oC under daylight lamps (2000 lumens). After 
ten days, the culture was centrifuged at 5000 x g and 4 oC for 10 min, and the pellet 
(11.8 g) was extracted with 1 L 90% MeOH in water and a magnetic stirrer. After an 
hour, the aqueous MeOH extract was partitioned with an equal volume of hexane to 
remove lipids and pigments, and the aqueous MeOH layer was centrifuged to remove 
the debris and then evaporated to get the residue (300 mg).  
The extract was loaded on a 43 g C18 column, previously equilibrated with 10% 
MeOH, and fractionated on an automated flash-chromatography system (CombiFlash 
Rf, Teledyne Isco) using 40 mL/min flow rate and a linear gradient from 10% to 100% 
MeOH in water (in 22 min) before washing the column with 100% MeOH (for 10 
min). Fractions containing the target compounds were combined and concentrated to 
dryness to give a residue amount of 38.3 mg. The residue was dissolved in 3 mL 
MeOH, and purification of the compounds was attempted using a semi-preparative 
C18 column on an Agilent 1290 Infinity UHPLC system equipped with a diode array 
detector with detection at 210 and 270 nm. Several methods were attempted to separate 
the metabolites including the method used to purify the E. gracilis metabolites, using 






4. Nutritional and epigenetic manipulation in Aspergillus 
4.1. Introduction 
Filamentous ascomycete fungi are the source of some of the major antibacterial 
and antifungal classes approved by the FDA, as demonstrated in chapter one. 
Aspergillus and Penicillium are the well-known natural product producers from this 
fungal class. Both Aspergillus and Penicillium are easy to cultivate under a wide range 
of conditions and have a fast growth rate. However, the large number of available 
genome sequences and accessibility of strains from culture collections are the main 
advantages to Aspergillus. Moreover, nutritional and epigenetic manipulation 
strategies have been successfully used with a great number of Aspergillus species, as 
explained in chapter one.  
Genome mining of Aspergillus nidulans revealed 56 putative secondary 
metabolite core genes including 29 PKS and PKS-like genes, 26 NRPS and NRPS-like 
genes, and one hybrid NRPS-PKS gene.[215] Fewer than 50% of those secondary 
metabolite biosynthetic genes could have been linked to known metabolites.[216] 
Similarly, it was reported that the soil fungus, Aspergillus niger, harbour 31 PKS, 15 
NRPS, and 9 hybrid NRPS-PKS BGCs and that fewer than 30% of these BGCs were 
transcribed under various culture conditions.[217] Although several metabolites remain 
to be identified from A. nidulans and A. niger, both nutritional and epigenetic strategies 
have been employed for the activation of cryptic BGCs in these two species, as 
described in chapter one. Therefore, over 20 Aspergillus genome sequences were 




4.2. Results and discussion 
4.2.1. Genome mining 
AntiSMASH[44] was used to search the genomes of over twenty Aspergillus 
species for natural product BGCs. The genomes of five Aspergillus species contained 
a large number of putative BGCs (>50): A. calidoustus NRRL 281, A. westerdijkiae 
NRRL 3174, A. bombycis NRRL 26010, A. carbonarius NRRL 369 and A. fischeri 
NRRL 181. Importantly, only a few of the predicted BGCs could be linked to known 
metabolites (Figure 4.1). Additionally, these five species are available in the US 
Agricultural Research Service (USDA-ARS) culture collection and have distinct 
coloured colonies that are helpful to differentiate them and avoid cross-contamination 
(Figure 4.1). Therefore, these Aspergillus species appeared to be appropriate 
candidates for natural product discovery. 
  
Figure 4.1 BGCs detected by antiSMASH in the genomes of  A. calidoustus, A. westerdijkiae, A. bombycis, A. 
carbonarius and A. fischeri, and their corresponding growth on PDA plates. 




































Gene clusters with ≥80% homology to known secondary metabolite BGCs.




4.2.2. Epigenetic manipulation of A. carbonarius in PDB 
A. carbonarius had the fastest growth rate on the PDA plates among the other 
species showing full growth after four days of inoculation. Therefore, agar plugs from 
the A. carbonarius plate were used to inoculate 10 mL of PDB containing 200 µM of 
the DNMT inhibitor 5-AC, 100 µM of the HDAC inhibitor vorinostat or a combination 
of 100 µM 5-AC and 50 µM vorinostat. The concentrations of epigenetic modifiers 
were selected based on the previous studies mentioned in chapter one, and higher 
concentrations of 5-AC were used due to its instability. After seven-day incubation, 
the effect of the epigenetic modifiers was apparent in the colour of the treated cultures 
compared to the control (Figure 4.2). Comparative chromatograms of EtOAc extracts 
displayed induced set of metabolites in the cultures treated with 5-AC or 5-AC and 
vorinostat combination, eluting between 7.70 and 7.90 min (Figure 4.3). The 
epigenetic effect observed in the colour of cultures and metabolic profiles is more 
significant with the concomitant addition of 5-AC and vorinostat compared to the 
cultures treated with only one modifier. 
 
Figure 4.2 A. carbonarius cultures treated with 100 µM vorinostat (B), 200 µM 5-AC (C), or a combination of 50 
µM vorinostat and 100 µM 5-AC (D) compared to the epigenetic-free control (A). 





































Figure 4.3 HPLC-UV chromatograms (360 nm) of A. carbonarius (first experiment, seven-day cultivation), 
control and with 100 μM vorinostat, 200 μM 5-AC or a combination of 50 μM vorinostat and 100 μM 5-AC. 
The experiment was repeated with 5-AC or a combination of 5-AC and 
vorinostat to test the metabolite production after one and two weeks of inoculation. 
Although the amount was still increased with the epigenetic modifiers, the induced 
metabolite was also detected in the control after one-week cultivation (Figure 4.4). In 
addition, a new peak, which was not detected in the previous experiment, appeared 
with the epigenetic modifiers at 4.46 min, and there was no difference between the 
colours of treated cultures and control. After two weeks, there was barely any 
difference between the treated cultures and the control (Figure 4.5). Nevertheless, it 
was apparent that the longer cultivation led to higher production of many metabolites 
that were produced at small or undetected amounts after one-week cultivation. The 
inconsistency in the results might be caused by the nonhomogeneous conidia 
employed for inoculation, which might cause some growth and metabolism variations 




experiments are performed with homogenised inocula and a minimum of six replicates, 




































Figure 4.4 HPLC-UV chromatograms (360 nm) of A. carbonarius (second experiment, one-week cultivation), 


































Figure 4.5 HPLC-UV chromatograms (360 nm) of A. carbonarius (second experiment, two-week cultivation), 




4.2.3. Epigenetic and nutritional manipulation of A. bombycis 
Two types of A. bombycis inocula were compared; PDA plugs and semi-solid 
SMYA medium (neopeptone 1%, maltose 4%, yeast extract 1% and agar 0.4%). Eight 
replicates of PDB (10 mL) were inoculated with agar plugs or homogenised SMYA 
inocula and cultivated for seven days. Cultures were extracted with an equal volume 
of acetone, and the samples were analysed by LC-MS. Volcano plots of the MS data 
(Figure 4.6) displayed significant differences between the cultures inoculated with 
agar plugs and those with SMYA inocula. Although some metabolites appeared to be 
produced in higher quantities with the agar inocula, SMYA inocula led to higher 
production of most metabolites. 
 
Figure 4.6 Volcano plot representation of variation in A. bombycis metabolite profiles with two different inocula, 
SMYA and agar plugs, (n = 8) (-log10 of t-test statistical p-value on y-axis vs. log2 of ion intensity ratio on x-
axes; the horizontal dashed line shows where p-value = 0.05). 
The effect of the epigenetic modifiers, vorinostat, VPA, 5-AC and hydralazine, 
was investigated in cultures inoculated with SMYA or agar plugs, eight replicates per 
condition. Volcano plots analysis of vorinostat-treated cultures demonstrated several 























and 4.8). The antibacterial activity of the treated cultures against MRSA was compared 
to the extracts of A. bombycis cultivated in eleven different media along with PDB 
controls. The treated cultures did not show higher antibacterial activity compared to 
the controls. Interestingly, the extract of one of the employed media (GSY) exhibited 
complete inhibition of MRSA that was not observed with other extracts (Figure 4.9, 
A). Similarly, the treated cultures did not have higher antifungal activity against A. 
fumigatus compared to the controls, while the cultures in MMK2 medium caused the 
strongest inhibition of A. fumigatus (Figure 4.9, B). Therefore, nutritional 
manipulation with different media appears to induce the production of some bioactive 
metabolites which are not produced with epigenetic modifiers. Since the employed 
media were trialled during my placement in Spain and the media were taken from 
Medina proprietary database, the following experiments including dereplication, 
isolation and structure elucidation are continued by our collaborators in Fundación 
Medina. 
 
Figure 4.7 Volcano plot representation of variation in A. bombycis metabolite profiles in the presence of 
vorinostat using SMYA inoculum, (n = 8) (-log10 of t-test statistical p-value on y-axis vs. log2 of ion intensity 
























Figure 4.8 Volcano plot representation of variation in A. bombycis metabolite profiles in the presence of 
vorinostat using agar plugs inoculum, (n = 8) (-log10 of t-test statistical p-value on y-axis vs. log2 of ion intensity 



































































































































































































































Figure 4.9 Growth inhibition of MRSA (A) and A. fumigatus (B) in the presence of A. bombycis extracts obtained 
from cultures grown in PDB with and without epigenetic modifiers using two types of inocula, SMYA inoculum 
(*) or agar plugs (#), along with extracts from cultures grown in elven different media inoculated with SMYA 























4.2.4. Epigenetic experiments in Aspergillus complete medium (this 
section is adapted from our publication in the Journal of Antibiotics[218]) 
Homogenised PDBA (PDB medium supplemented with 2.5 g/L agar) cultures 
of the five Aspergillus species were used to inoculate Aspergillus complete medium 
(glucose 2.5% and yeast extract 0.5%) containing 200 µM 5-AC or 100 µM vorinostat. 
After seven-day incubation, the metabolite profiles of EtOAc extracts from A. 
calidoustus and A. westerdijkiae revealed significant differences in the presence of 
vorinostat compared to the control fermentations. Therefore, a detailed analysis of the 
secondary metabolite profiles in these two species was performed. Six replicates of 
small-scale (10 mL) fermentations were carried out in Aspergillus complete medium 
in the presence or absence of 100 µM vorinostat. The extracts from each fermentation 
were characterised by LC-MS with UV detection at a single wavelength of 254 nm 
and electrospray ionisation mass spectrometry. Data analysis through volcano plots 
(Figure 4.10) revealed significant global effects of vorinostat on metabolite 
production, with many metabolites either increased or reduced in their levels compared 
to control fermentations.  
Subsequently, lists were compiled for natural products predicted from these 
species by antiSMASH and natural products previously reported from these or closely 
related species on the Aspergillus website (https://www.aspergillus.org.uk/) and DNP 
(Appendix 8.13). As a result, a total of five metabolites could be tentatively identified: 
emericellamide A, emericellamide B and phenylahistin from A. calidoustus, and 
ochratoxin A and penicillic acid from A. westerdijkiae (Figure 4.11). These results 
powerfully illustrate the OSMAC concept.[42] Thus, the majority of metabolites 
observed under the employed specific fermentation conditions could not be readily 




undetectable under these conditions. Nevertheless, the high sensitivity of mass 
spectrometry and the ability to detect metabolites at low abundance enables 
preliminary conclusions on metabolite diversity and identity to be drawn without the 
need to isolate pure compounds from the extract. 
 
Figure 4.10 (A) Volcano plot representation of variation in metabolite profiles of A. calidoustus extracts (n = 6), 
(-log10 of t-test statistical p-value on y-axis vs. log2 of ion intensity ratio on x-axes; the horizontal dashed line 
shows where p-value = 0.05). Three metabolites were identified: emericellamides A and B were reduced in 
production levels by vorinostat whereas phenylahistin was increased. (B) Volcano plot representation of variation 
in metabolic profiles of A. westerdijkiae extracts (n = 6). Two metabolites were identified: ochratoxin A was 
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Figure 4.11 Chemical structures of emericellamide A, emericellamide B and phenylahistin from A. calidoustus, 
and ochratoxin A and penicillic acid from A. westerdijkiae. 
A more detailed LC-PDA-MS analysis was carried out, generating UV-visible 
spectra, MS and MS/MS fragmentation data (Appendix 8.14) for the extracts. The 
additional data confirmed the identity of emericellamide A, emericellamide B and 
ochratoxin A although the actual amounts in the small-scale fermentation were 
insufficient for isolation. Furthermore, antiSMASH identified putative BGCs in A. 
calidoustus and A. westerdijkiae (Appendix 8.15) with 80% homology to the reported 
emericellamide and ochratoxin BGCs in other species.[219,220] Meanwhile, the HPLC 
chromatograms indicated one main metabolite each in A. calidoustus and A. 
westerdijkiae whose production levels were increased by the action of vorinostat 
(Figure 4.12). While the MS molecular ions and UV spectra suggested they were 




fragmentation patterns. In order to elucidate the structures of these two compounds, 








































Figure 4.12 (A) HPLC-UV chromatograms (254 nm) of A. calidoustus fermentations, control and with 100 μM 
vorinostat. The metabolite I induced by vorinostat is indicated. (B) HPLC-UV chromatograms (254 nm) of A. 
westerdijkiae fermentations, control and with 100 μM vorinostat. The metabolite II induced by vorinostat is 
indicated, as well as the drug itself. 
The metabolite profiles of large-scale fermentations of A. calidoustus (4 L) and 
A. westerdijkiae (4.5 L) treated with 100 µM vorinostat were similar to the smaller 
scale experiments. With A. calidoustus, 0.7 mg of the pure induced compound was 
isolated and analysed by HRMS to reveal an accurate mass m/z 351.18164 [M + H]+, 
suggesting a molecular formula of C20H22N4O2 (calcd. for C20H23N4O2, 351.18155, Δ= 
0.3 ppm). The molecular formula, together with the UV spectrum (λmax 202, 233, 
320 nm) and 1D/2D NMR spectra (Appendix 8.14) all matched with the reported 




of tubulin polymerisation which displays in vivo antitumor activity,[221,222] and the 
synthetic analogue plinabulin (Figure 4.13) is currently in phase III clinical 
development for the treatment of advanced non-small cell lung cancer.[223]  
Phylogenetically, the species A. calidoustus under investigation is closer to the 
drimane sesquiterpenoid producers A. pseudodeflectus, A. insuetus and A. keveii rather 
than A. ustus,[224] the previously reported source of I. In A. ustus,  I was isolated as a 
scalemic mixture from a culture in solid agar medium and its production associated 
with conidia formation, whereas in this experiment I is isolated as a scalemic mixture 
from the liquid culture of A. calidoustus. In the A. calidoustus 4 L-scale fermentation, 
the isolation of sufficient phenylahistin for structure elucidation would be impossible 
without the significant induction (ten-fold in the volcano plot, Figure 4.10) by 
vorinostat. Although the genomes of A. ustus and A. calidoustus were compared by 
antiSMASH, it was not possible to clearly identify a common BGC that might be 
responsible for phenylahistin biosynthesis. 
 
Figure 4.13 Chemical structure of the phenylahistin synthetic analogue, plinabulin. 
From the large-scale fermentation of A. westerdijkiae, 162 mg of the major 
metabolite induced by vorinostat were purified and analysed by HRMS to reveal a 




H]+ (calcd. for C8H11O4, 171.06519, Δ= 0.1 ppm). Together with the UV absorption at 
224 nm and NMR spectra (Appendix 8.14), the data confirmed the identity of the 
natural product as the polyketide penicillic acid (II), first isolated from Penicillium 
puberulum in 1913 and later from other Penicillium and Aspergillus species.[225,226] A 
broad spectrum of biological activity including antibacterial, antifungal, antiviral, 
antitumor and herbicidal activity has been reported for II. It is produced in substantial 
amounts by Aspergillus species grown on sucrose-based media, but normally in 
limited or undetectable amounts in the glucose-based media employed in this 
experiment.[227] Only about 1 mg of penicillic acid could be isolated from a large scale 
(1.5 L) control fermentation without vorinostat. Thus, the induction of penicillic acid 
levels by vorinostat in the large-scale fermentation was more than fifty-fold and much 
higher than the three-fold effect observed in the small-scale fermentation. While 
penicillic acid production was previously induced in an Aspergillus species grown in 
glucose peptone yeast-extract medium (GPY) by the addition of anthracenone,[228] the 
mechanism is unknown whereas in this study the induction could be attributed to the 
epigenetic effect of HDAC inhibition by vorinostat. 
4.2.5. Concomitant use of epigenetic modifiers in Aspergillus complete 
medium at different stages (the experiments in this section were performed by 
undergraduate students under my supervision) 
The experiments in this section were primarily performed to investigate the 
concomitant use of epigenetic modifiers on metabolite profiles. The second purpose 
of these experiments was to test the effect of the presence of epigenetic modifiers in 
the seed cultures as it has been reported that the epigenetic influence on secondary 




cultures as well as the production stage.[159] Additionally, it has been demonstrated that 
the epigenetic effect can be inherited by the next fungal generations without exposing 
them again to epigenetic modifiers.[156] Based on these precedents, seed cultures of the 
five Aspergillus species were prepared in 10 mL PDBA in the presence of 200 µM 5-
AC, 100 µM vorinostat or a combination of 100 µM 5-AC and 50 µM vorinostat. Seed 
cultures with DMSO were also cultivated under the same conditions to be employed 
as controls. After seven days, these cultures were used to inoculate 10 mL of 
Aspergillus complete medium in the presence or absence of the epigenetic modifiers, 
and the production cultures were cultivated for seven days before extraction.  
Based on the HPLC analysis (UV detection at 210, 254, 280 and 360 nm), the 
metabolite profiles of EtOAc extracts from all species did not show any enhanced 
effect when the modifiers were added in both seed and production cultures compared 
to addition only in production cultures. In the modifier-free production cultures, there 
was no apparent influence of the addition of epigenetic modifiers in seed cultures 
compared to the controls. Furthermore, the combination of epigenetic modifiers did 
not display a significant effect on the metabolite profiles compared to the presence of 
a sole modifier. Nevertheless, the results from these experiments were inconclusive 
due to the presence of inconsistencies between the replicates. Due to finance and time 
limitations, it was only possible to produce two replicates per condition which were 
insufficient for statistical analysis.  
4.3. Overall discussion and conclusion 
The cultivation of A. carbonarius led to higher yields of some metabolites; 
however, a more significant effect on metabolite profiles was observed with longer 




was significantly affected by epigenetic manipulation, nutritional manipulation 
resulted in the production of bioactive metabolites that were only detected in GSY and 
MMK2 media. The bioactive metabolites are under investigation by our collaborators 
in Fundación Medina. A. calidoustus and A. westerdijkiae experienced significant 
changes in secondary metabolite production upon laboratory fermentation with the 
HDAC inhibitor vorinostat. Both metabolite induction and repression were observed. 
Through analysis of putative BGCs, the likely BGCs responsible for the production of 
emericellamides in A. calidoustus and ochratoxin in A. westerdijkiae could be 
identified. The titre levels of phenylahistin (I) in A. calidoustus and penicillic acid (II) 
in A. westerdijkiae were substantially increased by vorinostat, illustrating the potential 
of epigenetic manipulation for improving the fermentation efficiency and yield of 
biologically active natural products. 
4.4. Materials and methods 
4.4.1. General experimental procedures 
Unless stated otherwise, all chemicals and solvents were purchased from Sigma-
Aldrich, Alfa Aesar or Fisher Scientific. All solvents were of HPLC grade or 
equivalent. Commercial media and media components were purchased from Sigma-
Aldrich, Alfa Aesar, Fisher Scientific or Formedium. UV spectra were acquired on an 
SPD-M20A photodiode array detector attached to a Shimadzu Prominence/Nexera 
UHPLC. NMR spectra of phenylahistin were recorded on a Bruker Avance Neo 
spectrometer equipped with a helium-cooled cryoprobe (600 and 150 MHz for 1H and 
13C NMR, respectively). Chemical shifts were reported in ppm using the signals of the 
residual solvent as internal reference (δH 7.26 and δC 77.1 ppm for CDCl3). NMR 




and 13C NMR, respectively). Chemical shifts were reported in ppm using the signals 
of the residual solvent as internal reference (δH 2.50 and δC 39.5 ppm for DMSO-d6). 
NMR solvents were purchased from VWR. The specific rotation of phenylahistin was 
recorded on a Perkin Elmer 341 polarimeter. IR spectrum of penicillic acid was 
recorded on a PerkinElmer Fourier transform infrared spectrometer. 
4.4.2. Fungal strains and inocula preparation 
A. calidoustus NRRL 281, A. westerdijkiae NRRL 3174, A. bombycis NRRL 
26010, A. carbonarius NRRL 369 and A. fischeri NRRL 181 were obtained from the 
US Agricultural Research Service (USDA-ARS). The spores were initially rehydrated 
by suspension in sterile MQ water for five hours, and a few drops of the spores 
suspension were used to inoculate a commercial potato dextrose agar solid medium 
(PDA0102, Formedium). The plates were incubated at 25 °C for 24 hours before 
sealing them with parafilm and incubating them until sporulation. Subsequently, 
conidia were harvested, and stocks were prepared and preserved as frozen conidia and 
mycelia in 10% glycerol at -80 °C.  
Solid inocula (agar plugs) were prepared by plating a sample of cryopreserved 
stocks on PDA, and 5-mm diameter agar plugs were cut from each plate with a sterile 
Transfer Tube (Spectrum Laboratories) and used to inoculate liquid media (two plugs 
/10 mL). Semi-solid inocula were prepared in SMYA (neopeptone 1%, maltose 4%, 
yeast extract 1% and agar 0.4%) or PDBA (a commercial PDB medium supplemented 
with 2.5 g/L agar, Formedium, UK) as described by Bills et al.[229] Briefly, agar plugs 
obtained from the strains cultivated on PDA at 25 °C for seven days were used to 
inoculate tubes containing 10 mL of SMYA or PDBA medium and two sterile 




shaking with the coverslips continually sheared agar plugs and Aspergillus hyphae.[229] 
After seven days, the tubes were vortexed to produce homogenous hyphal inocula that 
were used to inoculate liquid media (300 μL /10 mL). 
4.4.3. Epigenetic manipulation of A. carbonarius in PDB 
A. carbonarius was cultivated in 10 mL of PDB containing 200 µM 5-AC (a 
DNMT inhibitor), 100 µM vorinostat (an HDAC inhibitor) or a combination of 100 
µM 5-AC and 50 µM vorinostat at 25 °C and shaking at 150 rpm for seven days. The 
control cultures contained 10 mL PDB, the inoculum and the same percentage of 
DMSO used in modifier-treated cultures. After seven-day incubation, ten μL of each 
vial were transferred to PDA plates to test morphological changes and contamination.  
The remaining cultures were extracted by adding an equal volume of EtOAc and two 
coverslips and shaking the tubes for five minutes to accelerate extraction. After 
centrifugation, the EtOAc layer was transferred to glass vials and the solvent removed 
in a centrifugal evaporator, and the residues were resuspended by shaking with 3 mL 
of UHPLC-grade MeOH for 5 minutes.  
A 1 mL aliquot of the MeOH solution was passed through a Thermo Scientific™ 
SOLA™ HRP SPE cartridge and analysed by an Agilent 1290 Infinity UHPLC system 
equipped with a diode array detector with UV detection at 210, 254 270 and 360 nm. 
A 5 μL sample from each sample was injected onto a 100×2.1mm 2.6μm Thermo 
Scientific™ Accucore™ C18 column and chromatographed using the following 
gradient (acetonitrile versus 0.1% formic acid in water, at 0.5 mL/min and 40 °C): 0.01 
min (20% acetonitrile), 10 min (100% acetonitrile), 12 min (100% acetonitrile), 12.1 
(20% acetonitrile), 16.1 min (20% acetonitrile). Results were analysed and processed 




4.4.4. Epigenetic and nutritional manipulation of A. bombycis 
Media used for cultivation were taken from Medina proprietary database 
although some have been published.[230,231] After seven days of incubation, ten μL of 
each vial were transferred to PDA plates to test morphological changes and 
contamination, and the remaining were extracted with an equal volume of acetone and 
shaking at 220 rpm for 1 h.[230] The resultant extracts were centrifuged, and 11 mL of 
supernatant from each vial were mixed with 600 μL DMSO in glass tubes. These 
mixtures were concentrated under nitrogen to a final volume of 3 mL and filtered 
through 96-well filter plates. The antimicrobial activities of the filtrates were evaluated 
against MRSA and A. fumigatus as described in chapter 3 (section 3.4.6) but using 90 
μL/well of the inoculum and 10 μL/well of each filtrate. Results were analysed using 
Microsoft Excel and GraphPad Prism 8.0 software.  
MS data of cultures treated with vorinostat and their corresponding controls were 
generated by injecting an aliquot (2 μL) of the filtrate in an Agilent 1100 LC-MSD 
system using a Zorbax SB‑C8 column (2.1 × 30 mm, 5 μm, flow rate 0.3 mL/min, 40 
°C) with a linear gradient from 10% B to 100% B in 6 min followed by 2 min hold at 
100% B before returning to10% B and equilibrating the system for 2 min. Solvent A 
was 10% acetonitrile in water, and solvent B was 90% acetonitrile in water, both 
supplemented with 1.3 mM trifluoroacetic acid and ammonium formate. The 
instrument collected MS spectra from m/z 150-1500 in both positive and negative 
modes. Mass ions and their corresponding intensities were extracted using MASS 
Studio software.[232] The t-test statistical p-value of ion intensities and volcano plots 
were performed using Microsoft Excel. The unpaired equal variance and two-tailed 
distribution options were used for the t-test. The x-axis of volcano plots represents log 




4.4.5. Epigenetic experiments in Aspergillus complete medium 
 Small-scale cultivation, extraction and LC-MS analysis 
Six replicates per condition were produced using 300 μL PDBA inoculum in 10 
mL of Aspergillus complete medium (glucose 2.5% and yeast extract 0.5%) in the 
presence of 200 µM 5-AC (a DNMT inhibitor) or 100 µM vorinostat (an HDAC 
inhibitor) at 25 °C and shaking at 150 rpm for seven days. The control cultures 
contained 300 μL inoculum in 10 mL of the Aspergillus complete medium and the 
same percentage of DMSO used in modifier-treated cultures.  
After seven-day incubation, ten μL of each vial were transferred to PDA plates 
to test morphological changes and contamination.  The remaining cultures were 
extracted by adding an equal volume of EtOAc and two coverslips and shaking the 
tubes for five minutes to accelerate extraction. After centrifugation, the EtOAc layer 
was transferred to glass vials and the solvent removed in a centrifugal evaporator, and 
the residues were dissolved in 3 mL of UHPLC-grade MeOH with shaking for 5 
minutes. A 1 mL aliquot of the MeOH solution was passed through a Thermo 
Scientific™ SOLA™ HRP SPE cartridge and analysed by an Agilent LC/MSD TOF 
system equipped with a single wavelength UV detector. A 5 μL sample from each 
replicate was injected onto a 100 × 2.1mm 2.6μm Thermo Scientific™ Accucore™ 
C18 column and chromatographed using the following gradient (acetonitrile versus 
0.1% formic acid in water, at 0.5 mL/min and 40 °C): 0.01 min (10% acetonitrile), 10 
min (100% acetonitrile), 12 min (100% acetonitrile), 12.1 (10% acetonitrile), 16.1 min 
(10% acetonitrile). The instrument collected UV data at 254 nm wavelength and MS 




Agilent MassHunter Workstation software was used for the analysis of LC-MS 
data. The software was set to extract ions with the following parameters: ion RT 
tolerance 0.1 min and ion intensity threshold 1000 counts. The t-test statistical p-value 
of ion intensities and volcano plots were performed using Microsoft Excel. The 
unpaired equal variance and two-tailed distribution options were used for the t-test. 
The x-axis of volcano plots represents log 2 of ion intensity ratio, and the y-axis 
represents −log 10 of t-test statistical p-value. The HPLC-UV overlay traces were 
produced using ACD/Spectrus software.  
MS/MS spectra were collected from the most abundant ions on a Shimadzu ion-
trap-ToF (IT-ToF) mass spectrometer attached to a Shimadzu Nexera UHPLC. 
Collision-induced dissociation energy was 50%, and precursor ion width was 3 Da. 
Spray chamber conditions were 250 °C curved desorbation line (CDL), 300 °C heat 
block, 1.5 L.min-1 nebuliser gas, and drying gas “on”. The instrument was calibrated 
using sodium trifluoroacetate according to the manufacturer’s instructions, 
immediately before use. The MS and MS/MS data were analysed using LabSolutions 
(Shimadzu). 
 High-resolution MS 
High-resolution MS analysis was performed by direct infusion of 1 μL of the 
sample dissolved in 70% MeOH into a Waters Synapt G2-Si mass spectrometer 
operated in positive ion mode with a mass range of m/z 50 to 1200. Leu-enkephalin 
peptide was continuously infused to generate a lock-mass calibration with m/z = 
556.2766 during the run. MS data were collected with the following parameters: 




formate), capillary voltage = 3.0 kV; cone voltage = 40 V; source temperature = 120 
°C; desolvation temperature = 350 °C. 
 Large scale fermentation and extraction (this part was conducted 
with the help of undergraduate students) 
Large-scale (8 × 500 mL in 1 L Erlenmeyer flasks) A. calidoustus and A. 
westerdijkiae (3 × 1500 mL in 3 L Erlenmeyer flasks) fermentations were conducted 
with Aspergillus complete medium containing 100 µM vorinostat and incubated at 25 
°C and 150 rpm. After seven days, the culture was extracted twice with an equal 
volume of ethyl acetate, and the organic layers were combined and dried using a rotary 
evaporator. The residue was then dissolved in 250 mL of 80% MeOH and partitioned 
with an equal volume of hexane. After removal of the hexane, the aqueous MeOH 
layer was dried using a rotary evaporator. 
 Isolation and structure elucidation 
The A. calidoustus fermentation yielded 1.3 g of material that was initially 
separated using an automated flash-chromatography system (CombiFlash Rf, 
Teledyne Isco) with 30 mL/min flow rate and a linear gradient from 30% to 100% 
MeOH in water (in 30 min) before washing with 100% acetonitrile (for 15 min). 
Further purification with a semi-preparative C18 column on an Agilent 1290 Infinity 
UHPLC system equipped with a diode array detector yielded phenylahistin (I): 0.69 
mg, white powder. [α]D
25 +71 (c 0.059, MeOH, 63% ee), lit. +123 (c 0.13, MeOH) for 
natural product (75% ee)[221] and +278 for purified (R)-enantiomer (98% ee).[222] 1H 
NMR (600 MHz, CDCl3) δ 8.93 (1H, br s, NH-1), 7.55 (1H, s, H-2), 6.88 (1H, s, H-
6), 12.00 (1H, br s, NH-8), 4.33 (1H, m, H-10), 5.68 (1H, br s, NH-11), 2.93 (1H, dd, 




overlap, H-15 and 19), 7.34 (2H, t, J = 7.36 Hz, H-16 and 18 ), 7.27 (1H, overlap, H-
17), 6.03 (1H, dd, J = 17.44, 10.49 Hz, H-21), 5.16 (1H, d, J = 17.44 Hz, H-22a), 5.20 
(1H, d, J = 10.49 Hz, H-22b), 1.51 (6H, s, H-23 and 24). 13C NMR (150 MHz, CDCl3) 
δ 132.26 (C2), 132.29 (C4), 136.5 (C5), 105.3 (C6), 123.9 (C7), 164.7 (C9), 57.2 
(C10), 159.9 (C12), 41.2 (C13), 135.5 (C14), 129.5 (C15 and 19), 129.1 (C16 and 18), 
127.5 (C17), 37.6 (C20), 144.6 (C21), 113.9 (C22), 28 (C23 and 24). 
The A. westerdijkiae fermentation yielded 3.3 g of material that was separated 
by an automated flash-chromatography system using 30 mL/min flow rate and a linear 
gradient from 10% to 100% MeOH in water (in 25 min) before washing with 100% 
acetonitrile (for 5 min). Further purification by automated flash-chromatography using 
30 mL/min flow rate and a linear gradient from 5% to 40% MeOH in water (in 30 min) 
yielded penicillic acid (II): 162 mg, white needles. IR νmax cm
−1 3281, 3125, 2852, 
1743, 1725, 1633. 1H NMR (DMSO-d6, 500 MHz) 7.87 (1H, br s, 4-OH), 5.41 (1H, s, 
H-2), 5.30 (1H, s, H-6a), 5.11 (1H, s, H-6b), 3.85 (3H, s, H-8), 1.65 (3H, s, H-7). 13C 
NMR (DMSO-d6, 125 MHz) 179.4 (C1), 170.0 (C3), 140.1 (C5), 115.3 (C6), 102.4 






5. Epigenetic and nutritional manipulation in actinomycetes  
5.1. Introduction 
Actinomycete bacteria are prolific producers of bioactive natural products, 
including the main classes of the approved antimicrobial and anticancer agents. The 
approved antibacterial classes including aminoglycosides, tetracyclines, macrolides,  
ansamycins, carbapenems, amphenicols, lincosamides, glycopeptides and cyclic 
lipopeptides all originated from actinomycetes.[13–18] Actinomycetes are the producers 
of the approved antifungal polyenes and anticancer agents such as actinomycins, 
anthracyclines, bleomycins, mitosanes and anthracenones.[25] Other medically 
important drugs that originated from actinomycetes include antihyperlipidemic agents 
such as pravastatin, immunosuppressive drugs such as rapamycin, antiparasitic agents 
such as avermectins (e.g. ivermectin), and antidiabetic drugs such as acarbose (Figure 
5.1).[47] 
 




Genome sequences suggest that up to 90% of microbial natural products are only 
produced under specific conditions.[233] Although actinomycete bacteria have been 
extensively explored for natural product discovery, genome mining of the well-
explored actinomycetes Streptomyces coelicolor A3 (2) and S. avermitilis unveiled 
many cryptic BGCs encoding natural products that have not been discovered from 
these species.[234] Several approaches have been used to activate those BGCs including 
the chemical epigenetic studies on Streptomyces coelicolor A3 (2).[108,235] DNMT 
genes and HDAC orthologues have been reported from Streptomyces and 
Saccharopolyspora genomes.[108,235] Nevertheless, there is a shortage of studies on the 
use of the epigenetic manipulation strategy for activation of cryptic bacterial BGCs. In 
Barrie’s lab (JIC, UK), genome mining revealed that Streptomyces sp. CMB-0406 and 
Saccharopolyspora KY21 each has at least 25 putative BGCs although only a few 
natural products have been identified from these two species.[236,237] Therefore, the 
epigenetic manipulation technique was trialled to activate the natural product BGCs in 
Streptomyces sp. CMB-0406 and Saccharopolyspora KY21. 
5.2. Results and discussion 
Streptomyces sp. CMB-0406 and Saccharopolyspora KY21 were cultivated in 
SV2 or SM7 medium in the presence of 0.5% DMSO (control), 10 µM vorinostat, 50 
µM vorinostat, 50 µM 5-AC, 100 µM 5-AC or a combination of 10 µM vorinostat and 
50 µM 5-AC.  The epigenetic modifiers were added after 24 h of inoculation, and the 
concentrations were determined based on previous studies on S. coelicolor A3 
(2).[108,235] Since 5-AC suffers from instability, higher concentrations of this modifier 
were utilized. EtOAc and MeOH solvents were used for extraction of molecules with 




SM7, comparative TACs of the EtOAc extracts revealed two new peaks (RT = 1.39 
and 1.60 min) in the presence of 10 or 50 µM vorinostat compared to the controls, 
while 5-AC did not show any effect on the metabolite profile either alone or in 



























Figure 5.2 Comparative TACs of Streptomyces sp. CMB-0406 EtOAc extracts from cultures cultivated in the 
absence (control) or the presence of epigenetic modifiers. 
Comparative TACs of the cultures extracted with MeOH after four days of 
cultivation demonstrated the same effect of the epigenetic modifiers observed in 
EtOAc (Figure 5.3). A sample of vorinostat in MeOH was analysed by LC-PDA-MS 
using the same experimental conditions to determine its retention time and spectra 
(Figure 5.3). The MS fragmentation patterns and UV spectra of the two new peaks 
were similar to those of vorinostat (Figure 5.4) but had retention times different from 
vorinostat (Figure 5.3). This confirmed that neither of these new peaks is an MS 
fragment of vorinostat as their retention times were different from vorinostat.  




metabolites or degradation products,[238,239] suggesting that they could be bacterial 
biotransformation products or reactants of vorinostat. Biotransformation products of 
epigenetic modifiers have been reported from vorinostat and hydralazine in previous 
studies,[240–242] but the ones detected in this experiment do not match any of the 
previously reported products. However, the small difference between the masses of 
the two new peaks and the mass of vorinostat as well as the presence of the main 
known fragment of vorinostat (m/z 232.13)[238,239] in the MS spectra of the new peaks 























Figure 5.3 Comparative TACs (200-600 nm) of Streptomyces sp. CMB-0406 MeOH extracts from cultures 
cultivated in the absence (control) or the presence of 10 µM or 50 µM vorinostat as well as the vorinostat control 





































































































































































































































































































































Figure 5.4 MS (positive ion mode) and UV spectra of vorinostat (vorinostat control) and vorinostat-related 
products (peak 1 and peak 2). 
The EtOAc extracts of the SV2 Streptomyces sp. CMB-0406 cultures did not 
show a remarkable difference between the epigenetic-treated cultures and the control 
cultures. Interestingly, the production of Streptomyces metabolites known as 
heronamides[243] was significantly affected by the medium employed for cultivation 
(Figure 5.5). The cultures cultivated in SV2 medium contained larger amounts of 
heronamides and lower or undetectable amounts of vorinostat products in comparison 
to the SM7 cultures using MS (Table 5.1) and UV traces (Figure 5.6). Moreover, the 
yield of heroanamides was negatively affected by the presence of vorinostat in SM7 
medium. After seven-day cultivation of Streptomyces sp. CMB-0406 in SM7 and SV2 
media, the metabolic profile fingerprint did not change, but the quantity of 





Figure 5.5 Chemical structures of heronamides A-C. 
 
Table 5.1 Comparison of the intensities of the vorinostat products and heronamides in Streptomyces sp. CMB-
0406 cultures in SM7 and SV2 media with and without 50 µM vorinostat. 
Ion m/z 
Ion 














249.1624 1.60 0 4276781 0 2452037 Peak 1 
265.1504 1.39 0 4008014 0 0 Peak 2 
466.2960 4.22 1256529 779317 3875258 4050196 
Heronamide A 
































Figure 5.6 Comparative TACs (200-600 nm) of Streptomyces sp. CMB-0406 cultivated in SM7 and SV2 medium 
for four days in the absence (control) and the presence of 50 µM vorinostat. 
The cultivation of Saccharopolyspora KY21 in SM7 and SV2 medium 
supplemented with epigenetic modifiers did not change the metabolic profile except 
for the presence of vorinostat-related products in the cultures supplemented with 
vorinostat. A new vorinostat-related product was observed in the SM7 
Saccharopolyspora KY21 culture treated with vorinostat (RT = 2.27) compared to the 
SM7 Streptomyces sp. CMB-0406 vorinostat-treated culture (Figure 5.7). The UV 
spectrum of the new peak was identical to that of vorinostat, and the MS spectrum 
contained the main vorinostat fragment (Figure 5.8), indicating that the structural 




















Retention time (min)  
Figure 5.7 Comparative TACs (200-600 nm) of vorinostat-related products observed with Streptomyces sp. 

















































































































Figure 5.8 UV and MS (positive ion mode) spectra of the new vorinostat-related product observed with 




5.3. Overall discussion and conclusion 
The epigenetic manipulation of the actinomycete strains did not lead to the 
production of any new metabolites compared to the control cultures. However, three 
vorinostat-related products were observed in the extracts of the cultures treated with 
vorinostat. This might be because these species are efficient in the metabolism of 
vorinostat converting it to an ineffective form. Although a high concentration of 5-AC 
was used, the neutral pH of the medium might have accelerated the degradation of this 
modifier. On the other hand, the cultivation of Streptomyces sp. CMB-0406 in SV2 
medium resulted in higher yields of heronamides compared to SM7 medium. This 
indicates that secondary metabolism in this species is affected by the media 
components and that nutritional manipulation might be an efficient strategy for the 
discovery of novel metabolites from this species. Nevertheless, this experiment was 
limited to two media and a more comprehensive range of media should be trialled to 
investigate the efficiency of nutritional manipulation in this species for natural product 
discovery. 
5.4. Materials and methods 
5.4.1. General experimental procedures 
Unless stated otherwise, all chemicals and solvents were purchased from Sigma-
Aldrich, Alfa Aesar or Fisher Scientific. All solvents were of HPLC grade or 
equivalent. Commercial media and media components were purchased from Sigma-




5.4.2. Epigenetic and nutritional manipulation 
Bacterial strains were provided by Prof. Barrie Wilkinson (molecular 
microbiology department, JIC, UK). Saccharopolyspora KY21 was isolated from the 
Kenyan plant ants, Tetraponera penzigi.[244] Streptomyces sp. CMB-0406 was isolated 
from marine sediment collected off the coast of Heron Island, Australia.[243] 
Streptomyces sp. CMB-0406 and Saccharopolyspora KY21 were cultured in SV2 
medium (1.5 % glucose, 1.5 % glycerol, 1.5 % soya peptone, 0.3 % NaCl, 0.1 % 
CaCO3; pH 7.0) for three days. These seed cultures were used to inoculate 10 mL of 
SV2 and SM7 medium (100 µL/10 mL) in the presence of 0.5% DMSO (control), 10 
µM vorinostat, 50 µM vorinostat, 50 µM 5-AC, 100 µM 5-AC or a combination of 10 
µM vorinostat and 50 µM 5-AC, added after 24 h of inoculation. SM7 medium was 
composed of (per L): MOPS, 20.9 g; glycerol, 20 mL; sucrose, 2.5 g; NaCl, 0.5 g; L-
proline, 15 g; K2HPO4, 2.0 g; L-glutamate 1.5 g; 0.2M MgSO4, 10 mL; 0.02M 
CaCl2.2H2O, 10 mL; 5 mL of a trace elements solution containing (g/L): MnCl2·4H2O, 
0.1; FeSO4·7H2O, 0.1; ZnCl2, 0.05. The medium was adjusted to pH 6.5 before 
sterilization.  
Two replicates of each condition were produced, a sample of 900 µL was taken 
after four and seven days of inoculation and extracted with an equal volume of MeOH 
or EtOAc and shaking for 20 min. The mixtures were then centrifuged, and 600 µL of 
each were transferred to HPLC vials. The MeOH extracts were analysed directly by 
LC-PDA-MS, while the EtOAc extracts were evaporated in a centrifugal evaporator, 
dissolved in 600 µL of MeOH and filtered before LC-PDA-MS analysis. LC-PDA-







6. Overall conclusion and future work 
This project aimed at activating natural product genes in Euglena microalgae, 
Aspergillus fungi and actinomycete bacteria through nutritional and epigenetic 
manipulation. Nutritional manipulation of Euglena resulted in the discovery of five 
novel natural products from E. gracilis, named euglenatides A-E, with moderate 
antifungal activity and potent anticancer activity. Further in-vitro and in-vivo 
experiments are needed to assess the pharmacodynamic and pharmacokinetic 
properties of euglenatides as antifungal and anticancer agents. Such experiments will 
require larger quantities of the natural products. While this is possible by scaling up 
the algal cultivation, engineered strains or heterologous hosts can be used to improve 
the yield. However, the genetic engineering and heterologous expression of 
euglenatides will require the identification of their BGCs. An alternative option 
involves chemical total synthesis of euglenatides. This strategy can be extended by 
chemical modification to produce ‘unnatural’ analogues that might have superior 
pharmacodynamic or pharmacokinetic properties compared to the original natural 
products. 
The investigation of E. mutabilis and E. sanguinea revealed that they produce 
metabolites related to euglenatides discovered from E. gracilis. The complexity of the 
E. sanguinea extract did not allow the separation and isolation of the euglenatide-
related metabolites to enable structure elucidation and pharmacological evaluation. 
Therefore, good separation might be achieved by using chromatography columns that 




protocols. Moreover, the extracts of other Euglena species including E. mutabilis can 
be another important source of euglenatide analogues. 
In Aspergillus fungi, nutritional manipulation of A. bombycis resulted in 
significant changes in metabolite profiles leading to a substantial increase in the 
antibacterial and antifungal activities. The following experiments including 
dereplication, isolation and structure elucidation of the bioactive metabolites are 
continued by our collaborators in Fundación Medina, Spain. The epigenetic 
manipulation of five Aspergillus species led to a significant increase in the titre levels 
of phenylahistin and penicillic acid in A. calidoustus and A. westerdijkiae, 
respectively. Further experiments can involve feeding biosynthetic precursor 
analogues to the fermentation broth of A. calidoustus to produce unnatural 
phenylahistin analogues. This procedure has been successfully utilised for the 
production of unnatural beauvericins by the endophytic fungus Fusarium 
oxysporum.[245] 
While epigenetic manipulation did not display noticeable effects on the 
metabolite profiles of the actinomycete strains, nutritional manipulation led to higher 
yields of heronamides in Streptomyces sp. CMB-0406. This indicates that secondary 
metabolism in this Streptomyces species is affected by the media components and that 
nutritional manipulation might be an efficient strategy for the discovery of novel 
metabolites from this species. Nevertheless, the nutritional manipulation experiment 
in the actinomycetes was limited to two media and a more comprehensive range of 
media should be trialled to investigate the efficiency of nutritional manipulation for 
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8.1. IR spectra of euglenatides A-E 
 
Figure 8.1 IR spectrum of euglenatide A. 
 






Figure 8.3 IR spectrum of euglenatide C. 
 
Figure 8.4 IR spectrum of euglenatide D. 
 




8.2. NMR tables of euglenatides C-E. 
 































7.64, d (7.8) 
1.69, m, 1.87, m 
3.43, m 
4.47, brd (4.7) 

















2.93, brd (13.0), 3.26, m 
6.94, overlap 




















7.87, d (7.9) 
2.57, dd (16.9, 3.7), 3.01, dd (16.8, 
5.0)  
 





















































2.16, dd (13.8, 3.3), 2.47, overlap 
(9.6) 





1.30, m, 1.48, m 
3.75, m 
5.51, dd (14.6, 7.6) 
6.19, dd (14.6, 10.2) 
6.15, dd (14.5, 10.3) 
6.24, dd (14.5, 10.3) 
6.07, dd (15.1, 10.4) 
5.72, dt (15.1, 7.1) 


























8.96, d (6.5) 
2.47, dd (15.9, 4.7), 2.87, dd (15.7, 
4.0) 
 







































7.65, d (7.8) 
1.86, m, 1.71, m 
3.18, m 
4.27, brd (5.9) 
3.39, m 
4.18, brd (4.9) 
















3.03, brd (11.2), 3.27, m 
7.06, s 


















7.76, d (8.5) 
2.57, dd (17.0, 3.6), 2.94, dd (16.9, 5.0)  
 





















































3.86, dd (9.6, 7.7) 
5.13, brd (7.7) 
3.92, m 
6.90 d (9.7) 
1.69, m, 1.20, m 
3.47, m 
4.31, m 
1.30, br dd (14.5, 5.2), 1.49, m 
3.73, m 
5.51, dd (14.6, 7.6) 
6.20, dd (14.6, 10.3) 
6.15, dd (14.6, 10.3) 
6.24, dd (14.5, 10.4) 
6.07, dd (15.1, 10.4) 
5.72, dt (15.1, 7.1) 
























9.02, d (6.3) 
2.86, dd (15.4, 3.9) 2.47, dd (15.5, 4.0) 
 





































7.71, d (7.5) 
1.85, m, 1.69, m 
3.42, m 
4.44, m 

















2.92, brd (12.4), 3.24, m 
6.93, overlap 


















7.87, d (8.2) 
2.58, dd (16.7, 3.2), 2.99, dd (16.9, 4.15) 
 





















































2.16, dd (12.8, 3.1), 2.47, overlap 
(9.6) 





1.30, m, 1.49, m,  
3.75, m 
5.51, dd (14.7, 7.7) 
6.20, dd (14.5, 10.5) 
6.15, dd (14.7, 10.6) 
6.24, dd (14.5, 10.5) 
6.07, dd (15.0, 10.5) 
5.72, dt (15.1, 7.7) 








































8.3. NMR spectra of  euglenatide A in DMSO-d6 
8.3.1. 1H NMR spectrum of euglenatide A in DMSO-d6 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8.3.2. 13C NMR spectrum of euglenatide A in DMSO-d6 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8.3.3. COSY NMR spectrum of euglenatide A in DMSO-d6 
























8.3.4. HSQC NMR spectrum of euglenatide A in DMSO-d6 



























8.3.5. HMBC NMR spectrum of euglenatide A in DMSO-d6 
























8.3.6. NOESY NMR spectrum of euglenatide A in DMSO-d6 




























8.4. NMR spectra of  euglenatide B in DMSO-d6 
8.4.1. 1H NMR spectrum of euglenatide B in DMSO-d6 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8.4.2. 13C NMR spectrum of euglenatide B in DMSO-d6 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8.4.3. COSY NMR spectrum of euglenatide B in DMSO-d6 
























8.4.4. HSQC NMR spectrum of euglenatide B in DMSO-d6 



























8.4.5. HMBC NMR spectrum of euglenatide B in DMSO-d6 
























8.4.6. NOESY NMR spectrum of euglenatide B in DMSO-d6 



























8.5. NMR spectra of  euglenatide C in DMSO-d6 
8.5.1. 1H NMR spectrum of euglenatide C in DMSO-d6 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8.5.2. 13C NMR spectrum of euglenatide C in DMSO-d6 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8.5.3. COSY NMR spectrum of euglenatide C in DMSO-d6 
























8.5.4. HSQC NMR spectrum of euglenatide C in DMSO-d6 



























8.5.5. HMBC NMR spectrum of euglenatide C in DMSO-d6 
























8.5.6. NOESY NMR spectrum of euglenatide C in DMSO-d6 



























8.6. NMR spectra of  euglenatide D in DMSO-d6 
8.6.1. 1H NMR spectrum of euglenatide D in DMSO-d6 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8.6.2. 13C NMR spectrum of euglenatide D in DMSO-d6 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8.6.3. COSY NMR spectrum of euglenatide D in DMSO-d6 
























8.6.4. HSQC NMR spectrum of euglenatide D in DMSO-d6 



























8.6.5. HMBC NMR spectrum of euglenatide D in DMSO-d6 
























8.6.6. NOESY NMR spectrum of euglenatide D in DMSO-d6 




























8.7. NMR spectra of  euglenatide E in DMSO-d6 
8.7.1. 1H NMR spectrum of euglenatide E in DMSO-d6 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8.7.2. 13C NMR spectrum of euglenatide E in DMSO-d6 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8.7.3. COSY NMR spectrum of euglenatide E in DMSO-d6 
























8.7.4. HSQC NMR spectrum of euglenatide E in DMSO-d6 

























8.7.5. HMBC NMR spectrum of euglenatide E in DMSO-d6 
























8.7.6. NOESY NMR spectrum of euglenatide E in DMSO-d6 



























8.8. Comparison of 1H and 13C NMR chemical shifts in 
euglenatides with nemamide A triene sidechain 
 
Proton position nemamide A euglenatide E euglenatide B  
C17 2.18, brd (J17a,17b = 14.5) 
2.47, overlap (J17b,18 = 9.8) 
2.16, dd (13.8, 3.3), 
2.47, overlap 
3.86, dd (9.6, 7.7) -0.02, 0 
C18 4.08, m (J18,19 =6.7) 4.08, m 3.92, m 0 
C19 1.32, m (J19,20 = 6.7) 1.31, m 1.20, m ,1.69 m -0.01 
C20 3.51, m (J20,21a = 8.2) 3.51, m 3.47, m 0 
C21a 1.30, m (J21a,21b =14.5) 1.30, m 1.30, m 0 
C21b 1.48, m (J21b,22 = 9.8) 1.48, m 1.49, m 0 
C22 3.76, m (J22,24 = 7.5) 3.75, m 3.73, m -0.01 
C23 3.13, s 3.13, s 3.13, s 0 
C24 5.51, dd (J24,25 = 15.4) 5.51, dd (J 14.6, 7.6) 5.51, dd (J 14.6, 7.6) 0 
C25 6.19, dd (J25,26 = 11.2) 6.19, dd (J 14.6, 10.2) 6.20, dd (J 14.6, 10.3) 0 
 
Carbon position nemamide A euglenatide E euglenatide B  
C16 170.3 170.4 172.3 0.1 
C17 40.6 40.9 72.9 0.3 
C18 44.9 45.2 49.1 0.3 
C19 43.7 44.2 40.3 0.5 
C20 63.3 63.3 63.0 0 
C21 43.5 43.6 43.8 0.1 
C22 77.6 77.8 77.8 0.2 
C23 55.5 55.6 55.5 0.1 
C24 133.7 133.8 133.9 0.1 





8.9. Key NOESY and J coupling in euglenatide E 
• Stereocenters at C-2 and C-18 
C2H (4.30 ppm) -N2H (7.64 ppm) (Observed in NOESY). 
C2H (4.30 ppm) -N18H (6.93 ppm) (Observed in NOESY). 
N2H (7.64 ppm) -N18H (6.93 ppm) (Observed in NOESY). 
H17b (2.47 ppm) -N18H (6.93 ppm) (Observed in NOESY). 
Strong J coupling H17b (2.47 ppm) -H18 (4.08 ppm) (J= 9.6). 
Weak J coupling H17a (2.16 ppm)-H18 (4.08 ppm) (J= 3.3). 
 
• Stereocenters at C-18 and C-20 
H17a (2.16 ppm) -H20 (3.51 ppm) (Observed in NOESY). 
H18 (4.08 ppm)-H21b (1.48 ppm) (Observed in NOESY). 
H18(4.08 ppm)-H20 (3.51 ppm) (Observed in NOESY). 
H17a (2.16 ppm)-H21b (1.48 ppm) (Not observed in NOESY). 
Strong J coupling H20 (3.51 ppm)-H21a (1.30 ppm) (14.5). 
Weak J coupling H20 (3.51 ppm)-H21b (1.48 ppm) (5.1). 
 
• Stereocenters at C-20 and C-22 
H20 (3.51 ppm)- H22 (3.75 ppm) (Observed in NOESY). 
H21a (1.30 ppm)- H24 (5.51 ppm) (Observed in NOESY). 
H21b (1.48 ppm)- H24 (5.51 ppm) (Observed in NOESY). 
Weak J coupling H22 (3.75 ppm)-H21a (1.30 ppm) (3.54). 





8.10. Key NOESY and J coupling in euglenatide B 
• Stereocenters at C-2 and C-18 
C2H (4.32 ppm) -N2H (7.65 ppm) (Observed in NOESY). 
C2H (4.32 ppm) -N18H (6.90 ppm) (Observed in NOESY). 
N2H (7.65 ppm) -N18H (6.90 ppm) (Observed in NOESY). 
H17 (3.86 ppm) -N18H (6.90 ppm) (Observed in NOESY). 
Strong J coupling H17 (3.86 ppm) -H18 (3.92 ppm) (J= 9.6). 
J coupling OH17 (5.13 ppm)-H17 (3.86 ppm) (J= 7.7). 
 
• Stereocenters at C-18 and C-20 
H17 (3.86 ppm) -H20 (3.47 ppm) (Observed in NOESY). 
H18 (3.92 ppm)-H21b (1.49 ppm) (Observed in NOESY). 
H18 (3.92 ppm)-H20 (3.47 ppm) (Observed in NOESY). 
H17 (3.86 ppm) - H21b (1.49 ppm) (Not observed in NOESY). 
Strong J coupling H20 (3.47 ppm)-H21a (1.30ppm) (14.5). 
Weak J coupling H20 (3.47 ppm)-H21b (1.49 ppm) (5.1). 
 
• Stereocenters at C-20 and C-22 
H20 (3.47 ppm)- H22 (3.73 ppm) (Observed in NOESY). 
H21a (1.30 ppm)- H24 (5.51 ppm) (Observed in NOESY). 
H21b (1.48 ppm)- H24 (5.51 ppm) (Observed in NOESY). 
Weak J coupling H22 (3.73 ppm)-H21a (1.30 ppm) (3.54). 



























8.12. Antimicrobial activity of E. gracilis metabolites (A-E) 
 
Figure 8.6 Dose–response curves of bacterial strains (MSSA, MRSA and E. coli) incubated with euglenatides A, 
B, C, D and E. 
 
Figure 8.7 Euglenatides A-E dose-response curves tested against C. tropicalis. The growth inhibition with the 
compound is calculated relative to the growth inhibition in the negative controls that is equal to 0. 



































































C. tropicalis ATCC 750 
⬛ euglenatide A 
⬛ euglenatide B 
⬛ euglenatide C 
⬛ euglenatide D 







Figure 8.8 Euglenatides A-E dose-response curves tested against C. krusei. The growth inhibition with the 
compound is calculated relative to the growth inhibition in the negative controls that is equal to 0. 
8.13. Lists of natural products known or predicted to be 
produced by A. calidoustus, A. westerdijkiae and their related 
species 
Table 8.4 Known metabolites from A. calidoustus and A. ustus. 
Chemical Name Molecular Formula 
11,12-Epoxy-7-drimene-6,9,11-triol; (6β,9α,11αOH)-form, 11-Ketone(lactone), 6-O-(2E,4E,6E-
octatrienoyl) 
C23H30O5 
11,12-Epoxy-7-drimene-6,9,11-triol; (6β,9α,11αOH)-form, 11-Ketone(lactone), 6-O-(2E,4E-
hexadienoyl) 
C21H28O5 
11,12-Epoxy-7-drimene-6,9,11-triol; (6β,9α,11αOH)-form, 11-Ketone(lactone), 6-O-(2Z,4E,6E-
octatrienoyl) 
C23H30O5 
11,12-Epoxy-7-drimene-6,9,11-triol; (6β,9α,11αOH)-form, 11-Ketone(lactone), 6-O-(5-carboxy-
2E,4E-pentadienoyl) 
C21H26O7 
11,12-Epoxy-7-drimene-6,9,11-triol; (6β,9α,11αOH)-form, 11-Ketone(lactone), 6-O-(6,6-
dimethoxy-2E,4E-hexadienoyl) 
C23H32O7 
11,12-Epoxy-7-drimene-6,9,11-triol; (6β,9α,11αOH)-form, 11-Ketone(lactone), 6-O-(6-oxo-
2E,4E-hexadienoyl) 
C21H26O6 
11,12-Epoxy-7-drimene-6,9,11-triol; (6β,9α,11αOH)-form, 11-Ketone(lactone), 6-O-(6R*,7R*-
dihydroxy-2E,4E-octadienoyl) 
C23H32O7 
C. kruseii ATCC 6258 
⬛ euglenatide A 
⬛ euglenatide B 
⬛ euglenatide C 
⬛ euglenatide D 






11,12-Epoxy-7-drimene-6,9,11-triol; (6β,9α,11αOH)-form, 11-Ketone(lactone), 6-O-(6R*,7S*-
dihydroxy-2E,4E-octadienoyl) 
C23H32O7 
11,12-Epoxy-7-drimene-6,9,11-triol; (6β,9α,11αOH)-form, 11-Ketone(lactone), 6-O-(6R*,7S*-
epoxy-2E,4E-octadienoyl) 
C23H30O6 
11,12-Epoxy-7-drimene-6,9,11-triol; (6β,9α,11αOH)-form, 11-Ketone(lactone), 6-O-(7-hydroxy-
6-oxo-2E,4E-octadienoyl) 
C23H30O7 
11,12-Epoxy-7-drimene-6,9,11-triol; (6β,9α,11αOH)-form, 11-Ketone(lactone), 6-O-(7ξ-
hydroxy-2E,4E-octadienoyl) 
C23H32O6 
11,12-Epoxy-7-drimene-6,9,11-triol; (6β,9α,11αOH)-form, 11-Ketone(lactone), 6-O-(9ξ-
hydroxy-2E,4E,6E-decatrienoyl) 
C25H34O6 
11,12-Epoxy-7-drimene-6,9,11-triol; (6β,9α,11αOH)-form, 11-Me ether,6-O-(2E,4E,6E-
octatrienoyl) 
C24H34O5 
11,12-Epoxy-7-drimene-6,9,11-triol; (6β,9α,11αOH)-form, 6-O-(2E,4E,6 E-Octatrienoyl) C23H32O5 
11,12-Epoxy-7-drimene-6,9-diol; (6β,9α)-form, 6-O-(2E,4E,6E -Octatrienoyl) C23H32O4 
2,11-Dihydroxy-7-drimen-6-one; 2α-form C15H24O3 
2,9,11-Trihydroxy-7-drimen-6-one; (2α,9α)-form C15H24O4 
2,9,11-Trihydroxy-7-drimen-6-one; (2β,9α)-form C15H24O4 
2-Hydroxy-1-(8-hydroxy-3-methyl-7-isoquinolinyl)-3-methyl-1-butanone C15H17NO3 
3,11-Dihydroxy-7-drimen-6-one; (3β,5α,9β,10β)-form C15H24O3 
3,7,16,18-Ophiobolatetraen-5-one; (16Z)-form C25H36O 
3,7,16,18-Ophiobolatetraen-5-one; (16Z)-form, 16,17-Dihydro C25H38O 
3,9,11-Trihydroxy-7-drimen-6-one; (3β,9α)-form C15H24O4 
5-Oxo-3,7,16,18-ophiobolatetraen-21-al C25H34O2 
5-Oxo-3,7,16,18-ophiobolatetraen-21-al; 2,6-Didehydro, 3β,4-dihydro, 21-alcohol C25H36O2 
5-Oxo-3,7,16,18-ophiobolatetraen-21-al; 21-Alcohol C25H36O2 
5-Oxo-3,7,16,18-ophiobolatetraen-21-al; 21-Alcohol, 18,19-dihydro, 18ξ,19-dihydroxy C25H38O4 
5-Oxo-3,7,16,18-ophiobolatetraen-21-al; Δ6-Isomer, 21-alcohol C25H36O2 
6-Ethyl-2,4-dihydroxy-3-methylbenzoic acid; Et ester C12H16O4 




7(21),18-Ophioboladiene-3,8-diol; (3α,6β,8β)-form C25H42O2 
7,8-Dihydro-7,8-dihydroxy-3,5,7-trimethyl-6H-2-benzopyran-6-one C12H14O4 
7-Chloro-2-(3-furanyl)-1,3,8-trimethoxyxanthone C20H15ClO6 
7-Drimene-6,9,11-triol; (5α,6α,9α,10β)-form, 6-Ketone C15H24O3 
7-Drimene-6,9,11-triol; (5α,6α,9α,10β)-form, 6-Ketone, 11-aldehyde C15H22O3 
7-Drimene-6,9,11-triol; (5α,6α,9α,10β)-form, 6-Me ether C16H28O3 
7-Drimene-6,9,11-triol; (5α,6β,9α,10β)-form, 11-Aldehyde, 6-O-(2E,4E ,6E-octatrienoyl) C23H32O4 
7-Drimene-6,9,11-triol; (5α,6β,9α,10β)-form, 12-Hydroxy, 6-Me ether C16H28O4 
7-Drimene-6,9,11-triol; (5α,6β,9α,10β)-form, 12-Hydroxy, 6-O-(2E,4E,6 E-octatrienoyl) C23H34O5 
8-Drimene-6,7,11-triol; (6β,7α)-form C15H26O3 
8-Hydroxyergosta-4,6,22-trien-3-one; (8β,9α,14α,22E,24R)-form C28H42O2 
Aspergillamide A C22H22N2O5 
Aspergillamide A; 2-Epimer C22H22N2O5 
Austalide B C26H34O8 
Austalide B; 13-Ac C28H36O9 
Austalide B; 19α-Hydroxy C26H34O9 
Austalide B; 19α-Hydroxy, 13-Ac C28H36O10 
Austalide B; 19α-Hydroxy, 19-Ac C28H36O10 
Austalide B; 19α-Hydroxy, di-Ac C30H38O11 
Austalide H acid; 13-Ac, Me ester C28H38O9 
Austalide H acid; Me ester C26H36O8 
Austalide I C27H34O8 
Austalide J C25H32O7 
Austalide K C25H32O5 





Austamide; 12S,13-Dihydro C21H23N3O3 
Austamide; 12ξ-Hydroxy, 12,13-dihydro C21H23N3O4 
Austdiol C12H12O5 
Austin C27H32O9 
Austin; O-De-Ac C25H30O8 
Austocystin A C19H13ClO6 
Austocystin A; 2,3-Dihydro, O4-De-Me C18H13ClO6 
Austocystin A; 2,3-Dihydro, O6-de-Me C18H13ClO6 
Austocystin A; 4,6-Di-O-de-Me C17H9ClO6 
Austocystin A; O4-De-Me C18H11ClO6 
Austocystin F C17H10O7 
Austocystin F; 2,3-Dihydro C17H12O7 
Austocystin F; 4-Me ether C18H12O7 
Austocystin F; 8-Chloro, 4-Me ether C18H11ClO7 
Austocystin H C22H18O7 
Austocystin H; 2',3'-Dihydro, 3'-hydroxy C22H20O8 
Austocystin H; 2',3'-Dihydro, 3'-hydroxy, 4-Me ether C23H22O8 
Austocystin H; 3a-Deoxy, 2',3'-dihydro, 3'-hydroxy C22H20O7 
Austocystin H; 3a-Deoxy, 2',3'-dihydro, 3'-hydroxy, 4-Me ether C23H22O7 
Averufanin; (+)-form C20H18O7 
Brassicadiol; (ξ)-form, 2''ξ-Hydroxy C15H22O4 
Brassicadiol; (ξ)-form, 3''ξ-Hydroxy, 1'',2''-didehydro(Z-) C15H20O4 
Cyclo[2-(1,1-dimethyl-2-propenyl) tryptophyl]prolyl C21H25N3O2 
Cyclo[2-(1,1-dimethyl-2-propenyl) tryptophyl] prolyl; 12,13-Didehydro C21H23N3O2 
Cyclopaldic acid C11H10O6 






Nidulin; 4-Dechloro, O-de-Me C19H16Cl2O5 
Nidulin; O-De-Me C19H15Cl3O5 
Ophiobolin H C25H38O3 
Ophiobolin H; 5,6-Diepimer C25H38O3 
Ophiobolin H; 5,6-Diepimer, 5-Me ether C26H40O3 
Ophiobolin H; 5-Me ether C26H40O3 
Ophiobolin K C25H36O3 
Ophiobolin K; 6-Epimer C25H36O3 
Pergillin C15H16O4 
Pergillin; 2,10-Dihydro C15H18O4 
Phenylahistin C20H22N4O2 
Pseudodeflectusin; 1-Deoxy, 3,4-didehydro C15H14O3 
Pseudodeflectusin; Diepimer, 8S,10-dihydro, Me ether C16H20O4 
Pseudodeflectusin; Me ether C16H18O4 
Terretonin E; 1-Deoxy C26H32O8 
TMC 120A C15H15NO2 
TMC 120A; 2,11-Didehydro C15H13NO2 
TMC 120A; 2-Hydroxy C15H15NO3 
Ustic acid C11H12O7 






Table 8.5 Known metabolites from A. westerdijkiae and A. ochraceus. 




2-Benzyl-3-hydroxy-1-methyl-5-nonylpyrrolidine; (2S,3S,5R)-form C21H35NO 
3-(2-Chloro-3-hydroxybutenylidene)dihydro-4-hydroxy-5-methyl-2(3H)-furanone C9H13ClO4 
3,4-Dihydro-3,8-dihydroxy-3-methyl-1H-2-benzopyran-1-one; (±)-form, 3-Me ether C11H12O4 
3,4-Dihydro-4,8-dihydroxy-3-methyl-1H-2-benzopyran-1-one C10H10O4 
3,4-Dihydro-7,8-dihydroxy-3-methyl-1H-2-benzopyran-1-one C10H10O4 
3,4-Dihydro-8-hydroxy-3-methyl-1H-2-benzopyran-1-one; (R)-form, 5-Bromo C10H9BrO3 
3,6-Bis(2-methylpropyl)-2(1H)-pyrazinone C12H20N2O 
3,6-Bis(2-methylpropyl)-2(1H)-pyrazinone; 1-Oxide C12H20N2O2 
3,6-Bis(2-methylpropyl)-2(1H)-pyrazinone; 1-Oxide, Fe complex C36H57FeN6O6 
3,6-Bis(2-methylpropyl)-2(1H)-pyrazinone; 2''-Hydroxy C12H20N2O2 
3,6-Bis(2-methylpropyl)-2(1H)-pyrazinone; NH-form, 1,2''-Dihydroxy C12H20N2O3 
4-(Hydroxymethyl)-4,6-octadiene-2,3-diol; (E,E)-form C9H16O3 
4,6,8-Nonatriene-2,3-diol C9H14O2 
5-Hydroxy-6-decen-9-olide; (5R,9R)-form C10H16O3 
6,8-Dihydroxy-1-oxo-1H-2-benzopyran-3-carboxylic acid; 6-Me ether C11H8O6 
6,9,14-Trihydroxy-7-drimen-12,11-olide; (6β,9α)-form, 6-O-(4-Nitrobenzoyl) C22H25NO8 
Amauromine; 2,3-Diepimer C32H36N4O2 
Amauromine; 2,3-Diepimer, N1'-Me C33H38N4O2 
Asperchrome B1 C37H58FeN9O16 
Asperchrome D C33H52FeN9O15 
Asperchrome E C41H64FeN9O17 





Asperlactone; Deepoxy, 8ξ-chloro, 9ξ-hydroxy C9H13ClO4 
Asperlactone; Deepoxy, 9ξ-chloro, 8ξ-hydroxy C9H13ClO4 
Aspinolide B C14H20O6 




Aspyrone; Deepoxy, 1'R-chloro, 2'S-hydroxy C9H13ClO4 
Aspyrone; Deepoxy, 1'S-methoxy, 2'R-hydroxy C10H16O5 
Aspyrone; Deepoxy, 2'S-chloro, 1'S-hydroxy C9H13ClO4 
Aspyrone; Deepoxy, 2'S-hydroxy C9H14O4 
Circumdatin A; (S)-form C21H19N3O5 
Circumdatin A; (S)-form, 5-Demethoxy C20H17N3O4 
Circumdatin C; (S)-form C17H13N3O3 
Circumdatin C; (S)-form, 6-Hydroxy C17H13N3O4 
Circumdatin C; (S)-form, Deoxy C17H13N3O2 
Circumdatin C; (S)-form, Deoxy, 15-hydroxy C17H13N3O3 
Circumdatin E; (S)-form C20H17N3O4 
Circumdatin E; (S)-form, 15-Deoxy C20H17N3O3 
Circumdatin E; (S)-form, 5-Methoxy C21H19N3O5 
Circumdatin L; (S)-form C17H13N3O3 
Cyclo(leucylprolyl); (3S,8aS)-form C11H18N2O2 
Cycloechinulin; (S)-form C20H21N3O3 
Des(diserylglycyl)ferrirhodin C33H53FeN6O13 




Diaporthin; (S)-form C13H14O5 
Diaporthin; (S)-form, O-De-Me C12H12O5 
Ergochromes; Ergochrome AA C32H30O14 
Ferrirubin; *-Deoxy C41H64FeN9O16 
Ferrirubin; 2,3 or 4-Ac C43H66FeN9O18 
Isoaspinonene C9H16O4 
Ochratoxin A C20H18ClNO6 
Ochratoxin A; 4R-Hydroxy-L-proline analogue C16H16ClNO7 
Ochratoxin A; 4S-Hydroxy C20H18ClNO7 
Ochratoxin A; Dechloro C20H19NO6 
Ochratoxin A; Et ester C22H22ClNO6 
Ochratoxin A; L-Lysine analogue C17H21ClN2O6 
Ochratoxin A; L-Serine analogue C14H14ClNO7 
Ochratoxin A; Me ester C21H20ClNO6 
Ochrindole A C29H28N2O3 
Ochrindole A; 10-Hydroxy C29H28N2O4 
Ochrindole A; O1-De-Me C28H26N2O3 
Ochrindole D C27H22N2O3 
Penicillic acid C8H10O4 
Sclerotiamide; (-)-form C26H29N3O5 
Sclerotiamide; (-)-form, 5-Chloro C26H28ClN3O5 
Sclerotigenin; 15-Hydroxy C16H11N3O3 
Stephacidin A; (+)-form C26H29N3O3 
Stephacidin A; (+)-form, 8,20-Dihydro, 8,9-didehydro, 20β-hydroxy, N9 -oxide C26H29N3O5 
Stephacidin A; (+)-form, 9,21-Didehydro C26H27N3O3 








Table 8.6 Natural product BGCs predicted by antiSMASH from A. calidoustus. 
Region Type Most similar known cluster Similarity 
 1.4 T1PKS asperthecin Terpene 85% 
 2.2 T1PKS,NRPS-like cichorine Polyketide 100% 
 2.3 terpene clavaric acid Terpene 100% 
 2.4 T1PKS naphthopyrone Polyketide 100% 
 2.7 T1PKS,indole neurosporin A Polyketide 26% 
 2.9 T1PKS epipyriculol Polyketide 29% 
 3.2 NRPS N-Acetyltryptophan NRP 66% 
 3.3 T1PKS trypacidin Polyketide 28% 
 4.4 T1PKS aflavarin Polyketide 60% 
 4.5 T1PKS pyranonigrin E Polyketide 100% 
 4.9 T1PKS,NRPS-like cichorine Polyketide 100% 
 5.2 terpene shearinine D Terpene 9% 
 6.6 T1PKS aspernidine A Polyketide 100% 
























 7.2 NRPS nidulanin A Polyketide 75% 
 8.2 T1PKS 
ankaflavin / monascin 
/ rubropunctatine / 
monascorubrin 
Polyketide: 
Iterative type I 
8% 




Region Type Most similar known cluster Similarity 
 8.4 T1PKS,terpene shearinine D Terpene 9% 
 10.1 NRPS,T1PKS 
emericellamide A / 
emericellamide B 
NRP 80% 
 14.1 NRPS-like,terpene clavaric acid Terpene 100% 
 21.1 indole,NRPS notoamide A NRP 16% 





Table 8.7 Natural product BGCs predicted by antiSMASH from A. westerdijkiae. 
Region Type Most similar known cluster Similarity 
 89.1 indole  notoamide A NRP 11% 
 136.1 T1PKS  viriditoxin Polyketide 22% 
 161.2 NRPS,T1PKS  pyranonigrin E Polyketide 100% 
 161.4 NRPS  ochratoxin A NRP + Polyketide 80% 
 181.2 NRPS-like  aspergillic acid NRP 57% 
 181.5 T1PKS,NRPS-like  equisetin NRP + Polyketide 18% 
 183.5 T1PKS  neurosporin A Polyketide 20% 
 183.7 NRPS,indole  notoamide A 
NRP + Terpene + 
Alkaloid 
38% 
 184.1 NRPS  asperphenamate NRP 75% 
 187.1 NRPS  
serinocyclin A / 
serinocyclin B 
NRP 100% 
 188.4 T1PKS  asperlactone Polyketide 100% 
 191.1 terpene  botrydial Terpene 13% 
 195.2 NRPS,indole  
hexadehydroastechrome 
/ terezine-D / astechrome 
NRP 75% 
 195.3 NRPS,T1PKS  UNII-YC2Q1O94PT Polyketide 100% 
 197.1 NRPS  
serinocyclin A / 
serinocyclin B 
NRP 100% 
 198.2 terpene  squalestatin S1 Terpene 40% 
 217.2 NRPS-like  ochrindole A Other 29% 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 8.11 1H NMR spectrum of phenylahistin in CDCl3. 
 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 8.13 COSY NMR spectrum of phenylahistin in CDCl3. 
 














































































































Figure 8.17 UV spectrum of penicillic acid. 
 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 8.19 1H NMR spectrum of penicillic acid in DMSO-d6. 
 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 8.21 DEPT 135 NMR spectrum of penicillic acid in DMSO-d6. 
 
























































Figure 8.23 HSQC NMR spectrum of penicillic acid in DMSO-d6. 

















































































































































































































































































[M + H − HCOOH]+
[M + H − H2O]
+
[M + H − HCOOH − NH3]
+
[M + H − Phenylalanin]+
 





8.15. Predicted gene clusters for emericellamides and 
ochratoxin A 
 









8.16. The complete chromatograms for chapter 2 
































































































































































































































































































































































































































Synthetic medium + 30 mM Glu
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Synthetic medium + 15 mM Asn





































































































































































































































































8.17. The complete chromatograms for chapter 3 






























































































































































8.18. The complete chromatograms for chapter 4 





















































































































































































































































































































8.19. The complete chromatograms for chapter 5 













































































































































8.20. The complete chromatograms for chapter 5 
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